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Abstract 
Ovarian cancer is the 5th leading cause of cancer-related death. The disease responds initially 
to treatment which is most often surgical cytoreduction followed by chemotherapy. The 
primary response rates to chemotherapy are approximately 80%. Unfortunately, most 
patients relapse and eventually tumours become refractory to frontline therapy. The lack of 
widely effective therapies at this points leads to a low 5-year survival. Therefore, new 
therapeutic agents or treatment strategies are required.  
It has been reported previously that gain of function mutations of p53 which upregulate the 
mevalonate pathway in breast cancer. TP53 is commonly altered in high grade serous ovarian 
cancer which might suggest that the mevalonate pathway may also be deregulated in ovarian 
cancer. The result reported in this thesis indicate that p53 upregulate the expression of key 
enzymes of the mevalonate pathway in ovarian cancer cell lines. In particular, it was found 
that 3-Hydroxy-3-Methylglutaryl-CoA Reductase (HMGCR), the rate limiting enzymes of 
the pathway, geranylgeranyl transferase-I (GGTI), GGTII and farnesyltransferase are 
upregulated in number of ovarian cancer cell lines. These observations suggest that 
pharmaceutical inhibition of the mevalonate pathway may be a promising therapeutic 
approach. 
Pitavastatin, a member of statin family of HMGCR inhibitors, has been found to have 
significant activity against ovarian cancer cells and induce regression of ovarian cancer 
xenografts in mice in previously published result from our laboratory. Although repurposing 
statins for use in oncology is an attractive strategy, there are legitimate concerns about the 
potential for the drug to cause myopathy. Therefore, other pharmacological agents which 
inhibit the mevalonate pathway were evaluated to test the hypothesis that dual inhibition of 
the mevalonate pathway would synergistically cause ovarian cancer cell death. 
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Bisphosphonates, such as zolendronic acid, are inhibitors of farnesyl diphosphate synthase. 
Zolendronic acid, and to lesser extends risedronate, potentiated the activity of pitavastatin in 
several assays assessing the growth and viability of ovarian cancer cells. In contrast, the 
geranylgeranyl transferase I inhibitor, GGTI-2133, antagonised the activity of pitavastatin. 
Similarly, knockdown of either GGTI-β or GGTII-β by RNAi failed to potentiate the activity 
of pitavastatin. However, combined knockdown of both geranylgeranyl transferases 
potentiated the activity of pitavastatin. 
To identify further drugs which could interact synergistically with pitavastatin, a library of 
100 off-patent drugs was screened in combination with pitavastatin in cell growth assays. 
Several compounds were identified which potentiated the activity of pitavastatin and/or had 
notable activity as single agents. The most striking hit from this screen was prednisolone, a 
synthetic glucocorticoid. Subsequent studies confirmed the synergistic interaction between 
prednisolone and pitavastatin in several cell growth and viability assays. To evaluate the 
mechanism underlying this synergistic interaction, publically-available expression data were 
interrogated to identify mevalonate pathway enzymes whose expression was regulated by 
prednisolone. The effect of these candidate genes was then tested in ovarian cancer cells and 
levels of HMGCR, farnesyl diphosphate synthase and geranylgeranyl transferase II were 
found to be reduced. 
These data suggest that drug combinations inhibiting multiple points in the mevalonate 
pathway may increase the therapeutic window for pitavastatin and offer a potential treatment 
for ovarian cancer. 
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1. Introduction  
1.1. Ovarian cancer 
Ovarian cancer (OC) is a group of molecularly and aetiologically distinct diseases that share 
the same anatomical location. It usually presents as complex cystic mass in the pelvis. OC 
consists of abnormal cells found in the ovary, that have the capability to spread or invade 
other tissues of the body and share other hallmarks of cancers (Figure 1-1). The disease tends 
to be diagnosed at an advanced stage, with limited prospects for successful treatment and 
usually poor overall survival. The incidence rates of OC are projected to rise by 15% in the 
UK between 2014 and 2035, to 32 cases per 100,000 females by 2035 (Figure 1-2) (Bast, 
Hennessy and Mills, 2009; Smittenaar et al., 2016; Cancer research UK, 2017). OC is a 
relatively uncommon but fatal disorder and considered as the leading cause of death among  
gynaecological cancers (Jessmon et al., 2017). Although the majority of patients respond 
initially to the treatment (Ledermann et al., 2012), relapse after an initial response to 
treatment can occur  and the development of resistance leads to failure of chemotherapy 
(Ling et al., 2005). The prognosis of OC patients had not changed significantly since three 
decades ago despite significant improvements in the understanding of the biology of the 
malignancy (Vaughan et al., 2011). 
 
The majority of OC patients, approximately 75%, are detected at an advanced stage due to 
the obscure nature of the symptoms and the lack of the precise detection method (Bharwani, 
Reznek and Rockall, 2011; Wright, Bohlke and Edelson, 2016). The lack of early diagnosis 
impairs patients’ prognosis and leads to a poor overall 5-year survival rate of around 40%. 
More specifically, the survival rate varies significantly from 85% for early stage disease to 
25% in the advanced stages (Colombo et al., 2006; Lu et al., 2016). Consequently, it could 
be argued that early diagnosis and resistance to chemotherapy are the key obstacles for 
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successful treatment. This review introduces the present status of our understanding of OC 
pathology and treatment. It also offers insights into the potential of the mevalonate pathway 
(MP) as a promising target for therapy.  
 
 
Figure 1-1 The Hallmarks of Cancer reproduced from (Hanahan and Weinberg, 2011) 
 
Figure 1-2 Observed and Projected Age-standardised Incidence Rates, Females, UK 
(Smittenaar et al., 2016). 
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1.1.1. Epidemiology of ovarian cancer 
Ovarian cancer is one of the most devastating diseases worldwide (Scarlett et al., 2012). It 
is the 5th and 7th leading cause of cancer-related mortality and is responsible for the death of 
approximately 4272, 14000 and 151000 patients per annum, in UK, USA and worldwide, 
respectively (Siegel, Naishadham and Jemal, 2013; Siegel, Miller and Jemal, 2015, 2016; 
Berek et al., 2017; Coburn et al., 2017; Kroeger and Drapkin, 2017). In the UK, OC is the 
5th most common cancer and the annual mortality equates to more than half of total newly 
diagnosed cases (7011 patients) each year (Figure 1-3) (Rooth, 2013; Ovarian cancer 
research UK, 2014). Many risk factors have been recognised which can increase the prospect 
of developing OC. 
 
Figure 1-3: Common Causes of Cancer Deaths in female, UK (Ovarian cancer research 
UK, 2014). 
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1.1.1.1. Age 
Age has a significant impact not only on the incidence and prevalence of OC but also on 
survival rate and prognosis. OC is primarily a disease of old age (Chan et al., 2006). The 
crude and age-standardized annual incidences are 20.9 and 16.2 per 100,000 females in UK, 
respectively. The incidence increases from approximately 5 per 100,000 females in the age 
group 30-34 to approximately 15 per 100,000 females in age group 45-49. After menopause, 
the prevalence of OC represents more than 80% of all diagnosed cases and the incidence 
increases abruptly, reaching a plateau at 69 per 100,000 for female age group 80-84 (Figure 
1-4) (Maas et al., 2005; Ovarian cancer research UK, 2014). 
 
Figure 1-4: Average number of new cases every year and age-specific incidence rates 
of ovarian cancer in UK, 2012-2014 (Cancer research UK, 2017). 
Survival rate of OC patients is inversely influenced by the age. The five-year survival rate 
declines from around 85% for age group 15-39 to less than 30% in the age group over 70 
year (Figure 1-5). In addition, age seems to be prognostic factor for OC treatment. Younger 
women with the disease exhibit better prognosis in comparison to old age women (Maas et 
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al., 2005; Ng, Low and Ilancheran, 2012). The accumulation of somatic mutations during 
lifetime is likely to contribute to the development of OC (Rooth, 2013). For instance, TP53, 
BRCA1, NF1 and CHK2 mutations was more frequently detected in older women with serous 
OC (Encinas et al., 2015). In addition, there is a dramatic increase in the loss of 
heterozygosity of chromosome 17, an event strongly linked to OC, with age reaching 80% 
in the 60-69 years’ group. Therefore, age is considered the most significant risk factor of 
cancer (Pieretti and Turker, 1997). 
 
Figure 1-5: Five-year survival rates of ovarian cancer by age. England 2009-2013 
(Cancer Research UK, 2017). 
 
1.1.1.2. Geographical factors  
There is a considerable variation in the incidence and mortality of OC according to 
geographical location (Figure 1-6). Generally, the incidence is high in Europe and USA 
(developed countries; 9.9 per 100,000) in comparison to Africa and Asia (less developing 
country; 5 per 100,000) (Hennessy, Coleman and Markman, 2009; Bharwani, Reznek and 
Rockall, 2011). In Europe, the incidence varies greatly in different regions and these 
disparities might achieve 40%, with peak incidence noted in Eastern and Northern Europe, 
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but lower incidence in Southern and Western Europe. For example, Lithuania, Latvia and 
Bulgaria had the highest incidence rate (approximately 19 per 100,000). In contrast, Portugal 
and Cyprus were had the lowest rate (7 per 100,000) (Cancer research UK, 2017). In 
addition, the incidence of OC in United States and the United Kingdom is 3–7 times greater 
than in Japan (Berek et al., 2017). The incidence is generally lower in countries with 
Hispanic, Asian and African women (Asia, Africa, Mexico) than predominantly Caucasian 
population countries (Europe, Canada). The reduced life expectancy in less developed 
countries may explain the low incidence, because OC is more prevalent in older women. In 
addition, race, social habits, life style and environmental factors might influence the national 
incidences variation (Chornokur et al., 2013; Lowe et al., 2013; Coburn et al., 2017). 
 
Figure 1-6: Incidence of ovarian cancer in different region worldwide (Reproduced with 
permission from (Chornokur et al., 2013)). NZ: New Zealand; S.E.: South-Eastern; S.C.: South-
Central.  
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1.1.1.3. Reproductive factors 
Several reproductive factors have a potential effect on the risk of OC. Multi-parity and the 
use of oral contraceptive pills for 5 years or more are established protective factors 
(Tworoger et al., 2007; Beral et al., 2008; Tsilidis et al., 2011). Epidemiological studies 
show that the relative risk of OC is inversely related to the number of children and to duration 
of use of oral contraceptive pills (Table 1-1). In addition, some studies illustrate that the risk 
decreased even in case of incomplete pregnancies. The evidence for breast feeding having a 
protective power are conflicting but feeding for more than 18 months has been shown to 
decrease the risk of OC by up to 30% (Jordan et al., 2010, 2012; Pasalich et al., 2013; Ferris 
et al., 2014). Recently, a meta-analysis emphasised the protective role of tubal ligation 
against OC (Cibula et al., 2011).  
Table 1-1 Relative risk of ovarian cancer by parity and duration of oral contraceptive 
use (Cancer research UK, 2017). 
Relative risk for 
OC by parity 
Number of children  Relative risk  
3+  1 
2  1.21 
1  1.60 
0  2.12 
Relative risk for 
OC by duration of 
oral contraceptive 
use (mean) 
Oral contraceptive use  Relative risk 
Never  1.0 
Less than 1 year (0.4 years)  1.0 
1-4 years (2.4 years)  0.78 
5-9 years (6.8 years)  0.64 
10-14 years (11.16 years)  0.56 
15 years or more (18.3 years)  0.42 
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In contrast to the protective factors, infertility and null-parity are assumed to raise the risk 
of OC by increasing the rate of exposure to ovulation. However, there are controversial data 
about in-vitro fertilization; some authors state that there is no association while other show 
there is increased risk of OC in women undergoing in-vitro fertilization (Le et al., 2012; 
Stewart et al., 2013). Endometriosis, which is the growth of endometrium tissue in other 
parts of the body, is also linked with an elevated risk of OC (Stewart et al., 2013; Wang et 
al., 2013). Progesterone, which is raised during pregnancy or supplied by oral 
contraceptives, might have a role in clearing the transformed epithelial cells from the ovarian 
surface (Smith and Xu, 2008). In summary it appears that factors associated with a reduced 
the frequency of ovulation might have a protective effect against OC. 
1.1.1.4. Genetic factors  
Inherited and somatic mutations are associated with an elevated risk of OC (Bast, Hennessy 
and Mills, 2009). Women with a family history (i.e. sister, daughter, and mother) of OC have 
a three-fold increased risk of developing OC (Schorge et al., 2010). Inherited mutations in 
genes such as BRCA1 and BRCA2 and DNA mismatch repair are reported to influence the 
risk of OC (Levy-Lahad and Friedman, 2007).  
BRCA1 or BRCA2 germline mutation account for 90% of inherited OC (Schorge et al., 
2010). However, only 10-15% of women with mutation in BRCA genes develop OC 
(Hennessy, Coleman and Markman, 2009). The lifetime risk of OC is 2% among UK women 
(Sasieni et al., 2011; Cancer research UK, 2017) but the cumulative risk is amplified to 30-
60% in woman with BRCA1 and 15-30% in woman with BRCA2 mutations and a family 
history of breast or OC (Gayther and Pharoah, 2010).  Furthermore,  woman whose family 
suffer from Lynch II syndrome, a hereditary nonpolyposis colorectal malignancy, have a 7% 
chance to develop OC (Bast, Hennessy and Mills, 2009). Genetic and non-genetic factors 
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within families might be the cause of familial aggregation of cancer. However, twin studies 
had suggested the importance of inherited mutation (Gayther and Pharoah, 2010).  
On the other hand, somatic mutations also contribute to the development of OC. The most 
common somatic mutations noted in epithelial OC include TP53, a tumour suppressor gene, 
and K-Ras (11%) and B-Raf (0.5%), signalling molecules. TP53 mutation is observed in 50-
80% of advanced OC. p53 controls the function of many genes involved in DNA repair, cell 
cycle arrest, programmed cell death and differentiation of damaged cells (Despierre et al., 
2010; Bell et al., 2011).  
Other factors that might contribute to OC risk are summarized below (Table 1-2). The key 
documented factors influencing OC risk, such as age, oral contraceptive use and parity, offer 
limited potential for alteration to reduce the incidence of OC. Therefore, factors such as 
hormone replacement therapy and breast feeding might of particular importance (Banks, 
2001). 
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Table 1-2 Summary of some factors influence ovarian cancer risk 
Factors Risk of OC Mechanism References 
Hormone 
replacement 
therapy 
Long term 
use increase 
the risk of 
OC 
Oestrogen might stimulate 
proliferation of ovarian cells  
(Beral et al., 2007; 
Zhou et al., 2008) 
Smoking Increase the 
risk of 
mucinous OC 
Unknown mechanism (Jordan et al., 2006; 
Tworoger et al., 2008) 
Physical 
activity 
Decrease the 
risk of OC 
Reducing oestrogens level, and 
decreasing the occurrence of 
ovulation, and subsequently 
exposure to progesterone in the 
luteal phase of the cycle 
(Chiaffarino et al., 
2007) 
BMI Increase the 
risk of OC 
Adiposity provoke the 
production of endogenous sex 
steroid hormones 
(Olsen et al., 2007) 
NSAID  No 
association, 
or decrease 
the risk have 
been reported  
possibly through the inhibition 
of prostaglandin synthesis, 
which in turn involved in 
promoting cell proliferation and 
inhibiting apoptosis 
(Pinheiro et al., 2009; 
Murphy et al., 2012) 
Hysterectomy Decrease the 
risk of OC 
Several factors have been 
postulated such as reducing 
growth factors, blood supply, 
anovulation and blocking of 
access of carcinogens to ovary 
(Chiaffarino et al., 
2005) 
Talcum 
powder and 
asbestos 
Increase the 
risk of OC 
 
Damage to epithelial cells 
which might induce 
inflammation 
(Schorge et al., 2010; 
Camargo et al., 2011; 
Lowe et al., 2013) 
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1.1.2. Classification of ovarian cancer 
Ovarian cancer is a heterogeneous disease (Domcke et al., 2013; Kroeger and Drapkin, 
2017). The World Health Organization classified OC based on histogenesis of the normal 
ovary, indicating the tissue the tumours appear to be derived from such as epithelial tumour, 
germ cell tumour, sex cord-stromal tumour (Kaku et al., 2003). It has been proposed that 
90% of primary malignant OC arise from either the epithelial surface of the ovary or the 
inclusion cysts or the mullerian system (Cho and Shih, 2009). However, there is a growing 
body of evidence which supports the theory that the primary site of origin of OC may not be 
the epithelial cells of the ovaries. Ovarian epithelial cancers share common characteristics 
that are similar to the cells lining the fallopian tube, endometrium and endocervix, and which 
have an embryological site of origin, the mullerian ducts, that is distinct from that of the 
ovary (Dubeau, 2008). This has raised the possibility that OC may originate in the fallopian 
tube (George, Garcia and Slomovitz, 2016). 
Epithelial OC is categorised into serous (60%), mucinous (12-15%), endometrioid (20-25%) 
and clear cell tumour (4-12%). The majority of serous ovarian carcinoma (90%) are high 
grade serous OC. Other less frequent histological type includes Brenner, mixed epithelial 
type, and undifferentiated carcinomas (Wang et al., 2005; Kroeger and Drapkin, 2017). Each 
subdivision might be further divided according to their behaviour into benign, border line 
(Low malignant potential) and malignant tumour (Mok et al., 2007); or depending on the 
morphological characteristics of the tumour into papillary, glandular and solid tumour 
(Soslow, 2008). 
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1.1.3. Staging of ovarian cancer  
In the absence of metastasis, histological conformation and accurate staging of OC is vital 
for determination of a prognosis and treatment strategy. It is usually done during surgery. 
The International Federation of Gynaecological Oncology (FIGO) developed a system for 
classification of OC. The system classifies OC into four major stages. Each stage is divided 
into sub-stages that reflect certain clinical, pathological, or biological prognostic factors 
(Table 1-3) (Colombo et al., 2006; Decruze and Kirwan, 2006). The stages reflect 
dissemination of the disease from the ovaries into the pelvis, peritoneal cavity and then the 
rest of the body. 
1.1.4. Signs, symptoms and diagnosis  
Ovarian cancer has been described as a silent killer because the symptoms do not commence 
until the late stage of the disease (Goff et al., 2007). The clinical presentation associated with 
OC might be not specific, vague, and usually have a common characteristic with other 
abdominal and gastrointestinal disorder (Goff et al., 2007; Lanceley et al., 2011). The 
majority of the patients are diagnosed at an advanced stage. Despite this, the OC patients 
might have discomfort for several months before diagnosis (Goff et al., 2004), but most of 
the patients symptoms go unreported and unrecognised by the primary clinical care. 
Furthermore, half of the women with OC are not referred to gynaecological cancer clinics 
(Vine et al., 2003). Doctors and patients must be alert to any symptoms to prevent any delay 
in diagnosis (Goff, 2012). The most frequently encountered symptoms with OC are listed 
below (Table 1-4).  
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Table 1-3 FIGO staging of ovarian cancer stage (Berek, et al., 2012) 
Stages Description  
I Tumour confined to ovaries 
IA Growth limited to one ovary; no ascites. No tumour on the external surface; 
capsule intact 
IB Growth limited to both ovaries; no ascites. No tumour on the external 
surfaces; capsules intact 
IC Tumour either Stage IA or IB, but with tumour on surface of one or both 
ovaries, or with capsule ruptured, or with ascites, or with positive peritoneal 
washings 
II Tumour comprising one or both ovaries with pelvic extension 
IIA Extension and/or metastases to the uterus and/or tubes 
IIB Extension to other pelvic tissues 
IIC Tumour either Stage IIA or IIB, but with tumour on surface of one or both 
ovaries, or with capsule(s) ruptured, or with ascites present containing 
malignant cells, or with positive peritoneal washings 
III 
 
 
Tumour involving one or both ovaries with histologically conﬁrmed 
peritoneal implants outside the pelvis and/or positive regional lymph nodes. 
Superﬁcial liver metastases equal Stage III. Tumour is limited to the true 
pelvis, but with histologically proven malignant extension to small bowel or 
omentum  
IIIA 
 
Tumour grossly limited to the true pelvis, with negative nodes, but with 
histologically conﬁrmed microscopic seeding of abdominal peritoneal 
surfaces, or histologic proven extension to small bowel or mesentery 
IIIB Tumour of one or both ovaries with histologically conﬁrmed implants, 
peritoneal metastasis of abdominal peritoneal surfaces, none exceeding 2 cm 
in diameter; nodes are negative 
IIIC 
 
Peritoneal metastasis beyond the pelvis >2 cm in diameter and/or positive 
regional lymph nodes 
IV Growth involving one or both ovaries with distant metastases. If pleural 
effusion is present, there must be positive cytology to allot a case to Stage IV. 
Parenchymal liver metastasis equals Stage IVa.  
 
Chapter One | Introduction 
15 
Table 1-4 Ovarian cancer symptoms and their frequency (Goff, et al., 2000) 
Symptom Frequency (% of patients) 
Increased abdominal size 61 
Abdominal Bloating 57 
Fatigue 47 
Abdominal pain 36 
Indigestion 31 
Urinary frequency 27 
Pelvic pain 26 
Constipation 25 
Urinary incontinence 24 
Back pain 23 
Pain with intercourse 17 
Unable to eat normally 16 
Palpable mass 14 
Vaginal bleeding 13 
Weight loss 11 
Nausea 9 
Bleeding with intercourse 3 
Diarrhoea 1 
Deep venous thrombosis 1 
None 5 
 
The confirmation of OC diagnosis is only made by histological analysis of a specimen during 
surgery. However, the urgent referral of suspected cases of OC to the diagnostic centre is 
required. In 1990, Jacobs, et al. established the risk of malignancy index (RMI), which 
combines the result of three independently associated variables to predict the likelihood of 
ovarian malignancy (CA125 blood level, ultrasound examination and menopausal status) to 
overcome the limitation of the ultrasound and CA125 alone. This also facilitates the referral 
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of the suspected patients to gynaecological oncologist (Jacobs et al., 1990; Cancer research 
UK, 2017).  
Carbohydrate antigen 125 (CA125) is a tumour marker for screening, diagnosis, and 
therapeutic  monitoring in OC (Felder et al., 2014). It was first discovered by Bast, Knapp, 
and colleagues (Bast et al., 1981) in 1981 and is also known as MUC16. CA125 is a 22,000 
amino acids protein encoded by MUC16 gene and it is a cell surface transmembrane 
glycoprotein which can be released extracellularly by proteolytic cleavage into body fluids 
such as blood and ascites (Bafna, Kaur and Batra, 2010). In addition, It is expressed by 
epithelial cells in endocervix, endometrium and fallopian tube to protect the luminal surface 
from physical stress (Hung et al., 2013). Elevated levels of CA125 were reported in 90% of 
women with advanced stage OC, but in only 50% of patient at early stage of OC (Gupta and 
Lis, 2009). Finally, utilizing CA125 in diagnosis of OC in the general population is 
complicated by its increase in other conditions such as endometriosis and ovarian cyst 
(Asher, Hammond and Duncan, 2010; Lutz et al., 2011; Babic et al., 2017). 
Human Epididymis protein 4 (HE4) is new cancer specific biomarker which has a relatively 
high sensitivity to detect OC and its expression in non-gynaecological cancers had not been 
observed (Li et al., 2009). The physiological role of HE4, which is encoded by the gene 
WFDC2, has not been identified. However, HE4 protein is upregulated in ovarian 
malignancies compared to benign OC and other type of  carcinomas (Chung et al., 2013; 
Steffensen et al., 2016). Several studies have recognized HE4 level is upregulated in cases 
where CA125 level is not elevated, so HE4 can be used as complementary biomarker for OC 
(Montagnana et al., 2009; Moore et al., 2009; Steffensen et al., 2011). Lastly, improved 
imaging techniques have been employed to diagnose cancerous tissue and angiogenesis at 
an early stages of the disease (Fleischer et al., 2012). 
Chapter One | Introduction 
17 
1.1.5. Aetiology of ovarian cancer 
There are several theories that explain the aetiology of OC. The earlier theories, incessant 
ovulation, gonadotropin and pelvic contamination theories, were based on the 
epidemiological data. Recently, the dualistic theory had connected the anatomical and 
molecular genetic with OC aetiology. The details anatomy and biology of the ovary in Figure 
1-7 
 
Figure 1-7 Anatomy and biology of the ovary, fallopian tube and uterus  
(a) The fallopian tube is responsible for fluid synthesis and egg transportation which is supported by 
muscular contraction of the tube wall. The fallopian tube comprises two principal types of epithelial 
cell secretory cells and ciliated cells. The small basally-situated cells stand for recently described 
epithelial stem and/or progenitor cells. In addition, immune surveillance plays an important role 
through the presence of immune cells in the epithelium and stromal tissue. 
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(b) The main cells of the ovarian cortex are ovarian surface epithelium (OSE) (these cells are 
implicated in the repair of ovarian surface after ovulation), stromal cells and follicles at various stages 
of maturation, such as theca cells, granulosa cells and oocytes. Theca cells and granulosa cells 
synthesize androgens and oestrogens, respectively, and support the development of oocyte.  
(c) The endometrium is composed of cells of the endometrial epithelium (EME) and endometrial 
stroma (EMS). These cells respond to systemic and paracrine signals and undergo cyclical changes 
during the menstrual cycle and support the nourishment of the embryo during fertilization and 
implantation. Reprinted with permission from (Karnezis et al., 2017). 
 
1.1.5.1. Incessant ovulation theory 
The incessant ovulation theory, which was proposed by Fathalla more than 40 years ago, 
linked the frequency of ovulation and the increased opportunity of developing ovarian 
malignancy (Fathalla, 1971). This theory is supported by the protective effects of the oral 
contraceptive pills (Fathalla, 2016). It was postulated that frequent injury to the ovarian 
epithelial cells, provoked through ovulation in nulliparous women, as a possible mechanism 
associated with development of OC. As consequence of repeated trauma, it was 
hypothesized that the cells required an increased rate of DNA synthesis and cell proliferation 
to repair the disruption of the epithelial cells. The increased rate of DNA synthesis might 
cause replication errors which trigger cells transformation into malignant or premalignant 
phenotype (Schüler et al., 2013).  
In addition, ovulation is accompanied by production of excessive amount of free radicals 
which might also contribute to DNA damage and hence be a causative factor of cancer 
(Murdoch, 2005). In vitro, it is found that frequent subculture of epithelial cells from the rat 
ovaries induces genetic mutation and malignant transformation (Testa et al., 1994). 
However, a  limitation to this theory is that the populations of the epithelial cells of the ovary 
that are affected by repeated repair would not be the same with each ovulation (Smith and 
Xu, 2003) and the use of the progesterone only contraceptive pills, that does not interrupt 
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ovulation, has the same potential in preventing OC as the combined oral contraceptive 
(Landen, Birrer and Sood, 2008). 
1.1.5.2. Gonadotropin stimulation theory 
The early evidence that led to the gonadotropin theory was the development of OC in rodents 
after oophorectomy caused by excessive gonadotropin stimulation (Schüler et al., 2013). 
Gonadotropin hormones (LH and FSH), that are secreted from the pituitary gland, increase 
the oestrogenic stimulus of the surface epithelial cells of ovary to initiate the ovulation 
process. This stimulation might promote malignant cellular transformation by promoting 
production of oestrogen (Fleming et al., 2006; Smith and Xu, 2008). After ovulation, the 
ruptured follicle becomes a corpus luteum which produces progesterone. Progesterone in 
turn, negatively inhibits gonadotropin levels that surge abruptly after menopause. The 
increment in gonadotropin levels in menopause women might contribute to the increased 
risk of OC, because it fosters the inflammatory milieu that could not induce ovulation. 
(Mertens-Walker, Baxter and Marsh, 2012). It has also been suggested that these hormones 
induce the evolution of OC rather than the causation (Landen, Birrer and Sood, 2008).  
1.1.5.3. Pelvic contamination theory 
The pelvic contamination theory hypothesised that inflammation induced by irritation of the 
peritoneum might be linked to the development of OC (Heintz, Hacker and Lagasse, 1985). 
Inflammation resulting from ovulation or exposure to xenobiotics such as asbestos and talc, 
might influence malignant transformation of ovarian epithelial cells (Mok et al., 2007; 
Camargo et al., 2011). Furthermore, endometriosis and pelvic inflammatory disease 
influence the risk of OC (Murdoch, 2005; Lowe et al., 2013). On the other hand, tubal 
ligation and hysterectomy have been shown to reduce the risk through preventing exposure 
of the ovary to environmental factors (Chiaffarino et al., 2005; Ness et al., 2011). 
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1.1.5.4. Dualistic theory 
The dualistic theory was proposed by Shih and Kurman (Shih and Kurman, 2004) and it is 
based on their idea that ovarian carcinoma might be divided into two distinctive broad 
categories (Figure 1-8) depending on analysis of the molecular pathogenesis of benign, 
borderline and malignant OC. Firstly, type I tumours have low proliferative activity, are less 
sensitive to chemotherapy and composed of  low grade serous, endometrioid, mucinous, 
clear cells and Brenner tumours. Type I carcinomas have distinctive molecular pathogenesis 
such as K-Ras mutation for mucinous and serous tumours and B-Raf for serous tumour and 
β-catenin and PTEN mutation for endometrioid tumours. In contrast, type II tumours, such 
as high grade serous, undifferentiated carcinomas and mixed mesodermal malignancy, 
evolve rapidly, are relatively responsive to chemotherapy, lack conclusive precursor lesions 
and are characterized by frequent TP53 mutation and CCNE1 amplification (Fleming et al., 
2006; Landen, Birrer and Sood, 2008; Kurman and Shih, 2010; Jones and Drapkin, 2013; 
Tang et al., 2017). 
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Figure 1-8  Classification of ovarian cancer according to dualistic theory (Jones and 
Drapkin, 2013). 
1.1.6. Treatment  
In UK, a team of different disciplines work together to manage OC including a 
gynaecological oncologist, pathologist, radiologist and non-surgical oncologist and this has 
improved the patient survival (Guppy, Nathan and Rustin, 2005).  
The management plan of OC is principally dependent on the stage of the disease at diagnosis 
and the patients associated co-morbidity. In the early stages of OC, surgery is considered as 
the cornerstone of the treatment plan and alongside tumour debulking, it also aims to confirm 
the diagnosis and inform optimal staging. Optimal staging includes palpation and careful 
inspection of the peritoneal surfaces with biopsies of suspected foci of cancers (Trimbos et 
al., 2003). Also, the standard surgery management includes bilateral salpingo-
oophorectomy, total hysterectomy, omentectomy, lymphadenectomy and removal of the all 
microscopic lesions (Lécuru et al., 2017). In contrast to the early stage disease, adjuvant 
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chemotherapy is essential in advanced stages OC. However, some cases, such as wide spread 
disease and extensive ascites, neoadjuvant therapy is used prior to surgery (Guppy, Nathan 
and Rustin, 2005). The success of surgery is the most important prognostic factors in the 
management of advanced OC (Agarwal and Kaye, 2003). Although the prognosis for 
patients with early stage OC is better than those with advanced disease, 10-30% of the early 
stage OC patients relapse after surgery and require chemotherapy (Colombo et al., 2006).  
1.1.6.1. Chemotherapy 
The chemotherapeutic schedules of OC treatment have been revised over the last 30 years. 
In the 1970, melphalan was replaced by combination therapy of cyclophosphamide and 
doxorubicin. Cisplatin was added to this combination or to doxorubicin alone in the 1980s. 
At the same time, it was established that carboplatin has approximately equivalent efficacy 
to cisplatin, but with a reduced toxicity profile.  In the late 20th century, it was found that 
paclitaxel is effective in the treatment of relapsed platinum-refractory disease. Currently, 
paclitaxel with either carboplatin or cisplatin used as first line chemotherapy for treatment 
of OC. Generally, the drug combination is given every three weeks for 6 cycles (Agarwal 
and Kaye, 2003). 
1.1.6.1.1. Platinum 
Rosenberg discovered cisplatin during an investigation of the electrical field effect on 
bacterial growth. He found that a small amount of platinum reacted with ammonium chloride 
present in medium to inhibit bacterial cell division. In 1967, cisplatin was shown to have 
anticancer activity by inhibiting the development of sarcoma in mouse tumour model 
(Rosenberg, 1985). The clinical applications of cisplatin include testicular, bladder and OC. 
It is also used for osteogenic sarcoma, head and neck cancer, endometrial and cervical cancer 
and non-small cell lung cancer (Reedijk, 1987; Pabla and Dong, 2008; Ahmad, 2010).  
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Platinum’s effect is mediated by aqueous hydrolysis of the drug inside the cell to form active 
species (Agarwal and Kaye, 2003). The cytotoxic effects of platinum complexes are 
mediated via the formation of DNA inter-strand cross links or intra-strand DNA cross links, 
mostly at N7 position of guanine and possible at N3 position of adenine and O6 position of 
cytosine, chelation of the O-atoms and N-atoms of guanine and lastly by cross linking of 
DNA to protein (Katzung, Masters and Trevor, 2012). Binding of platinum to DNA inhibits 
DNA replication and protein synthesis that eventually leads to cancer cell apoptosis (Ahmad, 
2010). The frequently encountered adverse effects of cisplatin are nausea, vomiting, bone 
marrow toxicity, neurotoxicity and nephrotoxicity (Reedijk, 1987; Pabla and Dong, 2008).  
Carboplatin has replaced cisplatin in many chemotherapeutic combination regimens. It has 
a similar pharmacological profile with the advantage of substantially less renal and 
gastrointestinal adverse effects. However, its main adverse effect remains bone marrow 
suppression. In addition, the third generation platinum analogue, oxaliplatin, has similar 
pharmacological activities as carboplatin and cisplatin, but with advantages of additive 
activities against the resistant tumours than the older generations of platinum (Katzung, 
Masters and Trevor, 2012). 
1.1.6.1.2. Paclitaxel 
Taxanes (paclitaxel and docetaxel) are either derived from natural sources or by 
semisynthetic processes. Paclitaxel, an ester alkaloid, was first derived from the Pacific yew 
(Taxus brevifolia) and the European yew (Taxus baccata). Docetaxel, a semisynthetic 
taxane, exhibits less neurotoxicity than paclitaxel. Both drugs act by interfering with the 
normal as well cancer cell mitosis through binding to the β-subunit of tubulin and 
consequently leads to the stabilization of the microtubules and cell cycle arrest (Harries and 
Gore, 2002). Furthermore, taxanes induce apoptosis and have anti-angiogenic properties 
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(Crown and O’Leary, 2000). Paclitaxel is effective in ovarian, advanced breast, non-small 
cell and small cell lung, head and neck, oesophageal, prostate, and bladder cancers. The 
adverse effects of taxane include hypersensitivity, neurotoxicity, bone marrow suppression, 
neutropenia and fluid retention (Katzung, Masters and Trevor, 2012). 
1.1.6.1.3. Pegylated liposomal doxorubicin 
Doxorubicin is a member of the anthracyclin antibiotics family that was isolated from 
Streptomyces peucetius var caesius. Four major mechanisms for the cytotoxic effect of 
doxorubicin have been proposed:(1) topoisomerase II inhibition; (2) blockade of the 
synthesis of DNA and RNA due to inter-chelation into DNA; (3) free radicals production 
via an enzyme-mediated reductive process; (4) changing the fluidity of cellular membrane 
and influencing ion transport (Katzung, Masters and Trevor, 2012).  
Doxorubicin has also been encapsulated in liposomes with a layer of polyethylene glycol to 
produce pegylated liposomal doxorubicin (PLD). The pegylation process improves the 
pharmacokinetic and toxicological properties of the drug and aids in drug delivery to the 
tumour (Thigpen et al., 2005; Shen et al., 2010). PLD has been shown to be useful in 
treatment of relapsed OC (Oskay-Oezcelik et al., 2008) as well as in combination with 
cyclophosphamide in platinum-sensitive cancers. The overall response for the combination 
was 31% and the overall survival was 8.2 months (Floquet et al., 2014).  
1.1.6.1.4. Topotecan  
Topotecan is a semisynthetic analogue of camptothecin. It inhibits the enzyme 
topoisomerase I which participates in key processes during DNA replication, transcription 
and repair mechanism. The enzyme relieves torsional stress by cutting and re-ligating a 
single DNA strand during DNA synthesis. Topoisomerase I binds covalently with DNA to 
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from a complex, and this forms the site of topotecan action. Topotecan stabilizes the complex 
and inhibits  DNA synthesis  (Goff et al., 2007; Lorusso et al., 2010).  
Topotecan is indicated as second line therapy for both platinum-sensitive and platinum 
resistant OC relapsed after platinum-based chemotherapy (Abushahin et al., 2008; Morris et 
al., 2008). Topotecan’s toxicity profile presents less challenges to the oncologist in 
comparison to the doxorubicin and paclitaxel therapy. The adverse effects of topotecan are 
usually short lived, reversible and noncumulative. However, neutropenia, alopecia, 
leukopenia, stomatitis, thrombocytopenia and anaemia are noted in patients using topotecan 
therapy (Dunton et al., 2002). 
1.1.6.1.5. Melphalan 
Melphalan, an alkylating agent which is phenylalanine derivative of nitrogen mustard and 
was initially synthesized in 1953 (Rothbarth, Vahrmeijer and Mulder, 2002). Melphalan 
exerts its cytotoxic effect by inhibiting DNA synthesis through the formation of the intra-
strand and inter-strand cross link and also by causing DNA-protein crosslinks. Cell death is 
usually the result of transfer of melphalan alkyl group to the DNA (Katzung, Masters and 
Trevor, 2012). The major adverse effects of melphalan, especially at large doses, are bone 
marrow suppression including leukopenia and thrombocytopenia and secondary neoplasm 
has also been reported (Rothbarth, Vahrmeijer and Mulder, 2002). Although melphalan was 
first chemotherapeutic agent for the treatment of OC (McGuire and Markman, 2003), it was 
replaced by a combination of cyclophosphamide and doxorubicin (Agarwal and Kaye, 
2003). 
1.1.6.2. Molecularly-targeted therapy 
Molecularly-targeted therapy might be defined as drugs that inhibit the cancerous phenotype 
of tumours by modulating the function of a specific protein or other cellular components. 
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These targets are critical for tumour development and progression and can act as “drivers” 
of carcinogenesis. Examples include c-Kit mutations in gastrointestinal stromal tumours, 
epidermal growth factor receptor mutations in non-small cell lung cancer, HER2 
amplification in breast cancer, and the BCR-ABL translocation in chronic myelogenous 
leukaemia (Ellis and Hicklin, 2009; Huang et al., 2014). Targeted therapy differs from 
traditional chemotherapy by acting selectively on cancer cells and less destructive to normal 
cells. However, the main obstacle to the success of these medications is heterogeneity of the 
cells in tumours and the development of drug resistance (Ellis and Hicklin, 2009).  
1.1.6.2.1. Angiogenesis inhibitors 
Angiogenesis is an essential factor for tumour growth and metastasis. Targeting the 
formation of new blood vessels is a promising strategy in breast, renal and OCs (Weis and 
Cheresh, 2011). The FDA had approved several inhibitors for cancer treatment such as the 
humanized antibody bevacizumab, which binds VEGF-A, the tyrosine kinase inhibitor 
sorafenib, which targets Raf and VEGF and PDGF receptors, and the tyrosine kinase 
inhibitor sunitinib, which targets VEGF and PDGF receptors (Chung, Lee and Ferrara, 
2010). Bevacizumab is a monoclonal antibody directed against vascular endothelial growth 
factor. It displayed substantial single agent activity in OC. However, the 21 % response rate 
was low and the 6-month progression survival rate were less than 50% in platinum-sensitive 
relapsed OC (Burger et al., 2007). Apart from the cost and resistance, hypertension, 
proteinuria, gastrointestinal perforation are the main limitation reported with angiogenesis 
inhibitors (Banerjee and Kaye, 2013).  
A recent  meta-analysis (Y. S. Wu et al., 2017) of 5 clinical trials (Perren et al., 2011; 
Aghajanian et al., 2012; Burger et al., 2012; Pujade-Lauraine et al., 2014; Coleman et al., 
2015)  indicated that bevacizumab combined with traditional chemotherapy significantly 
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prolongs the progression free survival and overall survival in OC patients. It had been 
suggested that these agents are relatively well tolerated and should be considered for further 
study as single agent or in combination with other cytotoxic agents (Banerjee, Bookman and 
Gore, 2011; Burger et al., 2012). The European Medicines Agency approved the use of 
Bevacizumab as first line therapeutic agent in combination with carboplatin and paclitaxel 
for treating advanced stage OC (Sapiezynski et al., 2016). 
1.1.6.2.2. Poly(ADP)Ribose Polymerase (PARP) inhibitors 
PARP enzymes, which was first described over 50 years ago by Mandel, are a family of 
proteins implicated in the regulation of several cellular processes such as DNA-repair, 
inflammation and cell fate. PARP-1, a nuclear enzyme, facilitates DNA repair (mild damage) 
or triggers cell death (severe damage) by binding to both single-stranded and double-
stranded DNA breaks (Wiggans et al., 2015; Meehan and Chen, 2016).  
Therapy directed at DNA repair pathways in OC had gained considerable interest because 
the lifetime risk of OC in women with BRCA mutations is elevated by 39–44% (Banerjee, 
Bookman and Gore, 2011; Shi et al., 2017). PARP inhibitors can kill cancer cells specifically 
by preventing the repair of single strand gaps which may be degenerate into double strand 
breaks in DNA if they encountered by a replication fork. In tumour cells which lack 
functional BRCA genes, replication forks collapse and chromatin breaks leading to loss of 
cell viability (Figure 1-9). However, normal cells which retain single wild type copy of the 
BRCA gene are spared (Farmer et al., 2005). This concept is called synthetic lethality 
because neither PARP inhibitors nor BRCA mutation alone are lethal but the combination 
results in cell death.  
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Figure 1-9 Role of PARP inhibitors in DNA repair and synthetic lethality. 
PARP1 binding to single strand break results in activation of base excision repair. In the presence of 
PARP inhibitors and the lack of DNA repair, DNA replication generates a double strand breaks. In 
homologous recombination deficient cells, the lack of accurate repair of the double strand breaks 
persist resulting in cell death. Reproduced with permission from (Sonnenblick et al., 2014). 
 
1.1.6.2.3. Other signalling molecules 
Several signalling mechanisms are aberrant in ovarian tumours which cause activation of 
oncogenic pathway participating in cell proliferation, angiogenesis, migration and survival. 
Many drugs are under development for targeting cellular changes implicated in malignant 
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transformation such as phosphoinositide 3-kinase/protein kinase B (PI3K/AKT), platelet-
derived growth factor receptor (PDGFR), protein kinase C (PKC) and mitogen-activated 
protein kinase (MAPK). These agents include SF1126 and GSK690693 (PI3 kinase/AKT 
pathway inhibitors), dasatinib (Src inhibitor), sorafenib (Raf and VEGF receptor inhibitor), 
imatinib (PDGFR, c-kit inhibitor), and enzastaurin–LY-31765 (PKC inhibitor). Lastly, 
MORab-003 (Morphotek, Inc.), a monoclonal antibody against the folate receptor which is 
overexpressed in > 90% of OCs, is being evaluated in a phase II trial (Banerjee, Bookman 
and Gore, 2011).  
Preclinical evidence suggests that epidermal growth factor receptor (EGFR) and human 
epidermal growth factor 2 receptor (HER2), tyrosine kinase receptors involved in cell 
proliferation and survival, are potential targets in OC. However, a clinical trial showed that 
the effectiveness of these agents were relatively limited (Teplinsky and Muggia, 2015). 
1.1.7. Cytotoxic drug resistance in ovarian cancer 
Resistance is main obstacle in management of cancer that leads to treatment failure and 
unsatisfactory overall patient survival (Holohan et al., 2013). The response rate to the initial 
treatment of advanced OC is ordinarily high and is successful in 60-80% of patients. 
However, the survival rate has not improved in the last two decades and the 5-year survival 
rate remains as low as 40 % of the total patients (Ling et al., 2005; Kigawa, 2013). The effort 
of incorporation of the newer cytotoxic agents (gemcitabine, liposomal doxorubicin and 
topotecan) to the conventional first line regimen (platinum-taxane) in GOG 182-ICON 5 
study was unsuccessful in improving the overall survival and progression free survival of 
patients with advanced OC after optimal or suboptimal cytoreduction (Bookman et al., 
2009). Therefore, there is a pressing demand to develop new drugs or (re)sensitize cancer 
cells to existing chemotherapy (Witham et al., 2007). 
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Several mechanisms of chemotherapy drug resistance in OC have been suggested, involving 
alterations in drug transport, changes in cellular detoxification, evading the induction of 
apoptosis and increased DNA repair activity (Figure 1-10) (Ling et al., 2005; Kigawa, 2013). 
The potential involvement of multiple resistance mechanisms might contribute to a drug-
resistant phenotype (Witham et al., 2007). 
1.1.7.1. Altered drug flux 
One of the major mechanisms of drug resistance is the decrease in drug accumulation in 
cancer cells by increasing the drug efflux or reducing the uptake or a combination of both 
mechanisms (Tapia and Diaz-Padill, 2013). In 1976, MDR1, which encodes P-gp protein, 
the first member of ATP-binding cassette transporters (ABC) family, was identified 
(Callaghan, Luk and Bebawy, 2014) and represents a major advance in the understanding of 
drug resistance. Generally ABC proteins are efficient large transmembrane pumps involved 
in transport of metabolic products, nutrients, lipids, wide variety of drugs and chemical 
compounds against a concentration gradient (O’Connor, 2007). 
At least eight ABC proteins are recognised in humans to have a role in resistance to cytotoxic 
agents as well as variety of other classes of drugs (Gottesman and Ambudkar, 2001) 
Specifically, P-gp overexpression is implicated not only in chemoresistance and failure of 
chemotherapy but it also associated with poor prognosis in patient with cancers such as OC, 
breast cancer, sarcoma and other malignancies (Ricciardelli et al., 2013). P-gp has been 
reported to decrease intracellular accumulation of platinum-based compounds and other 
cytotoxic drugs and its expression has been shown to correlate with drug resistance. 
Therefore, it is considered as an attractive target to improve the clinical outcome of 
anticancer therapy (Tapia and Diaz-Padill, 2013; Kilari, Guancial and Kim, 2016).  
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Figure 1-10 General principles of drug resistance. 
Drug absorption, distribution, metabolism and elimination control the quantity of drug that reaches 
the tumour. The anticancer activity of a drug can be reduced by: poor drug influx or excessive efflux; 
drug inactivation or lack of activation; alterations in the drug target, such as mutation or changes in 
expression levels; activation of adaptive pro-survival responses; and a lack of cell death induction 
due to dysfunctional apoptosis. Reproduced with permission from (Holohan et al., 2013). 
 
Co-administration of P-gp inhibitors with chemotherapeutic drugs has given mixed results. 
P-gp inhibitors such as Valspodar, might elevate drug plasma concentrations beyond 
acceptable toxicity caused by pharmacokinetic drug interactions which reduce drug 
clearance and metabolism (Fracasso et al., 2001). Yakirevich, et al., (Yakirevich et al., 
2006), studied consecutive sections from 60 patients of ovarian serous carcinoma and 
showed that P-gp is an independent prognostic factor and its expression directly correlated 
with the chemotherapeutic response and was inversely correlated with survival rate.  
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The entry of cisplatin and carboplatin into cancer cells is regulated by copper transporter-1 
(CTR1). This protein is encoded by CTR1 gene and deletion of this gene result in a reduction 
of the intracellular accumulation of cisplatin and ultimately triggers cisplatin resistance in 
various cell line including OC cell lines (Holzer, Manorek and Howell, 2006). In addition, 
ATP7A and ATP7B, copper exporters, have been reported to participate in resistance to 
cisplatin by retaining the drugs in intracellular compartment and blocking their interaction 
with DNA (Samimi et al., 2004). Lastly, overexpression of ATP7A and ATP7B had been 
reported in OC and associated with increased resistance and lower survival rate (Samimi et 
al., 2003). 
1.1.7.2. Increase cellular detoxification  
Glutathione (GSH) is a hydrophilic tripeptide composed of cysteine, glycine and glutamate. 
It is one of the most copious intracellular thiol molecules in cells and  plays a crucial function 
in eliminating the toxicity of various cellular toxins include cisplatin and its analogues 
(Forman, Zhang and Rinna, 2009; Traverso et al., 2013). Cysteine and methionine residues 
have the ability to inactivate the platinum-based drugs by binding to the sulphur atom in 
GSH (Jansen, Brouwer and Reedijk, 2002). This reaction is under the control of the 
glutathione S-transferase and the product is inactive and eliminated from cancer cells  (Wang 
And and Guo, 2007). The role of GSH in acquired and intrinsic drug resistance might be 
explained by increased detoxification and elevated efflux of the cytotoxic drugs (Belotte et 
al., 2014). It has been observed that several tumours with elevated level of GSH might be 
more resistant to chemotherapy (Traverso et al., 2013). It has also been demonstrated that 
acquisition of the resistance to chemotherapy in cell lines derived from OC patients was 
associated with higher levels of GSH and glutathione-dependent enzymes (Lewis, Hayes and 
Wolf, 1988). Therefore, clinical development of a glutathione analog prodrug was initiated 
to reduce intracellular levels of GSH and overcome platinum inactivation. Canfosfamide 
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preferentially targets cancer cells that overexpress glutathione S-transferase. In vitro and in 
vivo antiproliferative activity of canfosfamide on cancer cells with glutathione S-transferase 
overexpression have been shown (Ramsay and Dilda, 2014). In addition, clinical trials 
demonstrated that canfosfamide was well tolerated and improve the clinical outcome when 
combined with standard chemotherapy in relapsed OC and non-small cell lung cancer 
(Sequist et al., 2009; Vergote et al., 2010). 
1.1.7.3. Increased DNA repair activity 
Chemotherapy drug resistance can be mediated by an increase in the capacity of DNA 
damage repair of the cancer cells (Housman et al., 2014). The inter- and intra-strand DNA 
adducts caused by platinum compounds induce cell cycle arrest or apoptosis in cancer cells. 
The cell fate after cytotoxic therapy is dictated by the balance between DNA damage and 
DNA repair (Florea and Büsselberg, 2011). Several DNA repair mechanisms can be 
activated depending on type of lesion inflicted including nucleotide excision repair (NER), 
mismatch repair (MMR), homologous recombination repair (HR) and base excision repair 
(BER) (Torgovnick and Schumacher, 2015).  
NER and MMR are among the well-recognized DNA repair pathways which appear to have 
a crucial function in mediating resistance to the treatment with platinum drug by 
participating in the detection and resolution of cisplatin induced DNA damage. Enhanced 
NER has been shown to be correlated with cisplatin resistance (Torgovnick and Schumacher, 
2015). At least 20 protein involved in the process of NER, the excision of the damaged DNA 
requires dimerization of the excision repair cross-complementing group 1 (ERCC1) with 
xeroderma pigmentosum complementation group F (XPF). The dimerized complex appears 
to play a fundamental role in DNA repair process (Martin, Hamilton and Schilder, 2008; 
Galluzzi et al., 2012).  
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More than 90% of the metastatic testicular cancer is cured by cisplatin. These tumours are 
associated with low levels of the NER proteins (XPA, XPF, ERCC1) and this might explain 
the testicular cell line higher sensitivity to cisplatin therapy in comparison to cell line from 
other tumour (Welsh et al., 2004). However, a GOG study failed to demonstrate an 
association between ERCC1 and platinum sensitivity, overall survival and progression free 
survival in OC patients (Deloia et al., 2012; Rubatt et al., 2012).  
MMR is another mechanism of DNA repair. This mechanism is divided into three steps, 
initiation, excision and resynthesis and involves several proteins including MLH1, MSH2, 
MSH3, MSH6, and PMS2. The marker of the MMR deficiency is microsatellite instability 
which is the occurrence of variable length of unpaired deletions in mono and dinucleotide 
repeats (Helleman et al., 2006). MMR inactivation has been associated with the resistance 
to cisplatin therapy in OC (Vasey, 2003). The MLH1 gene appear to be essential for normal 
physiological function of MMR system (Martin, Hamilton and Schilder, 2008). Cisplatin 
resistance in a significant proportion of OC patients is correlated with MLH silencing 
induced by methylation (Agarwal and Kaye, 2003). 
1.1.7.4. Evasion of apoptosis 
Apoptosis, or programmed cell death, is an irreversible process characterized by chromatin 
condensation, nuclear fragmentation, membrane blebbing and cell shrinkage, and formation 
of apoptotic bodies (Kerr, 2002). The ability to evade programmed cell death is a hallmark 
of the human cancer and is implicated in resistance to chemotherapy (Hanahan and 
Weinberg, 2011).  
The intrinsic apoptotic pathway (Figure 1-11) is regulated by Bcl-2 family proteins and 
includes mitochondrial outer membrane depolarization, release of cytochrome c from the 
mitochondria, apoptosome formation and the subsequent activation of the caspase cascade 
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(Ichim and Tait, 2016). Lethal stimuli induce the interaction of Bid and Bim with Bax and 
Bak inducing their activation and oligomerization in the mitochondrial membrane to form 
pores that allow cytochrome c and other proteins including Smac and Omi to be released 
from the mitochondrial intermembrane space into cytoplasm. Cytochrome c binds to Apaf1 
to form the apoptosome complex which activates caspase-9. In addition, Smac and Omi 
deactivate the IAP proteins, an inhibitors of caspases, to facilitate the commitment of cell 
death (Tait and Green, 2010). 
In the extrinsic apoptotic pathway (Figure 1-11), the initiators are specific transmembrane 
death receptors triggered by their respective ligands. Apoptosis is initiated by the binding of 
death ligands, receptor, adaptor molecules (FADD) and caspase 8 to form the death-inducing 
signalling complex (DISC) (Lavrik, 2014).  This complex triggers a series of events and 
causes activation of effector caspases and cell death (Ichim and Tait, 2016). The death 
receptor family is a main inducer of the pathway and include FAS (also named CD95 /APO-
1), TNF-R1, TRAIL-R1,TRAIL-R2, DR3 and DR6 (Lavrik, 2014).  
Many proteins are involved in apoptosis pathway regulation, which are tumour suppressor 
genes (such as TP53), oncogenes (such as Ras and Akt) and apoptotic machinery proteins 
(Bcl-2 Family) (Agarwal and Kaye, 2003). An increase in the anti-apoptotic proteins and/or 
reduction of the pro-apoptotic molecules can be a major cause of cancer cell resistance to 
cell death signals and consequently this may lead to tumour progression and development of 
clinical drug resistance (Fulda, 2009). Chemotherapeutic drug resistance has been correlated 
with expression of anti-apoptotic proteins (Bcl-2 and Bcl-XL) and the caspase inhibitor, X-
linked inhibitor of apoptosis protein (XIAP) in OC cell lines (Yang et al., 2004, 2005; 
Williams et al., 2005).  
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Figure 1-11 Extrinsic and intrinsic apoptotic signalling pathways  
In the extrinsic apoptotic pathway, the stimulation of death receptor by ligand can activate initiator 
caspases (caspase 8 and caspase 10) by dimerization mediated by adaptor proteins (FAS-associated 
death domain protein (FADD)). The effector caspase 3, 7 is activated by caspase 8 and 10 which 
eventually lead to apoptosis induction. The intrinsic (or mitochondrial) pathway of apoptosis is more 
complicated than the extrinsic pathway and needs mitochondrial outer membrane permeabilization 
(MOMP). BAX and BAK activation process triggered by cell stress activation of BH only protein 
stimulation leading to MOMP. However, Bcl-2 family proteins counteract this process. 
Subsequently, cytochrome c and mitochondria-derived activator of caspases (SMAC) released from 
the mitochondrial intermembrane space into cytosol. SMAC release facilitates apoptosis by opposing 
the caspase inhibitor X-linked inhibitor of apoptosis protein (XIAP). Triggering of apoptosome 
formation by interaction of cytochrome C with apoptotic protease activating factor 1 (APAF1) lead 
to activation of caspase cascade and finally induction of cell death. Caspase-8 cleavage of the 
BH3-only protein BH3-interacting death domain agonist (BID) allows crosstalk of the extrinsic and 
intrinsic apoptotic pathways. ER, endoplasmic reticulum; MCL1, myeloid cell leukaemia 1; tBID, 
truncated BID. Reproduced with permission form (Ichim and Tait, 2016).  
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1.2. Mevalonate pathway 
The diversity of the products of the mevalonate pathway (MP) and their biological activity 
provides an insight into the importance of this pathway  in health and disease (Burg and 
Espenshade, 2011; Ghavami et al., 2017). The cornucopias products of MP, about 30,000 
compounds identified to date and many new chemical structures being described annually, 
are involved in crucial functions necessary for life. For instance, dolichol, ubiquinone, heme 
A, vitamin D, cholesterol, bile acid and steroids are some products of the pathway. These 
metabolites play a fundamental role as  mating pheromones, in reproductive hormones 
synthesis, membrane structure and signal transduction (Sacchettini and Poulter, 1997; 
Osmak, 2012; Dhar, Koul and Kaul, 2013; Likus et al., 2016). In particular the, MP 
intermediate metabolites regulate diverse cellular functions by controlling the function of 
small GTPases proteins (Mullen et al., 2016; Brandi et al., 2017). Disruption in the MP has 
been associated with a number of disorders such as autoinflammatory disease and 
atherosclerosis (Thurnher, Gruenbacher and Nussbaumer, 2013). 
1.2.1. Biochemistry of mevalonate pathway 
The MP can be divided into three main stages. The 20 enzymes of the MP catalyse the 
biochemical reactions which culminate in the formation of the 27 carbon atom structure of 
tetracyclic molecule, cholesterol (Figure 1-12) (Burg and Espenshade, 2011). 
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Figure 1-12: Mevalonate pathway. 
The figure shows the details of the mevalonate pathway biosynthesis. The pathway started by 
condensation of Acetyl-CoA to HMG-CoA, which in turn reduced to Mevalonate. The later product 
is decarboxylated to isopentenyl which involve in synthesis of other intermediate metabolite of the 
pathway. It also shows some of the inhibitors of pathway enzymes such as statins and 
bisphosphonates. HMGCS, Hydroxymethylglutaryl-CoA synthase; HMGCR, 3-Hydroxy-3-
Methylglutaryl-CoA Reductase; GGT-I, geranylgeranyl transferase-I; GGT-II, geranylgeranyl 
transferase-II. 
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The first stage of mevalonate biosynthesis pathway occurs in the cytoplasm while the 
remaining stages take place in the endoplasmic reticulum. In the first stage, acetyl-CoA, 
derived from carbohydrate, amino acid and fatty acid metabolism, supplies two carbon atoms 
for conversion by condensation reactions into the six carbon atom compound 3-hydroxy-3-
methyl-glutarate conjugated to coenzyme A (HMG-CoA). The condensation reaction is 
catalysed by Acetyl-CoA thiolase and HMG-CoA synthase (HMGCS). Further reduction of 
HMG-CoA produces mevalonate and this reaction is catalysed by the enzyme HMG-CoA 
reductase (HMGCR) and is considered the rate limiting step of the MP. HMGCR is 
extensively regulated at multiple levels of transcription, translation and degradation. 
The second stage, which is considered as a branching step leading to the synthesis of many 
intermediate metabolites, involves phosphorylation and decarboxylation of the mevalonate 
molecules to yield isopentenyl pyrophosphate via the action of the mevalonate kinase and 
mevalonate decarboxylase. This molecule is a fundamental precursor to many biological 
compounds required by animals and plant cells. Subsequently, farnesyl pyrophosphate (FPP) 
is produced from the condensation of three isopentenyl moieties (isopentenyl pyrophosphate 
and dimethyl allyl pyrophosphate) in a reaction catalysed by farnesyl synthase. Next, 
geranylgeranyl pyrophosphate synthase (GGPPS) catalyses the addition of isopentenyl 
moiety to farnesyl pyrophosphate to yield geranylgeranyl pyrophosphate (GGPP).  
In the third stage, squalene synthase facilitates the condensation of two molecules of FPP to 
produce squalene, a 30-carbon atom compound with a half dozen double bonds. Finally, 
cholesterol, “the most highly decorated small molecule in biology”, is synthesised from 
lanosterol by three decarboxylation reactions  (Hooff et al., 2010; Burg and Espenshade, 
2011; Berg, Tymoczko and Stryer, 2013; Dhar, Koul and Kaul, 2013; Nelson and Cox, 2013; 
Likus et al., 2016). 
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1.2.2. Regulation of mevalonate pathway 
The MP is precisely regulated at multiple levels (Goldstein and Brown, 1990; Likus et al., 
2016).  This is not surprising because cholesterol synthesis requires carbon atoms and large 
amount of energy (ATP) expenditure. The balance of cholesterol synthesis is maintained by 
controlling both cholesterol synthesis and uptake in which the cholesterol itself is the main 
mediator of this regulation. Cholesterol synthesis is also regulated by negative feedback 
inhibition of HMGCR, since a high intracellular concentration is toxic and associated with 
several disorders (Sharpe and Brown, 2013).  
Cholesterol is mainly produced by the liver and transported to other tissue via low-density 
lipoproteins. This lipoprotein in turn reduces the activity of HMGCR to 10% which is only 
required to maintain production of non-sterols by the MP (Likus et al., 2016). Indeed, 
HMGCR activity is regulated not only by cholesterol concentration but also by other 
intracellular factors (sterol and non-sterol products of the MP) and extracellular factors 
(insulin, tri-iodothyronin, glucagon and cortisol) (Räikkönen et al., 2009; Burg and 
Espenshade, 2011).   
HMGCR is one of the most tightly controlled enzymes in human body and its activity 
regulated by several mechanisms (Goldstein, DeBose-Boyd and Brown, 2006; DeBose-
Boyd, 2008; Kamisuki et al., 2009; Sato, 2010; Burg and Espenshade, 2011; Berg, 
Tymoczko and Stryer, 2013; Spann and Glass, 2013; Luu, Gelissen and Brown, 2017): Sterol 
Regulatory Element Binding Protein (SREBP), a transcription factor that regulates the rate 
of HMGCR expression, acts on sterol response element (SRE), a short sequence of 
nucleotides in the reductase gene, to initiate gene transcription (Figure 1-13). There are three 
mammalian SREBP isoforms (SREBP-1a, SREBP-1c and SREBP-2) which are encoded by 
SREBF1 and SREBF2 genes. They have distinct but overlapping lipogenic transcriptional 
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function. SREBP-1a activates fatty acid and cholesterol biosynthesis, SREBP-1c enhance 
fatty acid biosynthesis, and SREBP-2 regulate cholesterol biosynthesis and uptake (Shao and 
Espenshade, 2012).  
 
Figure 1-13 Regulation of cholesterol synthesis. 
Cholesterol level controls the rate of HMGCR and LDL-R expression. Insulin-induced gene (Insig); 
sterol response element- binding proteins (SREBP); SREBP cleavage-activating protein (SCAP); 
endoplasmic reticulum (ER); site 1 protease (S1P); site 2 protease (S2P); helix–loop–helix domain 
of SREBP (HLH); sterol regulator element (SRE). Reproduced with permission from (Cyster et al., 
2014). 
In low cholesterol conditions, SREBP cleavage-activating protein (SCAP) escorts SREBP 
in small membrane vesicles to the Golgi apparatus. Activation of the SREBP requires the 
activity of two proteolytic enzymes, namely S1P and S2P. The first protease enables the 
dissociation from SCAP and the second one permits the cleavage and release of SREBP from 
the vesicles membrane. The amino-terminal domain, containing a basic helix-loop-helix 
(HLH) transcription factor, is transported to the nucleus and binds to SRE in target genes 
encoding proteins required for cholesterol synthesis (HMGCR) and uptake (LDL receptor) 
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which results in their transcriptional activation. At the same time, LXR-RXR transcription 
factor heterodimers recruit corepressor complexes and actively repress genes encoding 
molecules that facilitate cholesterol efflux, such as ABCA1, and decrease degradation of the 
LDL receptor which result in higher cellular concentrations of cholesterol.  
In contrast, during high intracellular levels of cholesterol, cholesterol and desmosterol cause 
retention of SCAP-SREBP by binding to SCAP. This induces conformational change in 
SCAP which in turn facilitate its binding to another ER protein called Insig. This protein 
prevents the release of SCAP-SREBP complex from the ER.  The proteolytic activity of the 
S1P and S2P enzymes is blocked and SREBP nuclear translocation is prevented. Oxysterols 
and desmosterol bind to LXRs, which causes dissociation of corepressors and recruitment 
of coactivators that induce the transcription of target genes, such as those encoding ABCA1 
which cause lower cellular concentrations of cholesterol. 
In addition to sterol regulation of HMGCR expression, its turnover is also regulated. 
HMGCR comprises 2 domains, the cytoplasmic domain which provides the catalytic activity 
of the enzyme and membrane domain which senses the signals from outside that participate 
in the regulation of reductase degradation. Lanosterol and 25-hydroxycholesterol trigger 
conformational changes of the reductase membrane domain that permits the binding to a 
subset of Insig proteins and ubiquitination of HMGCR. Degradation of the reductase is a 
result of polyubiquitination and dissociation from membrane. 
Lastly, phosphorylation also regulates the reductase enzyme. At low level of ATP, AMP-
protein kinase phosphorylates the reductase enzyme and consequently inhibits cholesterol 
synthesis (Figure 1-14). 
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Figure 1-14 Regulation of HMGCR.  
The HMGCR level is regulated by multiple mechanisms. The left figure shows the process of the 
HMGCR degradation by high cholesterol level. The right figure shows the changes in the HMGCR 
status between active and inactive state by AMPK and HMGCR phosphatase. Reproduced with 
permission form (DeBose-Boyd, 2008). 
 
1.2.3. Deregulation of the mevalonate pathway in cancer  
Deregulation of MP was first reported around 50 years ago in mouse hepatomas (Siperstein 
and Fagan, 1964). Several reports suggest that HMG-CoA reductase play an important role 
in human cancer. Many cancers have been shown to exhibit either increased expression and 
activity of HMGCR or deficient feedback control of the HMG-CoA reductase activity 
(Clendening et al., 2010). The increase cholesterol synthesis may depend on the availability 
of MP precursors such as acetyl-CoA (Cruz et al., 2013).  Cancer cells require de novo lipid 
synthesis for growth. It has been found that increased lipid synthesis participates in the 
pathogenesis of cancer, including ovarian neoplasm (Pyragius et al., 2013). The earliest 
evaluation  the of MP in  cancer was by Fumagalli et al., (1964) (Fumagalli et al., 1964) who 
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reported that human glioblastomas cells synthesize large quantities of cholesterol. In 
addition, the failure of the pathway’s negative feedback inhibition in mouse hepatoma cells 
was reported at the same time by Siperstein and Fagan (Siperstein and Fagan, 1964). 
Furthermore, it has been shown that exogenous mevalonate administration promotes tumour 
growth in xenograft-bearing mice (Duncan, El-Sohemy and Archer, 2004). 
HMGCR is considered as metabolic oncogene as the ectopic expression of full length 
HMGCR increases anchorage dependent growth of cells and cooperates with Ras to 
transform cells (Clendening et al. 2010). The expression of SREBP-2, a transcription factor 
that regulates several MP genes, correlated with viability of prostate tumour cells (Krycer, 
Phan and Brown, 2012). In addition, it was reported that 40% of genes of the MP are either 
amplified or show increased expression (Bell et al., 2011). In contrast, overexpression of 
HMGCR has been correlated with prognosis in ovarian, breast and colorectal cancers 
(Borgquist et al., 2008; Brennan et al., 2011; Bengtsson et al., 2014). Intermediate products 
of the MP (GGPP and FPP) are involved in post-translational modification of several 
important proteins implicated in cell signals, proliferation and differentiation. This includes 
the RAS superfamily of GTPases, a large family of proteins encompasses of more than 150 
members. Ras itself is mutated in about 20% of human cancers. Mutated Ras can be 
stabilized in a constitutively active conformation and efforts are ongoing to develop novel 
therapies that inhibit Ras actions (Konstantinopoulos, Karamouzis and Papavassiliou, 2007; 
Zhang et al., 2013). It has been observed that neoplastic tissue can show not only an increase 
in the rate of cholesterol synthesis but also in the HMGCR activity.  Collectively, this has 
led to the proposal that inhibition of sterol synthesis can impede tumour growth (Thibault et 
al., 1996). Taken together, these findings pointed to the importance not only the cholesterol 
but also reflect the activity of the MP, as driver in cancer. 
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1.2.4. Protein prenylation 
Isoprenylation (“prenylation”) is considered as a key physiological process and one of the 
most important functions of the MP (Wang and Casey, 2016). Many prenylated proteins 
functions as signalling molecules which are activated by extracellular stimuli to control 
intracellular activities. This can include regulation of gene transcription which influences 
diverse biological processes including differentiation, cell division, cell proliferation, vesicle 
transport, nuclear assembly, and cytoskeleton reorganization (Heasman and Ridley, 2008; 
Karnoub and Weinberg, 2008; Nilsson, Huelsenbeck and Fritz, 2011). These post-
translational modifications are essential for protection of Ras superfamily from proteolytic 
degradation, facilitate protein-protein interaction and the most importantly assist anchoring 
to membrane and subcellular localization (Schafer and Rine, 1992; Konstantinopoulos, 
Karamouzis and Papavassiliou, 2007).  
The prenylation process is catalysed by three prenyl transferase enzymes (farnesyl 
transferase and Geranylgeranyl transferase-I and II) and involves the covalent addition of 
the isoprene moiety to the C termini of proteins (details of protein prenylation in Figure 1-15 
and Figure 1-16) (Vinet and Zhedanov, 2010; Li and De Souza, 2011). The addition of 15-
carbon atom farnesyl moiety to proteins (Ras, RhoB and HDJ2) is called farnesylation and 
catalysed by the enzyme farnesyl transferase. In contrast, geranylgeranylation, which include 
the addition of one 20 or two 20 C-atom molecules to proteins (Rab, Rap1A, RhoA, Rac1 
and Cdc42), is catalysed by geranylgeranyl transferase-I (GGT-I) and geranylgeranyl 
transferase-II (GGT-II), respectively (Swanson and Hohl, 2006; Gao, Liao and Yang, 2009; 
Rogers et al., 2011).  
The terminal tetrapeptide amino acid sequences of the protein (CAAX box) is the main 
determinant of the prenylation type. In the CAAX motif, C represent the cysteine residues, 
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A represents an aliphatic amino acid and X a range of other amino acids (Winter-Vann and 
Casey, 2005). Ras farnesylation arises when X is glutamine, methionine or serine while 
geranylgeranylation occurs when X is leucine or phenylalanine amino acid. However, NRas 
and KRas4A can be farnesylated or geranylgeranylated. Rho GTPases are 
geranylgeranylated if X is either leucine or phenylalanine and farnesylated if X are other 
amino acids. In contrast, HRas is only farnesylated. In addition, the CAAX motif is replaced 
by CXC or CC in case of substrates of GGT-II (Shimoyama, 2011; Holstein and Hohl, 2012).  
After prenylation, the AAX tripeptide undergo proteolytic removal by Ras-converting 
CAAX endopeptidase 1 (RCE1) and carboxymethylation by isoprenylcysteine 
carboxylmethyltransferase (ICMT) in the endoplasmic reticulum. They are palmitoylated in 
the Golgi apparatus and then anchored by farnesyl or geranylgeranyl, and palmitoyl moieties 
to plasma membrane. KRas4B does not require palmitoylation to anchor it to the plasma 
membrane. Rho is associated with guanine nucleotide dissociation inhibitors (GDIs), which 
deliver them to their membrane locations (Konstantinopoulos, Karamouzis and 
Papavassiliou, 2007; Wang and Casey, 2016). 
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Figure 1-15 Prenylation of Ras GTPases. 
Prenylation process of Ras GTPase involve the addition of either geranylgeranyl or farnesyl and 
palmitate moiety. FTase, farnesyltransferase; GGT-I, geranylgeranyl transferase I; SAM, S-
adenyosyl methionine; RCE1, Ras-converting CAAX endopeptidase 1; ICMT, carboxymethylation 
by isoprenylcysteine carboxylmethyltransferase.  
 
 Figure 1-16 Prenylation and post-prenylation reactions of Rab GTPases. 
Rab with C terminal C-X-C or C-C residues are geranylgeranylated in both C residues by GGT-II. 
Unprenylated Rab are presented by a REP1 (Rab escort protein 1) to GGT-II. Subsequently only 
RAB GTPases ending in C-X-C undergo carboxymethylation by ICMT. Lastly, these RabGTPases 
bind to RabGDIs, which recognize their two geranylgeranyl moieties and deliver them to their 
membrane locations. RCE1, Ras-converting CAAX endopeptidase 1; ICMT, carboxymethylation by 
isoprenylcysteine carboxylmethyltransferase; SAM, S-adenosylmethionine. Reproduced with 
permission from (Konstantinopoulos, Karamouzis and Papavassiliou, 2007). 
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1.2.5. Activation of Ras superfamily proteins 
Ras superfamily proteins possess the same molecular switch system despite the functional 
and structural diversity of their members (Reuther and Der, 2000). The switching system of 
these proteins form is firmly controlled by a complex regulatory network. GTPase activating 
proteins (GAPs), guanine nucleotide exchange factors (GEFs) and guanine nucleotide 
dissociation inhibitors (GDIs) are classes of proteins that control activation of the inactive 
GDP-bound to active GTP-bound conformation (Wennerberg, 2005; Ahearn et al., 2012). 
The activation cycle induces conformational changes resulting in modulation of binding 
affinities to the effector proteins (Agarwal et al., 2009). 
GEFs and GAPs regulate the cycling of Rho and Rab GTPases between active and inactive 
status (Bos, Rehmann and Wittinghofer, 2007). However, the extraction and delivery of 
prenylated inactive Rab and Rho from Rab escort protein 1 (REP1) is catalysed by GDIs 
(Alexandrov et al., 1994). GDI displacement factors (GDFs) are another family of protein 
that interact with Rab and Rho proteins to regulate their detachment from GDIs and 
subsequently transfer to subcellular membranes (O’Neill et al., 2012). In addition, heat-
shock protein 90 (HSP90) involve in the extraction of Rab proteins from membrane by 
stimulating the activity of GDI. The series of activation and inactivation process of Ras 
superfamily is associated with the transduction of an upstream signal to activation of 
downstream effectors by activation of second messenger cascades (Konstantinopoulos, 
Karamouzis and Papavassiliou, 2007). 
1.2.6. Prenylated proteins overview of the classical families 
Guanine nucleotide-binding proteins (G proteins) comprise of two groups of proteins, the 
heterotrimeric G proteins (large G-proteins) and the monomeric small G-proteins (small 
GTPases) (Konstantinopoulos, Karamouzis and Papavassiliou, 2007). The Ras superfamily 
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of small GTPases, a large family of proteins encompasses more than 150 members, which 
accounts for about 0.5-2% of all human proteins  (Reigard et al., 2005; McTaggart, 2006; 
Gao, Liao and Yang, 2009; Vigil et al., 2010). The human Ras superfamily  can be grouped 
into five major branches (Figure 1-17) (Colicelli, 2004; Vigil et al., 2010). Ras, Rho, Rab, 
Ran and Arf are major subfamilies of the Ras superfamily. The family is involved in 
regulation of crucial biological processes such as intracellular signal transduction (Ras), 
reorganization of the cytoskeletal (Rho), gene expression (Ras, Rho), trafficking of the 
intracellular vesicle (Rab), organization of microtubules (Ran) and nucleocytoplasmic 
transport (Ran) (Takai, Sasaki and Matozaki, 2001). The role of the prenylated proteins is 
now evident in the pathogenesis and progression of cancer and similarly in atherosclerosis 
and Alzheimers’ disease (McTaggart, 2006). So, it is reasonable to consider MP as potential 
target in cancer therapy by virtue of its ability to affect the function of Ras family members 
through prenylation (Dudakovic et al., 2008).  
The Ras superfamily is the most studied group of small GTPase proteins. Historically, the 
Ras family, which comprising HRas, KRas, and NRas, were the founding members of the 
Ras-related superfamily. 25 years ago, Valencia et al.,(Valencia et al., 1991)  proposed the 
first classification of this family of proteins which included about 30 family member. Since 
then, the studies of the family have increased exponentially due to the fact that Ras 
superfamily has a great impact on human diseases and also provided a promising target for 
drug development (Rojas et al., 2012).  
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Figure 1-17 Ras superfamily proteins. 
 
1.2.6.1. Ras GTPases 
Ras GTPases affect several different signalling pathways (Figure 1-18) (Coleman, Marshall 
and Olson, 2004). This family consists of 36 members (Vigil et al., 2010) and the most well 
know of these are H-Ras, N-Ras and K-Ras which have been reported to be frequently 
mutated in human cancer (Gysin et al., 2011). Ras proteins are mutated in about 30% of all 
human cancers and up to 90% in pancreatic cancer (Goldfinger and Michael, 2017). 43-65% 
of mucinous OCs were reported to contain mutations in K-Ras proteins (McCluggage, 2011). 
It has been claimed that K-Ras and N-Ras are overexpressed and mutated in OC (Cho and 
Shih, 2009; Gysin et al., 2011; Emmanuel et al., 2014).  However, the activity of wild-type 
Ras is also increased in cancer due to other genetic lesions such as mutational activation or 
increased expression of tyrosine kinases receptors (Fiordalisi, Der and Cox, 2006). 
Activation of these oncogenes result in prolonged activation of Ras proteins and the 
downstream effector signalling pathways which in turn might cause malignant 
transformation (Gysin et al., 2011). 
Rab, 61
Ras, 36
Arf, 27
Rho, 20
Other, 9 Ran, 1
Rab Ras Arf Rho Other Ran
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 Figure 1-18 Ras signalling pathway  
RAS proteins are activated by guanine nucleotide exchange factors (GEFs). This enzyme catalyses 
the exchange of GDP for GTP. These proteins are inactivated by the GTPase activating proteins 
(GAPs) which stimulate the intrinsic RAS GTPase activity. The cell surface receptor complex is 
activated by binding of growth factors. The activated complex which include multiple adapters like 
GRB2 (growth-factor-receptor bound protein 2), SHC (SH2-containing protein) and Gab (GRB2-
associated binding) proteins, recruit SHP2 and SOS. Ras-GTP level is increased by the recruitment 
of SOS which in turn catalyses exchange of GDP nucleotides for GTP on Ras. Conversely, Ras-GTP 
binds to GTPase-activating protein (GAP) such as neurofibromin (NF1) which terminates the 
signalling by accelerating the conversion of the Ras-GTP to Ras-GDP. The Raf-MEK-ERK cascade 
which is usually deregulated in cancer, controls the rate of proliferation. In addition, Ras activates 
the PI3K-Akt pathway which regulate the cell survival. TIAMI are exchange factor for the Rac which 
in turn regulates actin dynamics and, thus cytoskeleton. Lastly, Ras activate phospholipase C 
(PLC) to produce IP3. The hydrolytic product of this enzyme, which regulates calcium signalling 
and diacylglycerol regulates the protein kinase C family (PKC). TKR, tyrosine kinase receptor; GF, 
growth factor; P, phosphate; Y, tyrosine residue. Reproduced with permission from (Schubbert, 
Shannon and Bollag, 2007). 
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1.2.6.2. Rho GTPases 
Rho GTPase subfamily consist of about 20 proteins such as RhoA, RhoB, RhoC, Rac1 and 
Cdc42 (Vigil et al., 2010; Hodge and Ridley, 2016). This family of proteins are 
geranylgeranylated with the exception of RhoB which can be either geranylgeranylated or 
farnesylated (Sarrabayrouse et al., 2017). Active Rho triggers signalling networks to direct 
cellular responses by binding to different effectors molecules. The most important of these 
cellular processes are actin and microtubule cytoskeleton organization, cell division, cell 
adhesion, motility, vesicular trafficking, phagocytosis and transcriptional regulation (Figure 
1-19)(Jaffe and Hall, 2005; Vega and Ridley, 2008).  
It has been shown that Rho GTPase contribute to the survival in some cancer cell type. They 
are also involved in transformation and angiogenesis but unlike Ras GTPases, mutation in 
the Rho subfamily in cancer are rare (Bryan and D’Amore, 2007). Rho expression is 
increased in number of cancers such as skin, liver, colon and ovarian (Vega and Ridley, 
2008; Karlsson et al., 2009). Specifically, RhoA, RhoC and Cdc42 are reported to increase 
their activity and/or expression, while RhoB is down regulated in human tumours (Vega and 
Ridley, 2008; Arias-Romero and Chernoff, 2013; D. Yang et al., 2017). In addition, the 
increased expression of RhoA, Rac and Cdc42 is correlated with prognosis, recurrence and 
progression as well (Kamai et al., 2004; Karlsson et al., 2009). 
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Figure 1-19 Effectors of Rho GTPases  
Rho family proteins are stimulated by receptors such as receptor tyrosine kinases, G-protein-coupled 
receptors and adhesion receptors (integrins and cadherins). Cell-cell adhesion and cell polarization 
is mediated by effectors of active Cdc42 and Rac1. The activity of Rho proteins is accomplished by 
actin polymerization at cell protrusions, stabilization and capture of microtubules and positioning of 
the cytoskeleton and organelles (such as Golgi, centrosomes and nucleus). One of the important 
mediators of the cytoskeleton organization is p21-activated kinase (PAK) which is an effector of 
Cdc42 and Rac. The active RhoA regulates a number of downstream signalling process include 
membrane retraction by actinomycin based stress fibre contraction, cell division and cell cycle 
progression. The assembly of the proteins machineries which is required for actin polarization are 
initiated by RhoA binding to mDia or Cdc42 binding to N-WASP. MRCK, myotonic dystrophy 
kinase-related Cdc42-binding kinase; F-actin, filamentous actin; IQGAP, IQ motif-containing 
GTPase-activating protein; PAR6, partitioning defective-6; PKN, protein kinase N; PLC, 
phospholipase C; SRA1, specifically Rac1-associated protein-1; mDia, formin mammalian 
diaphanous; N-WASP, neural Wiskott–Aldrich syndrome protein. Reproduced with permission from 
(Iden and Collard, 2008). 
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1.2.6.3. Rab GTPases 
There are more than 60 members of Rab subfamily (Vigil et al., 2010). The main function 
of Rab GTPase is to control vesicle trafficking between organelles which regulates protein 
secretion, endocytosis, recycling and degradation (Figure 1-20) (Recchi and Seabra, 2012; 
Srikanth, Woo and Gwack, 2017). Rab GTPases have been demonstrated to contribute to 
tumour-stromal cell communication and cell cycle progression in some tumour types (Recchi 
and Seabra, 2012). In addition, Rab proteins have been implicated in cancer progression and 
metastasis (Yang et al. 2017). Rab25 has been found to promote migration and invasion of 
cancer and its over-expression also correlates with poor survival in OC (Cheng et al., 2004; 
Caswell et al., 2007). Lastly, a number of proteins from this family are also involved in drug 
resistance. For example, Rab4a and Rab6, are underexpressed in MDR cells while their 
overexpression is associated with increased sensitivity of cancer cells to cytotoxic drugs as 
a result of increased intracellular accumulation. In contrast, Rab8 overexpression in sensitive 
cancer cells enhances their resistance to cisplatin (Recchi and Seabra, 2012). 
1.2.6.4. The Arf family 
The Arf family consist of about 27 proteins and there are three classes of Arf proteins, class 
I (Arfs1–3), class II (Arfs 4–5), and class III (Arf6). They had been implicated in number of 
cellular processes such as vesicle membrane traffic, morphology, metabolism, actin 
cytoskeleton, endocytosis and exocytosis (Kahn, 2003). Despite being a part of the Ras 
superfamily, Arfs are not subjected to prenylation, instead they are localized to membrane 
by the addition of 14 C-atom myristate fatty acid (Konstantinopoulos, Karamouzis and 
Papavassiliou, 2007). The Arf family play a critical role in cancer progression and might be 
a prognostic factor for cancer patients. The aberrant activity or expression of Arf family 
proteins has been shown to have a role in migration, invasion and proliferation (Casalou, 
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Faustino and Barral, 2016). The expression of some Arf proteins were found to be 
upregulated in breast cancer cell lines (Schlienger et al., 2016). Lastly, it was recently 
reported that Arf is negatively correlated with miR-221-3p, whose higher expression is 
associated with better overall survival in epithelial OC patients (Q. Wu et al., 2017). 
 
Figure 1-20 The functions and localization of Rab-GTPase. 
 This figure shows epithelial cells and the localization of selected Rab proteins in the vesicle transport 
pathways. Rab1 is located at the ER (blue) exit sites and the Golgi (grey) intermediate compartment 
and is responsible for mediating the trafficking from the ER to the Golgi apparatus. Rab6, 33 and 40 
mediate trafficking within the Golgi apparatus. The formation of autophagosomes is controlled by 
Rab33 together with Rab24. Lipid droplet formation is mediated by Rab18 and the trafficking 
between the Golgi network and early endosomes is mediated by Rab22. Biosynthetic trafficking from 
Golgi apparatus to plasma membrane is mediated by Rab8. In addition, Rab8 together with Rab10 
and Rab14 involved in GLUT4 vesicle translocation and with Rab17 and Rab23 in ciliogenesis. 
Rab3, 26, 27 and 37 mediate translocations of melanosomes to the cells periphery and also mediate 
several types of regulated exocytic events. The assembly of tight junction between epithelial cells 
are regulated by Rab13. Rab32 and 38 participate in biosynthesis of melanosomes and Rab32 also 
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regulates mitochondrial fission. Rab5 is positioned to early endosomes, phagosomes, caveosomes 
and the plasma membrane stimulate endocytosis and endosome fusion of the clathrin coated vesicles 
(CCVs). Rab5 together with Rab34 mediate micropinocytosis and with Rab14 mediate maturation 
of early phagosomes. Integrin endocytosis is mediated by Rab21. Rab4 mediate the fast-endocytic 
recycling whereas Rab11 and 35 mediate the slow endocytic recycling from early endosomes. Rab15 
is participated in the trafficking from the apical recycling endosomes to the basolateral plasma 
membrane and in trafficking from early endosomes to recycling endosomes. The trafficking form the 
apical recycling endosomes to the apical plasma membrane is regulated by Rab17 and Rab25. 
Maturation of the late endosomes and phagosomes and their fusion with lysosomes is mediated by 
Rab7. Lastly, Rab9 regulate trafficking form the late endosomes to the Golgi networks. Reprinted 
with permission from (Stenmark, 2009). 
 
1.2.6.5. Ran GTPase  
The fundamental cellular function of the Ran GTPase is nucleocytoplasmic transport (Figure 
1-21). The Ran protein is  involved in mitotic spindle assembly, microtubule nucleation and 
dynamics and post-mitotic nuclear assembly (Dasso, 2002). A number of studies have 
showed that Ran GTPase is implicated in cancer cell growth, tumour transformation, 
resistance to apoptosis, tumour aggressiveness and increased metastasis in several types of 
cancers (Abe et al., 2008; Kurisetty et al., 2008; Xia, Lee and Altieri, 2008; Ly et al., 2010; 
Yuen et al., 2012). Ran is differentially overexpressed in cancer tissue as compared with 
normal tissues and its expression is correlated with tumour progression (Kau, Way and 
Silver, 2004). Acute silencing of Ran in cancer cells induces mitochondrial dysfunction and 
causes cell death. Therefore, these evidences suggest that Ran pathway might be an 
important target for cancer treatment (Xia et al. 2008).  
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Figure 1-21 Nucleocytoplasmic Transport by Ran GTPase. 
(a) the GTP (active) and GDP (inactive) cycle of Ran. Guanine nucleotide-exchange factor and 
Regulator of chromosome condensation 1 (RCC1) catalyse the conversion of Ran GDP to Ran GTP, 
which in turn interact with the Karyopherins, a transporter factor for the family of importin-β. In 
contrast, Ran-binding protein-1 (RanBP1) or RanBP2 stimulate Ran GTPase-activating protein, 
RanGAP1 to induce the hydrolysis of GTP to GDP which does not interact strongly with karyopherin. 
There are number of mutation that prevent GTP-GDP cycle of Ran such as RanT24N and RanQ69L. 
(b) The nuclear transport factor-2 (NTF-2) facilitates the active transport of Ran through the nuclear 
pores across the nuclear membrane.  In the nucleus, the chromatin-bound RCC1 catalyses the 
generation of high concentration of the Ran GTP by nucleotide exchange. High concentration of Ran 
GTP induce the separation of the imported complexes by binding to importin-β and ejection of the 
cargo which carry the nuclear localization signal (NLS). On the contrary, the assembly of the export 
complexes, which contain protein with a nuclear export signal (NES), is promoted by binding of the 
RanGTP to the chromosome-region maintenance protein-1 (CRM1).  In cytoplasmic compartment, 
RanGTP hydrolysis is stimulated by RanGAP1 and RanBP1 or RanBP2 to release the exported 
complexes. Reprinted with permission form (Clarke and Zhang, 2008). 
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1.2.7. Clinical implication 
A significant body of research has demonstrated the importance of the MP in health and 
disease. Inactivation of the MP appears to be fatal in some animal models. Mice deficient in 
HMGCR stop developing at the blastocyst stage, whereas, mice that have squalene synthase 
deficiency demonstrate retardation in growth and defects in neural tubes (Ohashi et al., 
2003). In addition, gunmetal mice, a GGT-II deficient mouse, matures normally but display 
a defect in platelets function and prolongation of the bleeding time (Zhang et al., 2002). 
Mevalonic aciduria (MAU) and Hyperimmunoglobulinaemia D syndrome (HIDS) are two 
inherited disorder caused by mutation in the mevalonate kinase (MK) gene which lead to a 
disruption in the activity of MK, one of the crucial enzyme in MP  (Haas and Hoffmann, 
2006). MAU is a rare autosomal recessive inborn disorder associated with multiple 
abnormalities (Normand et al., 2009). The main sign and symptoms of the disorder are 
recurrent febrile crises and inflammatory episodes, which are also associated with 
psychomotor retardation, failure to thrive, ataxia, cataracts, retinitis pigmentosa, uveitis, 
hepatomegaly, lymphadenopathy, vomiting, diarrhoea, arthralgia, myopathy, skin rash and 
mucosal ulcers. MAU has a poor prognosis and the patients usually die in early childhood 
(van der Burgh et al., 2013).  
In contrast to MAU, in which MK activity is completely abolished, the residual activity of 
the MK is 5-15% in HIDS which is characterized by early childhood onset of recurrent 
febrile attacks, triggered by infection, trauma, stress, surgery and vaccination. Some patients 
may develop neurological symptoms, mental retardation, ataxia, epilepsy and ocular 
disorder. The defect in the MK leads to increases in the concentration of mevalonic acid in 
plasma. In addition, the accumulation of mevalonic acid in plasma is accompanied by a 
Chapter One | Introduction 
59 
shortage in the production of the downstream products of the MP in both MAU and HIDS 
(Haas and Hoffmann, 2006; Buhaescu and Izzedine, 2007).  
Scientists have failed to produce effective treatment for these disorders in spite of the huge 
improvement in understanding of the molecular pathogenesis of both disorders. However, 
two options are available, etanercept and anakinra, but these drugs have unreliable beneficial 
effects. The counter intuitive use of statins in MAU and HIDS is support by limited and 
conflicting data. Lovastatin can provoke a severe clinical crisis while, simvastatin shows a 
reduction of the febrile attacks in HIDS patients (Buhaescu and Izzedine, 2007). However, 
the clinical crisis might be resolved within one day of corticosteroid administration. 
Administration of vitamin C, vitamin E and ubiquinione-50 for long-term have a stabilizing 
effect on the clinical course and improve the development (Haas and Hoffmann, 2006).  
1.2.8. Mevalonate pathway as therapeutic target 
The foregoing discussion illustrates that pharmacological manipulation of the MP is a novel, 
attractive and promising therapeutic target for the treatment of many disorders such as 
autoimmune disorder, Alzheimer’s disease, atherosclerosis and cancer (Swanson and Hohl, 
2006; Buhaescu and Izzedine, 2007). Statin administration to mice with multiple sclerosis 
(MS), an autoinflammatory disease, at earlier stage reverses the symptoms and prevents the 
progression to recurrent or chronic paralysis (Weber et al., 2006). In transgenic mice of 
Alzheimer disease, the use of statins assists in inverse learning and memory deficits (Li et 
al., 2006). In addition, the immunomodulatory effects of statin might reverse 
neurodegeneration in MS, Alzheimer’s and Parkinson disorders, through reduction of 
protein isoprenylation (Butterfield, Barone and Mancuso, 2011). 
There are multiple pharmacological targets in the MP that might be targeted for treatment of 
cancer (Figure 1-12). Beside statins and nitrogenous bisphosphonates (NBPs) which inhibits 
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the HMG-CoA reductase and Farnesyl pyrophosphate synthase respectively, there are 
number of other drugs which modulate the MP (Table 1.5). In addition, toxic effects in non-
diseased cells might result from complete inhibition of single enzyme activity or from off-
target effects. Hence, targeting more than one enzyme in the MP might be a superior option 
to overcome toxicity and being more effective for the treatment of cancer.  Moreover, many 
studies show that the synergistic effect of MP inhibitors with conventional anticancer drugs 
might augment the therapeutic outcomes (Swanson and Hohl, 2006). 
1.2.9. Mevalonate pathway enzymes inhibitor  
1.2.9.1. Statins 
In 1971, Endo, the father of statins, started searching thousands of fungi with the hope of 
discovering a compound that will be able reduce cholesterol level in human. By the end of 
one year of searching, he found a compound called compactin or mevastatin that inhibits 
HMGCR activity with high potency. However, the compound was soon withdrawn from the 
market because of the suspected adverse effect. In the 1990, the development of the analogs 
of mevastatin opened the way for the marketing authorization of statins such as lovastatin, 
simvastatin and pravastatin (Endo, 2010).  
Globally, statins ranked as the most commonly used drug (Collins et al., 2016). Their main 
indication is to treat hypercholesterolemia particularly for preventing myocardial infarction, 
ischemic heart disease and peripheral arterial disease (Taylor-Harding et al., 2010; Osmak, 
2012). Nonetheless, due to the pleiotropic properties of statins, their beneficial effect have 
been demonstrated in other disease, for instance Alzheimer’s, multiple sclerosis and 
ischemic stroke disorders (Sławińska-Brych, Zdzisińska and Kandefer-Szerszeń, 2014). 
Statins have anti-inflammatory and immunomodulatory effects, neuro-protective effects, 
positive effects on bone metabolism and improve the prognosis in chronic kidney disease. 
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Therefore, statins might be a potential therapeutic option for different disorders (Gazzerro et 
al., 2012). 
Table 1-5 Targets in the MP with anticancer activity. 
Drugs  Site of 
action 
Mechanism of action  References 
Statins  
(Simvastain, 
Fluvastatin, 
Atorvastatin, 
Lovastatin) 
HMGCR -Cell cycle arrest 
-Induction of apoptosis 
and autophagy 
 
(Liu et al., 2009; Li et al., 
2010; Martirosyan et al., 
2010; Scoles et al., 2010; 
Taylor-Harding et al., 
2010; Robinson et al., 
2014) 
Apomine HMGCR -Down regulation of the 
HMGCR by increase 
degradation 
-Induction of apoptosis 
-Cell cycle arrest  
(Edwards et al., 2007; 
Roelofs et al., 2007; 
Moriceau et al., 2010, 
2012) 
NBP 
( Aldronate, 
Ibandronate, 
Clodronate, 
Zoledronic 
acid) 
FPPS -Cell cycle arrest 
-Induction of apoptosis 
-Inhibition of proliferation, 
migration and invasion 
-Antiangiogensis 
(Hashimoto et al., 2007; 
Stresing et al., 2007; 
Mahtani and Jahanzeb, 
2010; Clézardin, 2011; 
Gnant and Clézardin, 2012; 
Winter and Coleman, 2013; 
Okamoto et al., 2014) 
Zaragozic 
acid 
Sequalene 
synthase 
-Reduction of cholesterol 
synthesis  
-Accumulation of the FPP 
products 
(Brusselmans et al., 2007; 
Henneman et al., 2011) 
FTase 
inhibitors  
(Tipifarnib, 
Lonafarnib) 
FTase -Inhibition of protein 
farnesylation which play 
crtical role in growth and 
proliferation 
(Buhaescu and Izzedine, 
2007; Holstein and Hohl, 
2012; Meier et al., 2012; 
Abuhaie et al., 2013; Volpe 
et al., 2013) 
GGT-I 
inhibitors 
( GGTI-2133) 
GGT-I -Cell cycle arrest 
-Inhibition of migration 
and invasion of tumour 
cells 
(Swanson and Hohl, 2006; 
Buhaescu and Izzedine, 
2007) 
GGT-II 
inhibitors 
GGT-II -Interruption of Rab 
protein function   
(Swanson and Hohl, 2006; 
Sane et al., 2010; Wasko, 
Dudakovic and Hohl, 2011) 
Dualprenyltr
ansferase 
inhibitors 
FTase & 
GGT-I 
-Inhibition of both 
farnsylation and 
geranylgeranylation of Ras 
GTPase proteins 
(Lobell et al., 2002; Zhang 
et al., 2009) 
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Statins are either naturally derived or chemically synthesized (Shah et al., 2015). Statins are 
structurally are composed of two components (Figure 1-22), the dihydroxyheptanoic acid 
which is the pharmacophore and the ring system with different substituents. Statins 
competitively inhibit HMGCR enzyme in dose-dependent and reversible manner. The 
stereoselectivity of the HMGCR enzyme to statins depends on chemical structure of the 
pharmacophore which are either an inactive closed lactone ring or active open hydroxy 
carboxylic acid moiety  (Gazzerro et al., 2012). The binding affinity of statins is 1000-fold 
more than the natural substrate for HMGCR enzyme (Clendening and Penn, 2012). The 
function of the ring system is to prevent statins displacement from the enzyme by the natural 
substrate. In addition, the substituents of the ring system are one of the major determinants 
of the pharmacokinetic characteristics of the statins (Wong, Dimitroulakos and Penn, 2002; 
Martirosyan et al., 2010). 
Generally, statins are well tolerated (Collins et al., 2016). The most frequently reported 
adverse effects of the standard doses are mild, such as constipation, flatulence, nausea and 
gastrointestinal pain. Rhabdomyolysis, myopathy, myositis, autoimmune disorders, cardiac 
dysfunctions and elevated liver enzymes are less common but potential serious adverse 
effects of this family of drugs (Gazzerro et al., 2012; Moon et al., 2014). Several factors 
have been recognized to increase the incidence of statins adverse effects such as the age, 
gender, family history, concomitant disease and drug-drug interactions (e.g. cimetidine, 
clarithromycin and erythromycin) (Ahmad, 2014). Even though the safety profile is 
understood, statin therapy requires careful monitoring. 
The antitumour activity of statin is a result of suppression of proliferation, cell cycle arrest 
and induction of apoptosis (Hindler et al., 2006; Matusewicz et al., 2015). Statins induces 
cell cycle arrest at G1/S phase boundary by up-regulation of the cell-cycle inhibitors 
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p21WAF1/CIP1 and/or p27KIP1  and reduce the expression of the CDK2, CDK4, Cyclin D1 and 
Cyclin E (Wong, Dimitroulakos and Penn, 2002; Morgan et al., 2005; Sleijfer et al., 2005; 
Clendening and Penn, 2012; Gazzerro et al., 2012). In addition, others have also reported 
G2/M phase cell cycle arrest in lymphoma cells and breast cancer cells  (Sánchez CA et al., 
2008). 
In contrast, statins activation of the extrinsic apoptotic pathway appears to be dependent on 
tumour type. Statins stimulate caspase-8 activation which amplifies the executioner caspases 
activity in myeloma cells (Cafforio et al., 2005). In prostate cancer cells, simvastatin cause 
activation of caspase-8 through upregulation of TNF-α and FasL (Chapman-Shimshoni et 
al., 2003; Goc et al., 2012). It has been suggested that statins activate the death receptor 
signalling pathway by interruption of cholesterol synthesis which leads to change the 
organization of cholesterol rich membrane raft. Mevastatin administration cause 
spontaneous ligand-independent clustering of Fas and formation of the Fas-FADD 
complexes which led to activation of caspase-8 and apoptosis  (Gniadecki, 2004).  
Numerous preclinical studies have evaluated statin activity against various cancers. It has 
been demonstrated that statins exhibit significantly different cytotoxic potentials. For 
instance, Wong, et al., (Wong et al., 2001) evaluated the antitumour activity of different 
statins (fluvastatin, atorvastatin, and cerivastatin) on human acute myeloid leukaemia cells. 
He found that AML cells are at least ten-fold more sensitive to cerivastatin-induced 
apoptosis in comparison with other statins. Furthermore, Glynn, et al. (Glynn et al., 2008) 
tested the statins’ (simvastatin, lovastatin, mevastatin and pravastatin) ability to inhibit 
tumour growth of lung carcinomas, breast carcinomas and malignant melanomas cell lines. 
Simvastatin had the highest potency compared with lovastatin and mevastatin. In contrast, 
pravastatin was ineffective for inhibiting proliferation. However, cell lines from lung and 
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malignant melanoma were more sensitive to statins in comparison to breast cancer cell lines 
(Swanson and Hohl, 2006). It has also been  concluded that lipophilicity is one of the major 
determinants of statins activity against cancer, as more potent effects are observed with 
lipophilic statins (Martirosyan et al., 2010; Corcos and Le Jossic-Corcos, 2013; Zhang et al., 
2013).  
 
Figure 1-22 Chemical structures of the statin family are shown in their open ring active 
form (Wong, Dimitroulakos and Penn, 2002). 
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Retrospective clinical studies had shown that statins have pleiotropic and multi-favourable 
effects in biological behaviour of tumour (Altwairgi, 2015). Several studies consistently 
demonstrate that patients using statins to control cholesterol have reduced cancer risk and 
cancer related mortality (Cuello F et al., 2013). Meta-analysis and retrospective cohort 
studies revealed that statins improve the overall survival of patients with kidney cancer, 
pancreatic cancer and OC (Habis et al., 2014; Huang et al., 2017; Nayan et al., 2017). In 
prostate cancer, Jespersen et al., (Jespersen et al., 2014) state that statin use is associated 
with reduced risk and Yu et al., (Yu et al., 2014) reported that statins use after cancer 
diagnosis correlated with a decreased risk of mortality. Statins also enhance the therapeutic 
activity and overall survival lung cancer patients receiving EGFR-TK inhibitors therapy 
(Hung et al., 2017). Randomized controlled trial in advanced hepatocellular carcinoma 
patients treated by transcatheter arterial embolization and 5-flurouracil or transarterial 
chemoembolization shows that the median survival time is doubled upon the addition of the 
statin to the previous treatment modality (Kawata et al., 2001; Graf et al., 2008). 
 The Cancer in The Ovary and Uterus Study (case-control study) evaluated the effect of 
statins prior to and following diagnosis of ovarian and endometrial cancers in a subset of 
424 patients and 341 cases as controls. It found that the use of statins for more than 1 year 
before diagnosis was associated with a  reduction in cancer risk and prolonged survival was 
noted among those patients when statins were prescribed after cancer diagnosis (Lavie et al., 
2013). In addition, it is observed that OC risk was reduced by the use of statins and the effect 
was stronger in patients using statins for a prolonged period (Liu et al., 2014). An 
improvement in survival was observed in epithelial OC patients using statin after the 
diagnosis (Elmore et al., 2008). In contrary, others had found no association between statin 
use and cancer incidence. Several meta-analysis did not support a protective effect of statins 
on cancer incidence such as lung cancer, bladder cancer and skin cancer  (Bonovas et al., 
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2005; Kuoppala, Lamminpää and Pukkala, 2008; da Silva et al., 2013; Li, Wu and Chen, 
2014). 
Evaluation of the antitumour activities of statins in clinical trials have had conflicting results 
and are faced by number of difficulties. In 1996, Thibault et al., (Thibault et al., 1996) 
investigated the effect of  2-45 mg/kg/day orally-administered lovastatin in four divided 
doses for one week course in monthly bases. It was found that lovastatin in a dose of 25 mg/ 
kg/day was well tolerated but only 1 minor response out of 88 patients was observed. In 
addition, the author observed that 35 mg/kg was associated with transient adverse effects 
such as myalgia and elevated level of serum creatinine phosphokinase. However, ubiquinone 
co-administration did not prevent the occurrence of the adverse effect but decreased their 
severity. In addition, pravastatin was investigated in advanced hepatocellular carcinoma. 
Random allocation of the patients to either pravastatin group or control group, after standard 
therapy, revealed that statin group had significantly longer median survival as compared to 
the control group (Kawata et al., 2001). Simvastatin (15 mg/kg/day) administered orally for 
multiple myeloma patients on days 1-7 was followed by intravenous infusion of vincristine, 
doxorubicin and dexamethasone orally on day 7 to 10. Haematological (neutropenia and 
thrombocytopenia) and gastro-intestinal toxicity but not rhabdomyolysis was reported. The 
study stopped as the response was insufficient and it was suggested that although simvastatin 
is very effective in vitro, its short half-life might be the main cause for failure of the study. 
In addition, it was proposed that statins with long half-life and continuous administration are 
required to maintain high plasma level in patients which is essential to induce cell death 
(Van Der Spek et al., 2006; van der Spek et al., 2007).  
Lastly, the data from experimental studies illustrate that stains had little toxicity on cells 
from normal tissue (Martirosyan et al., 2010; Corcos and Le Jossic-Corcos, 2013; Zhang et 
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al., 2013). Likewise, some statins might have protective effect against doxorubicin induced 
toxicity on liver, renal and cardiac tissue (El-Moselhy and El-Sheikh, 2014). Statins, in 
combination with radiotherapy in clinical trial, demonstrated a reduction in rectal toxicity 
and also delay the intestinal damage in animal models (Begg, Stewart and Vens, 2011). It 
has been reported that normal cells, for example, ovary, neuronal, lung fibroblast and 
endothelial cells, might be more resistant to collateral damage produced by statins than 
cancer cells (Hindler et al., 2006; Liu et al., 2009; Clendening and Penn, 2012; Sławińska-
Brych, Zdzisińska and Kandefer-Szerszeń, 2014). Taken together, it appears reasonable to 
propose that statins might be  potential candidates for repurposing in cancer therapy 
(Konstantinopoulos, Karamouzis and Papavassiliou, 2007; Gazzerro et al., 2012).  
1.2.9.2. Nitrogenous bisphosphonates  
Nitrogenous bisphosphonates (NBPs) drugs are commonly indicated for management and 
prevention of bone disease such as postmenopausal osteoporosis, corticosteroid-induced 
bone loss, Paget's disease and skeletal lesions due to malignancy (Issat et al., 2007; Bosch-
Barrera et al., 2011). The therapeutic effect of NBPs is mainly through inhibition of bone 
resorption mediated by osteoclasts and reduction of calcium release and other minerals from 
bone. Although, NBPs are widely used, their adverse effects are not well defined. However, 
jaw osteonecrosis is a rare but reported adverse effect (Rennert, Pinchev and Rennert, 2010). 
Bisphosphonates can be classified in to two classes according to structure and mechanism 
of action. The first class is pyrophosphate-resembling bisphosphonates (e.g. clodronate, 
etidronate), which are converted into cytotoxic non-hydrolyzable ATP analogues products 
which decrease mitochondrial membrane potential by inhibiting the ATP-dependent 
enzymes to produce cytotoxic effects. The second class is nitrogen-containing 
bisphosphonate (e.g. alendronate, pamidronate, risedronate, ibandronate and zoledronic 
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acid) which inhibit a crucial enzyme, FFP synthase, in the mevalonate biosynthetic pathway 
(Okamoto et al., 2014; Zekri, Mansour and Karim, 2014). Therefore, NBPs deplete the 
isoprenoid pools and prevent the prenylation process of GTP proteins (Manoukian et al., 
2011).  
Several studies emphasize the ability of NBPs use to reduce the risk of several cancer types 
such as colon and breast cancer (Chlebowski et al., 2010; Rennert, Pinchev and Rennert, 
2010). In addition, evidence suggest that NBPs have direct antitumour activity against 
number of transformed cell lines for instance myeloma, breast, pancreatic, prostate, ovarian, 
colon and hepatic cancer (Siddiqui et al., 2014). The antitumour effects of NBPs include 
inhibition of proliferation by induction of cell cycle arrest and programmed cell death (Shai 
et al., 2014). Furthermore, combining NBPs with the standard anticancer agents enhance the 
therapeutic activity of several regimens in vitro (Horie et al., 2007). 
1.2.9.3. Prenyltransferases inhibitors  
There is major challenge associated with development of direct pharmacological inhibitors 
of Ras. The picomolar affinity of Ras for GTP makes the intervention of the nucleotide-
binding pocket of Ras much more difficult than interfering with ATP-binding pocket of 
kinases (Bommi-Reddy and Kaelin, 2010; Samatar and Poulikakos, 2014) with exception of 
sorafenib which has some Ras kinase inhibitor activity (Asati, Mahapatra and Bharti, 2016). 
It is known that proper Ras function requires prenyl transferase enzyme activity (Maynor et 
al., 2008). This has been prompted the development prenyl transferase inhibitors as potential 
anticancer drugs (Maynor et al., 2008).  
The crystal structure of FTase revealed that the enzyme has two binding sites which are 
involved in recognition of the FPP and  of the CAAX box of the protein substrate (Appels, 
Beijnen and Schellens, 2005). Therefore, several strategies have been developed to inhibit 
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farnesylation of Ras and inhibitors can be divided into three main categories based on site 
and mechanism of action. These are FPP competitive inhibitors, CAAX competitive 
inhibitors and bi-substrate analogue compounds that inhibit both FPP and CAAX (Crul et 
al., 2001; Downward, 2003; Wasko, Dudakovic and Hohl, 2011). However, there are major 
concerns about the action of these inhibitors because Ras proteins can be geranylgeranylated 
when the FTase enzyme is inhibited. Thus, the potential of cross prenylation of Ras by GGTI 
might reactivate these proteins and cause failure of the therapy (Brunner et al., 2003; Appels, 
Beijnen and Schellens, 2005).  
Several FTase inhibitors have been identified in each category and have undergone extensive 
assessment both in vitro and in vivo. The antitumour effects of FTase inhibitors in laboratory 
studies has been associated with induction of programed cell death, inhibiting angiogenesis 
and cell cycle arrest of some cancer cell lines regardless of Ras mutational status (Sebti and 
Hamilton, 2000; Wang, Yao and Huang, 2017). In addition, these inhibitors showed activity 
in vivo on xenografts of nude mice (Yeganeh et al., 2014). However in clinical trials FTase 
inhibitors have generally performed poorly except in myeloid leukaemia and pituitary 
adenomas (Bell, 2004; Asati, Mahapatra and Bharti, 2016). 
Inhibitors of geranylgeranyl transferases (GGTIs) enzymes was not initially considered as a 
promising target due their expected toxic effects (Yeganeh et al., 2014). Like FTase 
inhibitors, GGTIs have displayed a promising result in vivo and in vitro (Berndt, Hamilton 
and Sebti, 2011). These inhibitors induce apoptosis, reduce tumour invasiveness, induce cell 
cycle arrest in several cell lines through preventing Rho isoprenylation, and some of these 
inhibitors act on N-Ras and Rab GTPase as well (Coxon et al., 2001; Kusama et al., 2003). 
Administration of GGTI-2154 to mouse mammary tumour virus Ha-Ras mice, a breast 
cancer model, causes tumour regression by induction of apoptosis (Sun et al., 2003). 
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Additionally, treatment of lung cancer mouse model with GGTI-297 or GGTI-2154 decrease 
the cancer tumour volume by 40 and 60%, respectively (Sun et al., 1999).  
1.3. Background of TP53  
Thirty years ago, an approximately 53 kDa protein which complexes with the viral SV40 T-
antigen was proposed as proto-oncogene in the first decade after its discovery (Brosh & 
Rotter 2009; Lane & Crawford 1979; Linzer et al. 1979). Later on, the potential of increased 
tumourgenicity by overexpression of mutant p53 in p53 null cells was demonstrated (Wolf, 
Harris and Rotter, 1984). In 1989, the Levine laboratory revealed the tumour suppressive 
activity of wild-type p53 overexpression in rat embryo fibroblast and they suggested that 
p53 might block transformation (Finlay, Hinds and Levine, 1989). Therefore, the initial view 
of p53 mislead researchers to consider it as an oncogene because they analysed mutated 
forms of TP53  isolated from tumour cells (Brosh and Rotter, 2009).  
The TP53 gene is widely acknowledged as one of the most frequent genetic alteration in all 
of human malignancies (Levine and Oren, 2009; Oren and Kotler, 2016; Napoli and Flores, 
2017). TP53 mutations range from 5-80% and depend on type, stage, and aetiology of 
cancers  (Petitjean et al., 2007)  and it is found in a broad range of cancers with highest rate 
in OC (47%), colorectal (43%), head/neck (42%), and oesophageal cancers (41%) (Kandoth 
et al., 2013; Sorrell et al., 2013; Cole et al., 2016). Over 96% of high-grade serous OC 
displaying TP53 mutation (Cole et al., 2016; Oren and Kotler, 2016). In addition, TP53 
mutation might be an early molecular event associated with malignant transformation of 
fallopian tube cells to OC (Lee et al., 2007). Li-Fraumeni syndrome patients, an inherited 
germline mutation in p53 allele, are more prone to develop a variety of cancer such as tumour 
of breast, brain, bone, bladder and soft tissue sarcoma (Olive et al., 2004; Brosh and Rotter, 
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2009). These data supported the conclusion that p53 was in fact a tumour suppressor (Levine 
and Oren, 2009).  
1.3.1. Function of wild type p53 
The tumour suppressor p53, guardian of the genome, is a central hub in living cells, which 
is allied to a complex network of signalling pathways. “The functional complexity of p53-
dependent events is the reflection of the complexity of p53 as a protein” (Laptenko and 
Prives, 2006; Goldstein et al., 2010). Functionally, p53 is a stress response protein that is 
activated by different cellular insults such as oncogenic activation and DNA damage (Silwal-
Pandit, Langerød and Børresen-Dale, 2017). Activation of p53 initiates cell cycle arrest, 
senescence or apoptosis by up-regulation or down-regulation of numerous target genes 
(Harris and Levine, 2005; Beckerman and Prives, 2010; Lane, Cheok and Lain, 2010).  
The activities of p53 as well as its half-life are regulated by site-specific modification of 
certain p53 residues (Laptenko and Prives, 2006). Structurally, p53 can be post-
translationally modified by phosphorylation, acetylation and ubiquitination. These 
modifications add another layer of complexity to p53 (Laptenko and Prives, 2006). For 
instance, p53 protein is very short lived under unstressed condition due to its continual 
ubiquitination by MDM2 and proteasomal degradation. In contrast, the half-life is extended 
in stressful condition by phosphorylation to promotes its stabilization and subsequently lead 
to accumulation of p53 protein (Brosh and Rotter, 2009; Beckerman and Prives, 2010).  
The activation of p53 arises after DNA double-strand breaks trigger activation of ataxia-
telangiectasia mutated (ATM), a kinase that phosphorylates the CHK2 kinase, or after 
collapse of the DNA replication forks enrols ATM and RAD3-related (ATR), which 
phosphorylates CHK1 (Kastan and Bartek, 2004). P53 is phosphorylated by both ATM and 
ATR, either directly or through CHK1 and CHK2 (Lavin and Gueven, 2006). This post-
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translational modification prevents the interaction of p53 negative regulators MDM2 and 
MDM4 with activation domains of p53. Thus this post translational modification preventing 
the ubiquitination and turnover of p53 (Wade, Wang and Wahl, 2010). P53 is also activated 
by hyperproliferative signals through stimulating the transcription of ARF which in turn 
antagonize MDM2 by inhibiting the enzyme’s ubiquitin ligase activity (Karni-Schmidt, 
Lokshin and Prives, 2016).  
Activation of the P53 (Figure 1-23) has been proposed as model for cisplatin-induced 
cytotoxicity through up-regulation of pro-apoptotic and down-regulation of the anti-
apoptotic proteins (Agarwal and Kaye, 2003). In contrast, inactivation of the p53 is one of 
mechanisms of cytotoxic drug resistance (Bast, Hennessy and Mills, 2009). Hence, the 
efficacy of cisplatin chemotherapy is higher in OC patients with wild-type TP53 than 
patients with TP53 mutations (Galluzzi et al., 2012). Lastly, it is well known that cell-cycle 
arrest and apoptosis are the main prominent consequences of p53 activation (Chen, 2016). 
 
Figure 1-23 The classical view of p53 activation and response 
P53 is activated in response to different stimuli that induce either DNA damage or Arf stimulation 
and lead to activation of several cellular responses. Reproduced with permission from (Bieging, 
Mello and Attardi, 2014). 
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1.3.2. P53 and cell cycle arrest 
Multiple checkpoint have evolved to monitor and respond to cellular distresses, arresting 
cellular progression until defects are repaired or the environment becomes acceptable to the 
faithful transmission of genetic information (Bartek and Lukas, 2007). Perturbations in 
checkpoint mechanisms not only harmful to the integrity of the genome, but also stimulate 
tumourigenesis and considerably affect the efficacy of cytotoxic drugs (Abbas and Dutta, 
2009).  
The cell cycle is a complex process which is strictly synchronized by multiple factors. 
Cyclins, cyclin dependent kinases (Cdks) and CDK inhibitors are fundamental regulatory 
machine of this process. There are multiple checkpoints to regulate progression through cell 
cycle phases, when DNA damage is detected. P53 mediates cell cycle arrest by 
transcriptional activation of p21WAF1, a negative regulator of cell cycle, which in turn binds 
to and inhibit cyclin E/Cdk2 and cyclin D/Cdk4 complexes to cause cell cycle arrest at G1 
(Chen, 2016). Inhibition of Cdk2 and Cdk4 impedes phosphorylation of Rb and promotes its 
physical association with E2F1. Therefore, blocking the ability of E2F1 to activate gene 
expression that encodes products essential for DNA replication and cell cycle progression 
(Giacinti and Giordano, 2006). P21 also inhibits cellular proliferation by preventing DNA 
replication which is vital for S phase cell cycle progression (Abbas and Dutta, 2009). 
Additionally, P53 is mediator of cell cycle arrest at G2/M phases by inhibiting cyclin B and 
Cdk2 (Deng et al., 1995; Russell et al., 1999). Consequently, p53 maintains genomic 
stability and improves the survival of damaged cells by allowing time for repairing of 
potentially lethal DNA damages (Gatz and Wiesmuller, 2006). 
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1.3.3. P53 and apoptosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
The earliest evidence of p53 acting as mediator of apoptosis was provided by study of 
temperature-sensitive mutant p53 which is discovered by accident owing to a misadjusted 
incubator. At 32ºC, the mutant p53 has a wild type activity but this activity is lost at 37ºC 
(Zhang et al., 1994). It has noted that M1 leukaemia cell line exhibit a typical feature of 
apoptosis upon reactivation of temperature sensitive p53 (Yonish-Rouach et al., 1991). In 
addition, stable transfection of wild-type p53 in human colon tumour-derived cell line EB 
promote morphological features of apoptosis  (Shaw et al., 1992). These studies presented 
the role of p53 as apoptosis stimulator for preventing tumour development (Levine and Oren, 
2009). P53 has the ability to induce a vast number of genes which contribute to different 
steps of  apoptosis signalling (Riley et al., 2008). This includes activation of the extrinsic 
apoptotic pathway through the induction of death receptor, such as Fas and DR5, stimulating 
the dimerization of the receptor, activation of procaspase-8 and activation of caspase-3/7. In 
contrast, stimulation of the Bcl-2 family proteins induces permeabilization of the 
mitochondrial outer membrane, which is the main step in the intrinsic apoptotic pathway 
(Tait and Green, 2010).  
1.3.4. The p53 family: p63 and p73 
Two p53 family gene products were identified decades after discovery of p53, namely p63 
and p73. Both of these genes are ancestors with structural and functional similarity to p53 
(Collavin et al. 2010; Li & Prives 2007). The existence of several variant isoforms of p63 
and p73, which have a vastly different activity, made these members more complex than p53 
itself (Flores et al., 2005). P63 and p73 contain 2 promoter region and as a consequence two 
classes of proteins are encoded: one comprising the N-terminal transactivation domain 
(TAp63, TAp73 which act similarly to wild-type p53) and the other which lack N-terminal 
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transactivation domain (ΔNp63, ΔNp73)  that act primarily in dominant-negative fashion to 
regulate the p53 family (Inoue and Fry, 2014).  
Many studies demonstrate the acquisition of the binding capability of p63/p73 with mutant 
p53. It has been shown that p63 and p73 can associate with each other to form homo- or 
hetero-tetramers. However, both p63 and p73 do not interact with wild-type p53 (Davison et 
al., 1999; Bensaad et al., 2003) but they do interact with mutant p53 (Irwin et al., 2003).  
This interaction has been connected to the ability of some tumour-derived p53 mutants to 
promote resistance to chemotherapy, metastasis and invasion (Flores et al., 2005). The 
binding of p63 and/or p73 isoforms might explain several gain-of-function properties of 
mutant p53 (Adorno et al., 2009; Muller et al., 2009). Genetic studies in mice revealed that 
p63 and p73 have an important function in normal development. In addition, the activity of 
both has been connected to induction of program cell death (Di Agostino et al., 2008). 
However, the precise role of p63 and p73 in tumourigenesis are unclear because they are 
rarely mutated in cancer, albeit with some exceptions (Fridman and Lowe, 2003).  
1.3.5. Therapeutic targeting of p53 in cancer 
The crucial role of p53 in regulation of cellular growth and apoptosis led to its consideration 
as an interesting target for therapy (Zeimet and Marth, 2003). Activation of p53 function of 
various established tumour in animal models can cause tumour regression (Lane, Cheok and 
Lain, 2010). Thus, many studies have investigated methods to restore p53 tumour suppressor 
function. These include wild type p53 gene therapy, reactivation of mutant p53 and relief of 
wild type p53 from overexpressed MDM2. 
The main aim of gene therapy is to re-introduce wild type p53 into tumour cells using several 
approaches. A viral vector is used to introduce an intact cDNA copy of the p53 gene into the 
tumour (Wang and Sun, 2010). Adenovirus-mediated transfer of the p53 gene to reconstitute 
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the wild type activity has shown some efficacy in clinical trial. P53 gene therapy stabilizes 
tumour growth or even cause regression without major toxic effects (Wiman, 2006). A 
combination of p53 gene therapy with traditional chemotherapy might enhance the clinical 
efficacy (Nemunaitis et al., 2000; Swisher et al., 2003). Despite this, adenovirus p53 therapy 
had been restricted to localized intratumoural injection. Therefore, novel method are 
required to overcome the systemic delivery problems for targeting disseminated disease and 
neutralizing antibody against viral antigens (Wiman, 2007; Lane, Cheok and Lain, 2010). 
 P53 Reactivation and Induction of Massive Apoptosis (PRIMA-1) and Mutant p53 
Reactivation and Induction of Rapid Apoptosis (MIRA-1) (Lambert et al., 2009) are 
compounds found to transactivate p53 target genes through restoring the sequence-specific 
DNA binding and mutant p53 conformation to wild type. This restores the expression of 
p21, MDM2 and PUMA in vitro and inhibit tumour growth in vivo (Bykov et al., 2002, 
2005). Another molecule, CP-313198, activates p53 and inhibit tumour growth in vivo as 
well. This compound increases the level of p53 by prevent its ubiquitination independently 
of MDM2 and p53 phosphorylation. However, CP-313198 molecules might have p53 
independent activity (Selivanova and Wiman, 2007). 
Blocking the interaction between p53 and MDM2, which is frequently overexpressed in 
tumours, is an effective approach to prevent wild-type p53 degradation (Bullock and Fersht, 
2001). Several compounds had been identified to do so, such as Nutlin-3a, which efficiently 
stimulate apoptosis in acute myeloid leukaemia and in colon and breast cancer cell lines 
(Wang and Sun, 2010). In addition, Nutlin act synergistically with ABT-737, Bcl-2 
antagonist, to activate the intrinsic apoptotic pathway and induce apoptosis (Kojima et al., 
2006). 
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1.4. Ovarian cancer experimental models  
1.4.1. Ovarian cancer cell lines 
Ovarian cancer cell lines were frequently used tumour models employed to study anti-cancer 
agents in OC (Konstantinopoulos and Matulonis, 2013). Cell lines can provide an insight of 
the molecular diversity and histological subtypes of cancer tissues. In addition, they are 
inexpensive, easy to manage in the laboratory and culture condition of the cell lines can be 
controlled easily. However, there is a lack of some aspects of representation by  cell lines of 
an authentic tumour such as the heterogeneity of the population (Sandberg and Ernberg, 
2005). Usually the OC cell lines are grown attached to the surface of the culture vessels in a 
flat layer. This monolayer form of growth is advantageous for the functional assay and 
microscopic study but generally it is considered not to be entirely physiologically relevant. 
Therefore, the use of spheroids might be an alternative model to evaluate therapy. 
1.4.2. Spheroids 
Spheroids, which are free-floating multicellular aggregate, are thought to more precisely 
represent OC in vivo. It has been shown that these aggregates have similar cellular, molecular 
and biochemical properties to OC (Zietarska et al., 2007; Ahmed and Stenvers, 2013). For 
example, monolayer cell culture was found to be considerably more sensitive to 
chemotherapy than spheroid cancer cells, which is consistent with the observed 
chemoresistance to metastatic cancers (Kobayashi et al., 1993; Achilli, Meyer and Morgan, 
2012). The central region of tumours is poorly vascularized and exhibits an oxygen/nutrient 
and proliferation gradient, which might be associated with accumulation of catabolites and 
limited access to essential component needed for growth (Carlsson and Acker, 1988; 
Friedrich et al., 2009). Aggregates (spheroid) also provide a 3D architecture that is lacking 
in monolayer cultures and which can be used for evaluation of drug combination efficacy 
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(Petrik, 2013). Thus, spheroid culture might provide a model which more closely resembles 
tumours in a clinical setting.
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2. Aims and Objectives 
The aims of this thesis were in three-fold. Firstly, to establish a link between the mevalonate 
pathway and TP53 which is the most frequently mutated gene in OCs. Secondly, to test the 
antitumour activity of the previously described mevalonate pathway inhibitors in 
combination with pitavastatin. Lastly, to identify additional compounds which are 
synergistic with the anticancer activity of pitavastatin. To achieve this, the following 
objectives were set. 
1- Expression and repression of wild-type and mutant TP53 to evaluate their effect on 
the expression of MP enzymes (HMGCR, GGTI, GGTII and FTase). 
2- Evaluate the anti-cancer effects of combinations of zoledronic acid, risedronate or 
GGTI-2133 with pitavastatin and investigate the mechanism of synergy between 
these agents. 
3- Evaluate whether the antitumour activity of pitavastatin can be potentiated by 
combination with off-patent orally available drugs by screening a library of such 
drugs. 
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3.1. Cell culture 
 
3.1.1. Ovarian cell lines 
A panel of ovarian cancer (OC) cells were used in these studies which were either selected 
previously as part of the “NCI-60” panel of cells or because they were subsequently shown 
to be better representative in vitro models of high grade serous ovarian cancer (HGSOC) 
(Table 3-1) (Domcke et al., 2013). 
Table 3-1 Cell line representation of HGSOC 
Cell line Representation of the HGSOC 
Cov-362 
Ovcar-4 
Cov-318 
Ovsaho 
Likely 
Ovcar-3 
Ovcar-8 
Possibly 
Skov-3 
A2780 
Unlikely 
Igrov-1 Hypermutated 
 
A2780 (cisplatin sensitive) and Cis-A2780 (cisplatin resistant) cell lines (ATCC) were 
derived from a human ovarian serous carcinoma (Langdon, 2004; Cree, 2011). CisA2780 
cells were developed by exposing A2780 cell line to increasing concentration of cisplatin. 
CisA2780 are 14 fold more resistant to cisplatin compared to the mother cell line (Behrens 
et al., 1987). 
Cov-318 and Cov-362 cells (European Collection of Authenticated Cell Cultures (ECACC) 
/Sigma Aldrich) were derived from peritoneal ascites and pleural effusion of patients 
Chapter Three | Materials and Methods 
83 
diagnosed with serous carcinoma and endometrioid cancer, respectively (van den Berg-
Bakker et al., 1993). 
Ovcar-3 (ATCC) and Ovcar-4 (NCI) cell lines originated from ascites of patients refractory 
to treatment with cyclophosphamide, adriamycin and cisplatin. Ovcar-3 and Ovcar-4 cell 
line were developed after the diagnosis of progressive poorly differentiated papillary 
adenocarcinoma and adenocarcinoma of the ovary, respectively. The cytological features of 
these cells were consistent with the primary tumour (Hamilton et al., 1983; Louie et al., 
1985).  
Ovcar-5 (ATCC) cell line was derived from patient ascites with ovarian adenocarcinoma but 
prior to the chemotherapy treatment (Hamilton, Young and Ozols, 1984).  
Ovcar-8 and Skov-3 (ATCC) cell lines were derived from carcinoma which is resistant to 
carboplatin and cisplatin, respectively (Hamilton, Young and Ozols, 1984; Buick, Pullano 
and Trent, 1985).  
Igrov-1 cell line (ATCC) was obtained from ovarian carcinoma patient (Bénard et al., 1985).  
Normal Human Ovarian Epithelial (HOE; Applied Biological Materials Inc.) cells originated 
from normal ovarian epithelium and immortalized using SV40 large T antigen (Tsao et al., 
1995). All these cell lines are adherent cells that require trypsin for detachment and sub-
culturing from the culture flask. 
3.1.2. Cell lines growth conditions 
Ovarian cancer cell lines (A2780, CisA2780, Cov-318, Cov-362, Ovcar-3, Ovcar-4, Ovcar-
5, Ovcar-8, Igrov-1 and Skov-3) and HOE cells were grown as monolayer in a humidified 
incubator (NAPCO water jacketed incubator, Precision Scientific) at 37 °C in 5% CO2. 
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Roswell Park Memorial Institute (RPMI 1640; Lonza) medium was used for all cell lines, 
except Cov-318 and Cov-362, for which Dulbecco's Modified Eagle Medium (DMEM, 
Lonza) was the base medium of choice as recommended by ECACC. The base medium of 
all cell lines were supplemented with 10 % (v/v) fetal bovine serum (FBS) (Lonza), 2 mM 
L-Glutamine (Lonza) and 50 IU/mL of Pen-Strep solution (penicillin/streptomycin; Lonza). 
However, Ovcar-3 cells were additionally supplemented with 0.01 mg/mL bovine insulin 
(Lonza) and 1 mM sodium pyruvate (Lonza).  
3.1.3. Ovarian cells subculture  
Cell lines in a T25 culture flask were inspected regularly using light microscopy (Olympus 
CKX41). Once confluent, the monolayer cells were rinsed with 2 mL of phosphate buffer 
saline (PBS) (Lonza) and exposed to 0.01% (v/v) trypsin in PBS and incubated at 37°C for 
2–5 minutes. When the cells had detached, the trypsin was neutralized with 1 mL cell culture 
medium containing 10 % (v/v) FBS. Cells were then centrifuged (150 g, 3 min) and re-
suspended in fresh growth medium and reseeded in T25 or T75 culture flask or tissue culture 
plate for experimentation. Cells were usually subcultured at 1:4 ratios. After several 
passages, cells were discarded (3-4 months) and replaced by new cells from liquid nitrogen 
stocks (Mitry and Hughes, 2012). 
3.1.4. Cryopreservation 
Healthy, contamination free, 50-80 % confluent and low passage number cells in T75 flask 
were collected by trypsinization. The cells pellet was resuspended in chilled growth medium 
containing 8 % (v/v) dimethyl sulfoxide (DMSO, Sigma-Aldrich). 0.3 mL Aliquots were 
transferred into 2 mL cryovials. The cryovials were slowly frozen in freezing container 
containing isopropanol in a Nuaire -80 °C Ultralow freezer (Parker, 2011) and next day 
transferred into liquid nitrogen. 
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To resuscitate cells, frozen cells were thawed rapidly at 37 °C. The medium was removed 
by centrifugation and the cells were resuspended in fresh medium and transferred into T25 
tissue culture flask. After overnight incubation, the growth medium was again replaced to 
remove residual DMSO and dead cells. Cells were grown to an appropriate density for 
experimentation or sub-culture. 
3.1.5. Three-dimensional spheroid culture 
Spheroids, a free-floating multicellular aggregate, are considered more closely represent OC 
in vivo. Multicellular GravityTRAP ULA Plates (InSphero) were used to growth spheroids. 
The plates were wet with 40 µL of medium before seeding cells. The medium was removed 
from the plates and 500 Ovcar-4 or Cov-362 cells in 70 µL growth medium added per well 
followed by brief centrifugation (ALC PK120 Centrifuge) for 1 min at 900 rpm. After 3-5 
day, spheroids could be observed. Thereafter, 30 µL of medium containing vehicle, 
pitavastatin (10µM or 7µM), prednisolone (70µM) or a combination with prednisolone were 
added. Ovcar-4 or Cov-362 cells were incubated for 72 or 120 hours, respectively. 
Intracellular ATP level was quantitated using the cell Titer-Glo Luminescent assay reagent 
(Promega, Madison, WI, USA) as described in 3.5.2.  The Bliss independence criterion was 
calculated to determine the expected effect of the drug combination as described in section 
3.7.2 and this was compared to the observed effect of the combination.  
3.2. Compounds 
Pitavastatin (Livalo, Adooq), Zoledronic acid (Selleckchem), Risedronate (Selleckchem) 
and GGTI-2133 (Sigma-aldrich) Tipifarnib (APExBIO), Prednisolone (Sigma) were 
prepared as 20mM solutions in DMSO except zoledronic acid which was dissolved in H2O. 
The library of compounds evaluated in chapter 6 was a generous gift form Dr. Farahat 
Khanim, School of life Science- Birmingham University. 
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3.3. Cell proliferation assay (sulforhodamine B assay) 
 
5000 cells (or 2500 cells of A2780, CisA2780 and Ovcar-8) were seeded in 80 µL medium 
per well of a 96 well plate. The cells were allowed to adhere for 24 hours. Then, 20 µL of 
18 serial dilutions of individual drugs were added to cells. The cells were incubated for 72 
hours, except for the Cov-318 and Cov-362 which were incubated for 120 hours. 
Subsequently, cells were fixed by adding 100 μL of 10 % (w/v) trichloroacetic acid (Sigma-
Aldrich) and incubated on ice bucket for 30 minutes. The plates washed three times by 
immersion in cold water. After drying, cells were stained with 100 µL of 0.4 % (w/v) 
sulforhodamine B (SRB, Sigma-Aldrich) for 30 minutes. The plate wells washed three times 
in 1 % (v/v) acetic acid (Sigma-Aldrich) to remove excess SRB. Lastly, the dye was 
solubilized in 100 μL Tris base (10mM, pH not adjusted) and the optical density measured 
at 570nm with a microplate reader (Synergy 2 Multi-Mode Microplate Reader-BioTek). 
Graphpad prism 6 (Graphpad Software, Inc.) was used to analyze the data obtained from the 
cell proliferation assay by fitting a four parameter sigmoidal dose response curve for each 
drug to calculate the IC50. The IC50 values obtained from each repeated experiment were used 
to calculate the mean IC50 and associated standard deviation. 
3.4. Cell growth assay for the screening of the library with 
pitavastatin 
 
A panel of 100 off-patent licensed orally-bioavailable drugs were tested alone and in 
combination with pitavastatin in cell growth assays. The experimenter was “blind” to 
compounds names which were labeled with numbers from 1-100. 
Ovcar-4 cell line were seeded (5000 cells/well) overnight in 96-well plate in 80 μL of growth 
medium. The next day, the cells were exposed to vehicle, pitavastatin (10 µM), library 
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compounds, or a combination of pitavastatin and a compound from the library. After 72 hour 
incubation, cells were fixed same as previous described in section 3.3 and relative cell 
number were estimated by measuring the optical density at 570 nm using plate reader as 
described in Section 3.3. Each drug was tested in triplicate in two independent experiments. 
The Bliss independence criterion (Section 3.7.2) was used to analyse the  drug combination 
data (Goldoni and Johansson, 2007; Zhao et al., 2014) and allows calculation of the expected 
effect from the drug combination if their activity were additive. The “Bliss excess” was 
calculated by subtracting the measured effect of combination from the expected additive 
effect. 
3.5. Cell viability assay 
3.5.1. Trypan blue assay 
To evaluate the effect of drug combination on cell viability using the Trypan blue exclusion 
assay, A2780, Ovsaho or Skov-3 cells were seeded at density of 2×105 cells/2mL/well in 6 
well plate. The next day, 20 µL of medium containing vehicle or pitavastatin or zoledronic 
acid or a combination of both were added to the indicated final concentration. After 
incubation for 72 and 96 hours, adherent cells were collected gently by trypsinization and 
combined with the medium that contain non-adherent floating cells. The cells were 
centrifuged at 150 g for 3 minutes and the pellet was re-suspended in 0.5 mL of medium 
then equal volume of cell suspension mixed with equal volume of 0.4 % (v/v) trypan blue 
(Sigma-Aldrich). The viable and non-viable cells were counted by Neubauer 
hemocytometer.  
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3.5.2. Cell Titer-Glo luminescent assay 
A2780, Ovsaho and Skov-3 cells were seeded in 96 well plates as described in the cell 
proliferation assay (Section 3.3). The next day, 20 µL of medium containing vehicle, or 
pitavastatin or zoledronic acid or a combination of both were added to the cells at the 
indicated final concentration. After 72 hours, 25 µL of CellTiter-Glo reagent was added to 
the sample in each well of the 96 well plates. After 2 min shaking (Platform shaker STR6, 
Stuart scientific) and 30 min incubation in dark at room temperature, 100 µL was transferred 
to opaque-walled multiwell plates. The luminescence was measured in a Synergy 2 Multi-
Mode Microplate Reader (BioTek). 
3.5.3. Assessment of apoptosis by Annexin V-FITC/Propidium 
iodide staining 
To measure the effect of drug combination on apoptosis, annexin V and propidium iodide 
(PI) labelling was used. For siRNA transfection studies (Section 3.10), Ovcar-4 cells were 
seeded at a density of 1×105 cell/mL/well in antibiotic free medium in 12-well plates and 
incubated overnight. The cells were transfected with 100 nM of siGGTI-β #6, #7, #8, #9 or 
GGTII-β #5, #6, #7, #8 or non-targeting#1 (NT#1) (Sequences are in Table 3.3) using 1% 
(v/v) Dhamafect-1 (Dharmacon). The next day, the medium was replenished with fresh 
antibiotic free medium and the cells exposed to pitavastatin (10µM) prepared in 20 µL of 
medium and incubated for additional 48 hours.  
To measure the effect of pitavastatin-prednisolone combinations on apoptosis, Ovcar-4 or 
Cov-362 cells were seeded at density of 2×105 cells/2 mL/well in 6-well plate and incubated 
overnight. The medium was replenished and 20 µL of medium containing vehicle or 
pitavastatin or prednisolone or a combination added to the indicated final concentration. 
Ovcar-4 and Cov-362 cells were incubated with drugs for 48 and 72 hours, respectively. 
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For flow cytometry, the cells were labelled using a Annexin-V FITC kit (Miltenyi biotech) 
following the manufacturer’s instructions. After collection of the media from each well, the 
cells were trypsinized and washed in ice-cold PBS and centrifuged at 300 g for 5 minutes. 
The pellets were re-suspended in 1 mL of annexin V binding buffer and centrifuged for 10 
minutes at 300 g. Again, the pellets re-suspended in 100 µL of annexin V binding buffer and 
10 µL of Annexin V were added and incubated for 10 minutes in dark at room temperature. 
The cells were once more washed with 1 mL of annexin V binding buffer. Lastly, cells were 
centrifuged and the pellet was re-suspended in 500 µL Annexin V Binding Buffer and 5 µL 
of propidium iodide (1µg/mL) were added at least 5 min before the analysis by flow 
cytometry. The viability of cells was defined as live (annexin V-negative and PI-negative), 
early apoptotic cells (annexin V-positive and PI-negative), late apoptotic cells or dead cells 
(annexin V-positive and PI-positive) and necrotic cells. 
3.6. Apoptosis assay 
3.6.1. Caspase -3/7, -8 and -9 assay 
Caspase-Glo -3/-7, -8, -9 assay kits were used to determine Caspase-3/7, -8 and -9 activity 
according to the manufacturer’s instructions (Promega, Madison, WI, USA). A2780, 
Ovsaho, Skov-3, Ovcar-4 and Cov-362 5000 cells/80 µL of medium were seeded in 96 well 
plate and incubated overnight. The next day, 20 µL of medium containing vehicle, 
pitavastatin, zoledronic acid, prednisolone or combination were added to each well to the 
indicated final concentration. 
Cells were incubated with drugs for 48 hours or 72 hours for Cov-362 cells. 25 µL of the 
reagent were added to each sample and incubated for 1 hour in dark, with continuous 
shaking. Next, 100 µL of the medium transferred to 96 opaque-walled multiwell plates. 
Lastly, Caspase activities were measured using a microplate reader.  
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A parallel plate was prepared and treated with drug in the same way as that used for the 
caspase assay and this was stained with SRB as described in section 3.3. The results of the 
caspase assay were normalized to the protein content (SRB assay) of the sample.  
3.7. Drug combination analysis  
Drug combinations are common strategy indicated for immune disease, infection and cancer 
treatment. There are several methods for quantitative measurement of the effects of  drug 
combinations (Bijnsdorp, Giovannetti and Peters, 2011). An effect-based Strategy can be 
achieved by calculating the  expected effect of the combination using the Bliss independence 
criterion; a dose based strategy can be achieved by measuring the concentration of drugs in 
a combination required to have the same effect as the single agents and calculating a 
combination index (Foucquier and Guedj, 2015). 
3.7.1. Combination index  
The combination index is the most widely used method for evaluation of the drug 
combination (CI) was developed by Chou and Talalay to allow a quantitative measurement 
of synergy, additivity or antagonism between two agents. 
 
(D)1, indicate the doses of first drug; (D)2, indicate the doses of second drug; D, the dose of 
the drug in combination which inhibit cell growth by X%; (Dx)1 is for (D)1 “alone” that 
inhibits a system X%; (Dx)2 is for (D)2 “alone” that inhibits a system X%.  
The combination index was quoted at fraction affected fa = 0.5 (at which 50% of cells were 
apparently affected) and were calculated and compared to deviation from unity using a 
paired t-test. If the CI = 1, then the interaction between the two drugs is considered additive, 
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whereas, if the CI value is greater than 1 the interaction is antagonistic, but if the CI value is 
smaller than 1, then the interaction is considered synergistic. 
3.7.2. Bliss independence 
Bliss independence (Goldoni and Johansson, 2007) effects were calculated according to the 
following equation to evaluate drug interactions when full dose response curves were not 
performed (e.g. for trypan blue assays and ATP-assay).  
        E(X,Y) =E(X) + E(Y) - E(X)E(Y) 
E(X) and E(Y) are the fractional effect (between 0 and 1) of drug x and y measured by the 
assay. E(X,Y) is the expected effect of the drug assuming Bliss independence. The calculated 
additive effect calculated using the Bliss independence criterion was compared to the 
observed effect of the drug combination measured to quantify the drug interaction. 
3.8. Western blot analysis 
3.8.1. Whole cell lysate  
Ovarian cancer cell lines, A2780, Skov-3, Ovsaho, Ovcar-4 and Cov-362 were seeded in 6 
well plates at a density of 2×105 cell/2 mL medium/ well (same as section 3.5.1). The cells 
were incubated with vehicle, different concentration of the drugs alone, and in combinations 
of the indicated final concentration for 48 hours. After trypsinization, the cells washed with 
ice cold PBS and lysed in a modified Radio immunoprecipitation assay (RIPA) buffer (20 
mM Hepes (CalbioChem), 150 mM sodium chloride (NaCl, Sigma-Aldrich), 2 mM 
ethylene-diamino-tetraacetic acid (EDTA, Sigma-Aldrich), 0.5% sodium deoxycholate 
(Sigma-Aldrich), 1% NP40 (Sigma-Aldrich)). Additionally, 120 µM leupeptin (Sigma-
Aldrich), 10 µM pepstatin (Sigma-Aldrich) and 1 mM phenylmethanesulfonyl fluoride 
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(PMSF, Sigma-Aldrich) were added as protease inhibitors. The lysate was centrifuged at 
14,000 RPM for 15 minutes at 4°C, and the supernatant was collected and stored at -80°C. 
3.8.2. Cytoplasmic and membrane protein fractionation 
A2780 and Skov-3 2×105 cells/ 2 mL medium were seeded in 6 well plates and incubated 
overnight. The next day, 20 µL of medium containing vehicle or pitavastatin or zoledronic 
acid or a combination of both were added to the indicated final concentration (section 3.5.1). 
Membrane and cytoplasm proteins were separated using Mem-PER™ Plus Membrane 
Protein Extraction Kit (Thermofisher) according to the manufacturer’s protocol. The cells 
washed twice with 2 mL of ice cold washing buffer, re-suspended in 0.25 mL cell 
permeabilization buffer and incubated for 15 minutes with constant mixing. The mixture was 
centrifuged at 16000 xg for 15 minutes at 4 °C and the supernatant collected in a new 
eppendorf tube (cytoplasmic fraction). The pellets were re-suspended again in 0.16 mL of 
solubilization buffer and incubated for a further 30 minutes at 4 °C with constant shaking. 
After centrifugation at 16000 x g for 15 minutes at 4 °C, the supernatant was collected 
(membrane fraction) and both the cytoplasmic and membrane fraction were stored at -80°C 
waiting for analysis. 
3.8.3. Bicinchoninic acid protein assay 
The bicinchoninic acid (BCA) protein assay used to determine total protein concentration of 
the samples. Eight standards of Bovine serum albumin (BSA, Sigma-Aldrich) were prepared 
at concentrations between 0.1 and 2 mg/mL. Copper (II) sulphate pentahydrate solution (4%) 
(Sigma-Aldrich) were added to BCA solution (bicinchoninic acid, sodium carbonate, sodium 
tartate and sodium bicarbonate in 0.1 M sodium hydroxide) at a ratio of 1:50 to prepare the 
BCA reagent. 10 µL of each BSA standard or duplicate of each cells lysate (10 µL) were 
added to 100 µL of the BCA reagent. After 30-minute incubation at 37 °C, the absorbance 
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for standards and samples were measured using a plate reader. A calibration curve was fitted 
to the data obtained with BSA using linear regression and used to determine the 
concentration of protein in each sample lysate. 
3.8.4. Gel electrophoresis and immunodetection of proteins using 
SDS-page and western transfer 
Equal amount of protein from each sample cell lysate were first mixed with 5 µL of NuPAGE 
sample buffer (Invitrogen) containing 5 % (v/v) β-mercaptoethanol (Sigma-Aldrich) and 
samples denatured at 70 °C for 15 minutes. Sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) was used to separate the protein according their molecular 
weight. PageRuler Plus Prestained Protein Ladder (10 to 250 kDa) (Thermo Scientific) and 
denatured samples were added to Tris-Glycine polyacrylamide gradient gel (4-20%) (Nusep) 
in an XCell SureLock Mini Cell (Invitrogen) with Hepes running buffer (100 mM Hepes, 
100 mM Tris and 1% sodium dodecyl sulphate (SDS, Sigma-Aldrich)), and electrophoresis 
performed at 65V for 2 hours. Subsequently, the proteins were transferred from the gel to 
PVDF Amersham Hybond membrane (Hybond-ECL, GE Healthcare) using a freshly 
prepared ice cold transfer buffer (25 mM Tris, 200 mM glycine (Sigma- Aldrich), 0.075 % 
(w/v) SDS and 10 % (v/v) methanol (Sigma-Aldrich)) at 30 V for 2 hours. Next, 5% (w/v) 
skimmed milk powder in Tris-Buffered Saline with Tween (TBST) buffer was added to the 
PVDF membrane as a blocking solution and incubated on a shaker (Stuart Scientific 
Platform, STR6) for an hour at room temperature. The membrane was then incubated 
overnight with primary antibody at 4 °C with continuous shaking. The antibodies used are 
described in Table 3-2.  The following morning, the membrane was washed five times (5 
minutes each) in TBST buffer and incubated with secondary antibody for an hour at room 
temperature with continuous shaking. The membrane was again washed five times (5 
minutes each) with TBST buffer and proteins visualized using UptiLight HRP US 
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chemiluminescent substrate (Interchim) and a FluorChem M Imager. AlphaView SA 
software (Protein Simple) was used to quantify protein bands by measure the total signal in 
the selected area after subtracting the mean background per pixel. The results were then 
normalized to the GAPDH loading control. 
Table 3-2 The primary and secondary antibodies used for protein immunodetection 
Antibody Dilution Product code Supplier 
Anti-Actin 1/5000 #4968 Cell signalling Technology 
Anti-CDC42 1/10000 Ab187643 Abcam 
Anti-RAB6A 1/500 Ab95954 Abcam 
Anti-Ras 1/10000 Ab52939 Abcam 
Anti-RhoA 1/5000 Ab187027 Abcam 
Anti-FDPS 1/5000 Ab153805 Abcam 
Anti-GAPDH 1/5000 Mab374 Millipore 
Anti-GGTII-β 1/1000 Sc365901 Santa cruz 
Anti-GGTI-β 1/1000 Sc376854 Santa cruz 
Anti-HMGCR 1/1000 Ab173830 Abcam 
Anti-IDI1 1/1000 Ab97448 Abcam 
Anti-MVD 1/5000 Ab129061 Abcam 
Anti-P53 1/5000 Ab179477 Abcam 
Anti-NaK ATPase 1/100000 Ab167390 Abcam 
Anti-PARP 1/2000 #95425 Cell signalling Technology 
Anti-mouse 
secondary antibody 1/2000 #7076 Cell Signalling Technology 
Anti-rabbit 
secondary antibody 1/2000 #7074 Cell Signalling Technology 
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3.9. Transient gene transfection 
3.9.1. Plasmid preparation 
Plasmids encoding TP53 and TP53 variants, pCMV-Neo-Bam (vector), pCMV-Neo-Bam 
p53 WT, pCMV-Neo-Bam p53 R175H, pCMV-Neo-Bam p53 R273H, pCMV-Neo-Bam, 
pCMV-Neo-Bam p53 R248W, were obtained from Addgene.  
Luria-Bertani (LB) Agar was prepared by adding Bacto-tryptone (10 g), yeast extract (5 g) 
and NaCl (10 g) to 800 mL of distilled H2O. The pH was adjusted to 7.5 with NaOH and 
then 15 g of agar were added to the medium. Lastly, the volume was adjusted to 1L with 
dH2O and the LB agar sterilized by autoclaving. In addition, LB medium was prepared by 
mixing Bacto-tryptone (10 g), yeast extract (5 g) and NaCl (10 g) in 800 mL of distilled H2O. 
The pH was adjusted to 7.5 with NaOH and the volume adjusted to 1 L with dH2O. The LB 
medium was sterilized by autoclaving. Ampicillin antibiotic was added immediately prior to 
use to a final working concentration of 100 µg/mL. 
Sterile spreaders were used to spread the stab culture of E. Coli carrying the plasmid on a 
Luria-Bertani (LB) Agar. After overnight incubation at 37 °C, picked colonies were used to 
inoculate a sterile conical flask containing 100 mL of LB medium. The flasks were place in 
incubator at 37 °C with continuous shaking (300 RPM) for 20 hours.  
The plasmid was purified from the culture using the HiSpeed Plasmid Midi Kit (Qiagen). 
The collected culture medium was centrifuged at 6000 xg for 15 minutes at 4 °C. The pellets 
were re-suspended in 6 mL of buffer P1 and 6 mL of buffer P2 was added and the tube 
contents mixed by gentle inversion several times. After 5 minutes incubation at room 
temperature, 6 mL of buffer P3 was added and followed by gentle inversion to mix. The 
lysate was added to the barrel of the QIAfilter cartridge and incubated for 10 minutes at room 
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temperature. 4 mL of Buffer QBT was used to equilibrate a HiSpeed Tip. The lysate was 
allowed to pass through the HiSpeed Tip which was subsequently washed with 20 mL of 
buffer QC. The DNA was eluted by 5 mL of buffer QF and precipitated by adding 3.5 mL 
of isopropanol. After incubation for 5 minutes, the eluate was collected with a 
QIAprecipitator and washed with 2 mL of 70 % ethanol. Once dried, the DNA was eluted 
with 1 mL of buffer TE and the concentration of plasmid was determined by 
spectrophotometer (Nanodrop2000) before storage at -20 °C. 
3.9.2. Plasmid transfection 
Expression studies were approved by the Keele genetic modifications of microorganisms 
committee. 32,000 Skov-3 cells per well of a 24 well plate were seeded in 500 µL antibiotic 
free RMPI medium. After an overnight incubation, the medium was replaced with 400 mL 
of fresh antibiotic free medium. Cells were transfected with 0.1 % CMV-Neo-Bam (vector), 
pCMV-Neo-Bam p53 WT, pCMV-Neo-Bam p53 R175H, pCMV-Neo-Bam p53 R273H, 
pCMV-Neo-Bam p53 R248W (Addgene) and 0.2 % of Lipofectamine 2000. The 
transfection mixture was prepared by adding 0.55 µg of DNA to 50 µL of Optimem media 
and 1.1 µL of lipofectamine 2000 (Invitrogen) to a separate aliquot of 50 µL of Optimem. 
The lipofectamine and DNA solutions were mixed and incubated for 30 minutes at room 
temperature to allow DNA-lipofectamine 2000 complex formation. 100 µL of the 
transfection mixture were added to each well of the plate and next day, the medium was 
changed and the cells incubated for a further 48 hours. The transfection efficiency was 
measured using western blotting to assess the expression of p53 level. 
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3.10. Small interfering ribonucleic acid (siRNA) transfections 
 
5000 Ovcar-4 and Ovcar-3 cells were plated in 80 µL of antibiotic-free growth medium per 
well in a 96 well plate and incubated overnight. A solution of 1% DharmaFECT-1 was 
prepared in Optimem (Invitrogen) and incubated for 10 minutes at room temperature. The 
siRNA oligos (Table 3-3) were prepared at 10 times the final concentration required at well 
(100 nM) and then mixed with 1% DharmaFECT-1 solution. The mixture was incubated for 
30 minutes at room temperature to facilitate complex formation between the siRNA and 
liposomes. The growth media on cells was replaced with 80 µL of fresh antibiotic free 
growth media, then 20 µL of siRNA and DharmaFECT-1 mixture were added to each well. 
The same process was made for the non-targeting siRNA control to demonstrate if there are 
any off-target effects on gene expression (off-target gene silencing). The next day, the media 
were replenished with 100 µL of fresh antibiotic free growth media and cells incubated for 
additional 48 hours. Subsequently, cells processed same as in section 3.8.1 for whole cell 
lysate and gene expression was assessed by immunoblotting. 
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Table 3-3 siRNA transfection Oligos 
Gene Name Used Concentration Target Sequence 
P53#smart pool 100nM - 
P53#1 100nM GAAAUUUGCGUGUGGAGUA 
P53#2 100nM GUGCAGCUGUGGGUUGAUU 
P53#3 100nM GCAGUCAGAUCCUAGCGUC 
P53#4 100nM GGAGAAUAUUUCACCCUUC 
GGTI-β#6 100nM CGACUUAAGCCGAGUAAAU 
GGTI-β#7 100nM GAGACAAGCAGGUUGACAA 
GGTI-β#8 100nM GGAUAAAGAGGUGGUGUAU 
GGTI-β#9 100nM CCACAUGAAUGAUUUUAGA 
GGTII-β#5 100nM UUACUUGGCUGGUGGCUUU 
GGTII-β#6 100nM GGAAUAAGUGCUAGUAUCG 
GGTII-β#7 100nM UCUGAGUAUUUGAGAAUGA 
GGTII-β#8 100nM UGGAAUAUGUUAAAGGUCU 
NT#1 100nM UGGUUUACAUGUCGACUAA 
NT#2 100nM UGGUUUACAUGUUGUGUGA 
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3.11. Quantitative reverse transcriptase polymerase chain 
reaction  
3.11.1. RNA extraction from culture cells 
5000 Ovcar-3 and Skov-3cells were plated in 80 µL of antibiotic free medium per well in 96 
well plate and incubated overnight. Cells were harvested using RNeasy mini kit (Qiagen) 
following the manufacturer instruction. 175 µL of RTL buffer, supplemented with 1% β-
mercaptoethanol, were added to each well (usually 2 well were combined to create one 
sample) and pipetted up and down several times to ensure cell lysis. Lysates were centrifuged 
for 3 min at maximum speed (16000xg). The supernatant transferred to a new 1.5 mL tube 
and mixed with 350 µL of 70% ethanol by pipetting up and down several times. Next, 
approximately 700 µL of each sample was transferred to mini spin column placed in 2 mL 
tube and centrifuged for 15 second at 8000 xg and the flow through discarded. The 
centrifugation process was repeated with another 700 µL of RW1 buffer and subsequently 
twice more with 500 µL RPE buffer. The column was dried by centrifugation for 2 minutes. 
Lastly, the spin column was placed in new 1.5 mL tube and 50 µL of RNase free water 
added, incubated for 2 minutes and then centrifuged for 1 minute at 8000xg in order to elute 
the RNA. The purity and concentration of the extracted RNA were measured using a Nano-
Drop2000 spectrophotometer (Thermo fisher scientific). The extracted RNA placed in -20 
°C. 
3.11.2. Synthesis of cDNA by reverse transcriptase 
SuperScript™ III Reverse Transcriptase was used to generate the complementary DNA 
strand (cDNA). The reaction mixtures were maintained in ice during the procedure.  A 
mixture of 11.5 µL of RNA extracted from cells and 1.5 µL (0.5 µg) of Oligo (dT)20 (50 µM) 
were mixed and denatured at 65ºC for 5 minutes in thermal cycler (MJ Research PTC-200 
Chapter Three | Materials and Methods 
100 
Thermal Cycler, USA) and stored on ice. The reaction mixture for each sample was prepared 
by mixing 4 µL of 5X reverse transcriptase RT reaction buffer, 1 µL of dNTP mix (10 mM), 
1 µL of reverse transcriptase and 1 µL of DTT (0.1 M). The reaction mixture (7 µL) was 
added to already prepared RNA mixture. The tubes were exposed to pulse spin using 
centrifuge and transferred to thermal cycler again which include incubation for 5 minutes at 
65 ºC, 30 minutes at 50 ºC, 5 minutes at 85 ºC and lastly cooling down to 4 ºC. 
The concentration and purity of the cDNA was measured using Nanodrop2000 
spectrophotometer. The DNA concentration is dependent on absorbance at 260 nm. The ratio 
of the 260/280nm were used to assess the purity of DNA. The reaction product was diluted 
5 times by adding 80 µL of water and the sample were stored in -20. 
3.11.3. qRT-PCR 
A master mix was prepared by adding 6.25 µL of syber green (Absolute SYBR Green ROX 
mix Thermo Scientific), 0.125 µL of forward and reverse primer (10 mM) (Table 3-4) and 
1.125 µL of nuclease free water for each sample and kept on ice. The master mix was mixed 
gently and collected by brief centrifugation. 7.5 µL reaction mixture were added to each 
wells of optical 8-tube strips, then 5 µL of DNA sample or dH2O were added to each tube in 
duplicate. The optical strips were briefly vortexed to remove any air bubbles and centrifuged 
to collect the reaction mixture at the bottom of the wells. A Stratagene Mx3005P thermal 
cycler (Agilent Technologies) was used to conduct the analysis (Table 3-5). To confirm that 
only one amplicon was detected the dissociation curves were analyzed for each sample. In 
addition, the efficiency of genes was confirmed by measuring the CT value of 4 serial of 4-
fold dilution of samples using qRT-PCR. The standard curve produced from the measured 
CT data and the log of the dilution factors were analyzed by liner regression and implemented 
in the following equation to measure the efficiency.  
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Efficiency = (10-1/slope)-1 
A comparative cycle threshold (CT) method was used to analyses the data, which compares 
the CT value of target gene to the CT value of the reference gene.  
ΔCT= CT (target gene) – CT (reference gene) 
ΔΔCT=2^(-ΔCT) 
Ratio (Fold changes) =
ΔΔCT of treated sample
ΔΔCT of control sample
 
 
Table 3-4 Primer sequences 
Primer 
Name 
Forward (5’ → 3’) Reverse (5’ → 3’) 
HMGCR CAGAATTACGTCAACTTGGATC AGAAGTGATGACAACTGTACTG 
GGTI-β GGATTTCTTACGGGATCGGC TTGTCAACCTGCTTGTCTCG 
GGTII-β CTGGTGGCTTTGTGAACGAC CAGGACCCACCATGAGTAGC 
FT-β CTTTTTGCCTCTATCCGCTCG TGTGTAGGACTCTGCTTCGT 
β-actin GCAAAGTTCCCAAGCACA AAGCAAGCAGCGGAGCAG 
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Table 3-5 Thermal cycling profile for qRT-PCR 
 First segment Second segment Third segment 
 Denaturation of 
DNA strands at 95
◦
C 
for 15 minutes 
Denaturation of the DNA 
at 95
◦
C for 30 second 
For dissociation 
curve at 95
◦
C for 
1 minutes, 55
◦
C 
for 30 second 
and 95
◦
C for 30 
second 
Primer annealing at 60
◦
C 
for 1minute  
DNA strand elongation at 
72
◦
C for 30 second 
Cycle Number  1 40 1 
 
3.12. Statistical analysis 
Number of experiments (n) of independent biological replicate were employed to calculate 
means and standard deviations (mean±SD). GraphPad Prism version 6.0 (GraphPad 
Software, San Diego, USA) was used to generate sigmoid dose response curves and to 
calculate the IC50s. t-tests were performed using Excel to compare two variables. One-way 
ANOVA followed by Tukeys post hoc was used to compare the mean of more than two 
variables. Results were considered statistical significance at P < 0.05. 
 
  
 
 
 
 
 
 
 
 
 
Chapter Four 
 
4. TP53 and mevalonate pathway interplay in 
ovarian cancer cell lines 
 
 
 
 
 
 
 
 
 
  
Chapter Four | TP53 and Mevalonate pathway 
104 
4.1. Introduction 
The early observation of p53 oncogenic properties was misled by the use of mutated clones 
of p53 extracted from cancer cells.  However, Shaulsky, et al., 1991 and Dittmer, et al., 1994 
were the first to report the gain of new functions of mutant p53 (Shaulsky, Goldfinger and 
Rotter2, 1991; Dittmer et al., 1993). While most tumour suppressor genes are inactivated by 
frameshift or nonsense mutation, missense is a common TP53 mutation that is associated 
with cancer and which often generates high levels of a stable mutant p53 (Olivier, Hollstein 
and Hainaut, 2010; Oren and Rotter, 2010; Goh, Coffill and Lane, 2011). Mutated TP53 not 
only abrogates the tumour suppressor function of the wild type TP53 allele via dominant-
negative mechanism, but also endows abnormal oncogenic gain-of-function (GOF) 
properties. This results in enhanced proliferation, metastasis and chemoresistance (Heublein 
and Sabine, 2016; Hientz et al., 2016; Oren and Kotler, 2016).  
TP53 mutation (90%) cluster in the DNA binding domain and about 1300 different single 
base-pair substitution of the core domain of p53 protein have been reported in cancer. 
TP53 missense mutation tend to cluster at hot-spot codons in the DNA binding domain 
(Figure 4-1) (Goldstein et al., 2010). The six most common hotspot mutations are R175, 
G245, R248, R249, R273, and R282 (Mello and Attardi, 2013) and ~20% of TP53 mutation 
occur at R273, R248 and R175 in ovarian cancer (OC) (Brachova, Thiel and Leslie, 2013). 
Mutations outside the DNA binding domain are also reported (Joerger and Fersht, 2007; 
Olivier, Hollstein and Hainaut, 2010). Even in cancers where TP53 mutation is rare, TP53 
function is inactivated by different mechanism such as nuclear exclusion, inactivation of 
p19ARF and interaction with over expressed MDM2 or with a viral protein (Soussi and 
Béroud, 2001). 
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Figure 4-1 Distribution of TP53 missense mutation  
TP53 mutation mostly located at the DBD with the six most common hotspot mutations are R175, 
G245, R248, R249, R273, and R282. PR, proline-rich domain; Reg, carboxy-terminal regulatory 
domain; TA, transactivation domain; Tet, tetramerization domain. Reprinted with permission from 
(Brosh and Rotter, 2009). 
 
TP53 mutation can be categorized according to the effect of mutation on the thermodynamic 
stability of the protein. These mutations can be classified in two groups, DNA contact and 
conformational mutations. The DNA contact group comprise mutations in residues that are 
involved in DNA binding (R273H and R248Q), while the second conformational group 
include mutation that led to global (R175H and R282W) or local (R249S and G245S) 
conformational distortion (Brosh and Rotter, 2009).  
Whereas, several GOF phenotypes have been noted, our understanding of the underlying 
mechanism remains incomplete (Hanel et al., 2013). The nature of the mutation at a 
particular residue can have a profound effect on the phenotype that is observed. For example, 
the p53R248Q mutant is linked with metastasis, whereas the p53R248W mutant is less metastatic 
(Mullany et al., 2015). In addition, the p53R175C mutant was wild-type in its phenotype; 
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R175K, R175P, R175I and R175S trigger only cell cycle arrest; R175N and R175T stimulate 
cell cycle arrest and partially stimulate programed cell death; and R175Y, R175W, R175D 
and R175F do neither (Goh, Coffill and Lane, 2011). The wide spectrum of TP53 mutations 
led to a widely established notion that not all mutations are equivalent in their structural and 
functional effects (Mullany et al., 2015). 
TP53R273 mutations are the most frequent mutation in OC. In this mutation, the amino acid 
residues at position 273 is altered to either histidine (46%) or cysteine (39%), the protein 
DNA target sequence is altered but without deforming the structure of p53 protein and thus 
maintaining its DNA binding ability (Wong et al., 1999; Joerger et al., 2009; Eldar et al., 
2013). In vitro and in vivo studies showed that R273 mutation increase cellular proliferation 
in culture and the liability to develop carcinomas in mice (Olive et al., 2004). Furthermore, 
resistance to cisplatin developed following ectopic overexpression of R273H on a TP53 null 
background cells (Chang and Lai, 2001). The interaction of p53R273H with several proteins 
such as NF, SP1, p63 and SREBP might be the likely cause of tumour progression and  
increased resistance to chemotherapy (Brachova, Thiel and Leslie, 2013). R273H also 
promote TGF-β induced metastasis (Adorno, et al. 2009).  
The second most commonly transformed codon in OC is R248 in which the arginine amino 
acid is replace by tryptophan or glutamine (R248W or R248Q) (Brachova, Thiel and Leslie, 
2013). This alteration affects the interaction of p53 with DNA binding response element 
without significant changes to the structural conformation of p53 (Wong et al. 1999). 
Acceleration of the tumour onset and shortened survival is reported in p53R248Q knock-in 
mice (Hanel et al., 2013). In addition, upregulation of the multidrug resistance gene (MDR1) 
mediated the resistance to doxorubicin and paclitaxel in hepatocellular carcinoma cells 
which harbour p53R248Q (Chan and Lung, 2004).  
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The third well characterized hotspot mutation is R175H, in which the arginine is replaced 
by histidine. The connection between R175H and tumourigenic potential and 
chemoresistance had been reported (Blandino, Levine and Oren, 1999). Transgenic 
expression of p53R175H enhances the proliferation capacity and increases the tumourigenic 
potential (Olive et al., 2004). The interaction of R175H with a number of proteins might 
mediate changes in proliferation, metastasis and chemoresistance. Overexpression of p53R175 
mediates resistance to cisplatin, etoposide and paclitaxel (Blandino, Levine and Oren, 1999).  
In OC, the most frequent hereditary genetic aberrations are germline mutation in BRCA1 
and BRCA2. In contrast, TP53 mutation are a common alteration in sporadic epithelial OC  
(Corney et al., 2008). There is little evidence of p53 mutation in benign and borderline 
epithelial ovarian tumours. Only one in a series of 48 borderline tumours was reported to 
have TP53 mutation and 2 of 48 cases were found to overexpress p53 (Russell, 2001). 
Mutant p53 had been associated with poor clinical outcome in ovarian carcinomas (Corney 
et al., 2008). High grade serous OC  patients with TP53 mutation are more likely to exhibit 
distant metastases and develop resistance to platinum chemotherapy (Kang et al., 2013; 
Zhang et al., 2016). In addition, progression-free survival is significantly shorter in patients 
with p53 mutation compared to patients with wild type p53 activity (Russell, 2001). Mutant 
TP53 is also considered as a poor prognostic factor in colorectal, prostate, lung and breast 
cancer (Yemelyanova et al., 2011; Mantovani, Walerych and Sal, 2016).  
A precise control of metabolism is vital for a normal cellular activity. It is increasingly 
evident that cellular metabolism is aberrant in cancer and plays a key role in maintaining the 
malignant state (Vousden and Ryan, 2009). Recently, several studies had identified a number 
of mevalonate pathway (MP) enzymes as crucial for the survival of different transformed 
cells by supplying sterol and isoprenoids and other products (Blomen et al., 2015; Hart et 
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al., 2015; Wang et al., 2015). In addition, the involvement of MP in several aspects of 
carcinogenesis led to it being considered as a target for therapy (Wong, Dimitroulakos and 
Penn, 2002; Clendening et al., 2010; Clendening and Penn, 2012). In addition, an emerging 
role of mutant TP53 in regulation of MP in breast cancer cells had been reported recently. 
Gain-of-function mutants of p53 interact with the SREBP to stimulate the transcription of 
genes involved in MP activity regulation in breast cancer cell lines (Freed-Pastor et al., 
2012). Therefore, it seems reasonable to evaluate the contribution of TP53 in regulation of 
MP in OC to support the application of statins to the treatment of OC. 
4.2. Aims 
The goal of this chapter was to evaluate the contribution of TP53 to the regulation of MP. 
To do this the effect of ectopic expression of TP53 and siRNA directed to mutant TP53 on 
the expression of MP enzymes, HMGCR, GGTI-β, GGTII-β and FT-β, was examined. 
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4.3. Results 
 
4.3.1. The expression of HMGCR in a panel of ovarian cancer 
cell lines 
It has been demonstrated that the activity of MP is deregulated in several different tumours. 
In order to study the activity of this pathway in OC cell lines, the level of HMGCR was 
measured to confirm if this correlated with mutational and expression of TP53. HMGCR 
enzyme were measured using western blot in a panel of OC cell lines, and compared to the 
level of HMGCR in normal human ovarian epithelial cells (HOE). Quantification of 
HMGCR enzyme levels reveals that all OC cell lines had a higher level of HMGCR protein 
expression than the normal HOE cells and it was statistically significant in A2780, 
CisA2780, Cov-318, Cov-362, Ovcar-3, Ovcar-5, Skov-3 cell lines compared to HOE cells 
(Figure 4-2 A and B).  
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Figure 4-2 The level of HMGCR protein in panel of ovarian cancer cell lines. 
The level of HMGCR was measured using western blot (A) in a panel of OC cell lines and normal 
human epithelial ovarian cell line and quantified (B). GAPDH was used as loading control. HMGCR 
protein were normalized to GAPDH (n = 3, *, P <0.05; **, P <0.01; paired t-test).  
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4.3.2. The expression of GGTI-Β and GGTII-Β in a panel of 
ovarian cancer cell lines 
In addition to HMGCR, the level of the GGTI-β and GGTII-β enzymes of the MP were 
determined by immunoblotting in a panel of OC cell lines (Figure 4-3 A) and quantified 
(Figure 4-4 A and B). The results showed that GGTI-β and GGTII-β protein are 
overexpressed in subset of OC cell lines compared to HOE. However, the differences in 
expression were statistically significant in A2780, CisA2780, Ovcar-4, Ovcar-8, Igrov-1 and 
Skov-3 cell line for GGTI-β and A2780, Ovcar-5, Ovcar-8 and Igrov-1 cell line for the 
GGTII-β. 
     (A) 
 
Figure 4-3 GGTI-β and GGTII-β level in panel of ovarian cancer cell lines. 
The level of GGTI-β and GGTII-β was measured using western blot in a panel of OC cell lines and 
HOE. GAPDH was used as loading control (n = 3).
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Figure 4-4 Quantification of GGTI-β and GGTII-β level in panel of ovarian cancer cell 
lines. 
The level of GGTI-β and GGTII-β was measured using western blot in a panel of OC cell lines and 
HOE and quantified (B and C). GAPDH was used as loading control. GGTI-β and GGTII-β were 
normalized to GAPDH (*, P <0.05; **, P <0.01; paired t-test). 
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4.3.3. P53 status in panel of ovarian cancer cell line 
To investigate the role of TP53 in regulation of MP enzymes in OC, the status of TP53 
mutations was first obtained from a public database (Bouaoun et al., 2016) (Table 4-1). Most 
of the cell lines harbour a mutation in TP53, only HOE and A2780 cell lines have a wild 
type TP53. In common with other cancers, the mutations were mostly in the DNA binding 
domain (Figure 4-5) (Bieging and Attardi, 2012). Ovcar-3 cells had a mutation R248Q, 
which is one of most frequent hotspot mutations in p53 and is considered a gain of function 
mutation. In contrast, Skov-3 cell line is an established cell line that does not express p53 at 
protein level (Mullany et al., 2015). 
 
Table 4-1 TP53 status in a panel of ovarian cancer cell lines (Bouaoun et al., 2016). 
Cell line TP53 status p53 Mutation  
HOE Wild-type - 
A2780 Wild-type - 
CisA2780 Mutated Q136 
Cov-318 Mutated I195F 
Cov-362 Mutated Y220C 
Ovcar-3 Mutated R248Q 
Ovcar-4 Mutated L130V 
Ovcar-5 Mutated - 
Ovcar-8 Mutated Y126C 
Igrov-1 Mutated Y126C 
Skov-3 Null - 
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Figure 4-5 Sites of p53 mutation on ovarian cancer cell line.  
Schematic representation of the 393 amino acid domain structure of human p53 showing the sites of 
mutation in OC cell lines. N-terminal transactivation domain (TAD); proline-rich domain (PR); 
tetrameriszation domain (TET); C-terminal regulatory domain (REG). 
 
 
In addition, the expression of p53 was examined in panel of OC cell lines by western blotting 
(Figure 4-6). The result showed that p53 was most highly expressed in Cov-362, Ovcar-3, 
Ovcar-4 and Ovcar-8 cell lines and to lesser extent in A2780, CisA2780, Cov-318 and Igrov-
1 cell lines. P53 expression was not been detected in Ovcar-5 and Skov-3 cell lines as 
previously reported (Mullany et al., 2015). 
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Figure 4-6 the expression of p53 in a panel of ovarian cell lines. 
The level of p53 was measured using western blot (A) in a panel of OC cell lines and normal HOE 
cell line and quantified (B). GAPDH was used as loading control. P53 protein were normalized to 
GAPDH (n=3, **, P <0.01; paired t-test). 
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The cells were classified according to the TP53 mutational status into wild type and mutated 
TP53 and the level of MP enzymes determine by western blot in section 4.3.1 and 4.3.2 were 
used to compared between these two groups. The results showed that HMGCR level (Figure 
4-7) in cell line that harbour TP53 mutation was significantly higher than in cell lines with 
wild type TP53. However, there were no significant differences in GGTI-β and GGTII-β 
expression between cell lines with wild type TP53 and mutant TP53 (Figure 4-8). 
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Figure 4-7 Comparison of the HMGCR expression in cells with wild type and mutant 
TP53. 
The cell lines were classified according the TP53 status into wild type and mutant TP53 and the level 
of the HMGCR were compared between these two groups of cell lines (Mean ± SD; * P < 0.05; 
unpaired t-test). 
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Figure 4-8 Comparison of the GGTI-β and GGTII-β expression in cells with wild type 
and mutant TP53. 
The cells were classified according the TP53 status into wild type and mutant TP53 and the level of 
the GGTI-β and GGTII-β were compared between these two groups of cell lines (Mean ± SD; * P < 
0.05; unpaired t-test). 
 
The expression of the MP enzymes was compared with that of mutant p53 in CisA2780, 
Cov-318, Cov-362, Ovcar-3, Ovcar-4, Ovcar-8 and Igrove-1 OC cell lines. There was no 
significant correlation between p53 and HMGCR and GGTII-β expression. In contrast, the 
GGTI-β were significantly correlated with p53 expression (R2 = 0.213; p < 0.05) (Figure 
4-9). In addition, when the expression of MP enzymes was compared with sensitivity to 
pitavastatin IC50 in cell growth assays, only GGTI-β showed a statistically significant 
correlation (R2 = 0.463; p < 0.05) (Figure 4-10). Although these correlations were 
statistically significant the correlation coefficient were weak to moderate linear correlation.   
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Figure 4-9 Relationship between the expression of mutant p53 and the expression of 
the mevalonate pathway enzymes in ovarian cancer cell lines. 
The expression of the p53 was correlated with HMGCR (A), GGTI-β (B) and GGTII-β (C) 
expression which are quantified from blotting in CisA2780, Cov-318, Cov-362, Ovcar-3, Ovcar-4, 
Ovcar-8 and Igrov-1 OC cell lines.
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Figure 4-10 Relationship between sensitivity to  pitavastatin and the expression of 
mevalonate pathway enzymes in ovarian cancer cell lines. 
Pitavastatin IC50s correlated to the expression of HMGCR (A), GGTI-β (B) and GGTII-β 
(C) which is quantified from blotting in a panel of OC cell lines. 
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4.3.4. The effect of p53 overexpression on mevalonate pathway 
4.3.4.1. The effect p53 overexpression on HMGCR in Skov-3 cell 
line 
It has been proposed that to understand mutations in TP53, cells lacking p53 can be used to 
overexpress of mutant TP53; alternatively, siRNA can be used to knockdown the TP53 in 
cells harbouring mutated p53 (Brachova, Thiel and Leslie, 2013). Therefore, Skov-3 (TP53 
null) and Ovcar-3 (TP53 R248Q) cells were tested to explore the effect p53 on the MP 
enzymes. 
In order to evaluate the effect of p53 in MP in OC cell lines. Skov-3 were transiently-
transfected with a plasmid encoding mutated TP53 variants R284W, R175H and R273H 
which are the most frequently reported mutation in OC  (Brachova, Thiel and Leslie, 2013). 
Skov-3 cells were also transfected with a plasmid encoding wild-type TP53 variant. The 
expression of HMGCR and p53 was monitored after 48 and 72 hours because transient 
ectopic expression was used in these experiments. The result showed that there is marked 
increase in level of expression of all p53 variants after transfection compared with cells 
transfected with vector. In addition, all p53 variants caused an increase in the level of 
HMGCR expression. However, only wild type and R248W gain of function variant led to a 
significant increase in the expression of HMGCR compared to cells transfected with vector 
measured by immunoblotting after 48 hour of transfection (Figure 4-11). 72 hours after 
transfection p53 was still detectable but the changes in the level of HMGCR were no longer 
significantly different to cells transfected with the empty vector (Figure 4-12). 
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Figure 4-11 The level of HMGCR and p53 in Skov-3 cell line transfected with p53 
after 48 hour incubation. 
Wild type (WT) and p53 variants were over expressed in Skov-3 cell lines. HMGCR and p53 
measured by immunoblotting (A) after 48 hours of incubation and proteins were quantified (B). 
HMGCR were significantly different to expression in cells transfected with vector where shown 
(mean ± S.D., n=3, *, P <0.05; paired t-test). 
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Figure 4-12 The level of HMGCR and p53 in Skov-3 cell line transfected with p53 
after 72 hour incubation. 
Wild type (WT) and p53 variants were over expressed in Skov-3 cell lines. HMGCR and p53 
measured by immunoblotting (A) after 72 hours of incubation and proteins were quantified (mean ± 
S.D., n=3) (B). HMGCR expression was not significantly different to cells transfected with the 
vector. 
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4.3.4.2. The effect of ectopic p53 transfection on mevalonate 
pathway genes expression 
To confirm that the increase in HMGCR protein was due to increased transcription of 
HMGCR, its mRNA was measured by QPCR. In parallel the expression of genes encoding 
farnesyl and geranylgeranyl transferases GGTI-β, GGTII-β and FT-β was also measured. 
The results showed that there was an increase in mRNA level of all tested MP enzymes in 
Skov-3 cells which were transiently-transfected with plasmids encoding wild type TP53 
variant and mutated TP53 variants R284W, R175H and R273H compared to cells transfected 
with vector. The expression of HMGCR were significantly increased by ectopic expression 
of the wild type TP53 variant and mutant TP53 variants. The increase in HMGCR mRNA 
was most pronounced in cells transfected with R248W variant, in agreement with our 
previous observation of increased HMGCR protein measured by western blotting (Section 
4.3.4.1). GGTI-β expression increased in a pattern similar to that of HMGCR expression 
with R248W variant inducing higher expression than other TP53 variants. In contrast, the 
expression of GGTII-β was consistently and significantly induced by all TP53 variants. 
Lastly, the expression of FT-β were also significantly elevated except in cells transfected 
with R248W, in which the change was not statistically significant (Figure 4-13).  
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Figure 4-13 mRNA expression of HMGCR, GGTI-β, GGTII-β and FT-β genes of Skov-
3 cell line transfected with p53.   
Wild type (WT) and p53 variants were over expressed ectopically in Skov-3 cell lines. Relative 
mRNA expression of HMGCR, GGTI-β, GGTII-β and FT-β genes were measured using QPCR after 
48 hour of transfection. Relative mRNA expression of genes was significantly different compared to 
cells transfected with vector (mean ± S.D., n=3, *, P <0.05, **, P <0.01; ***, P <0.001; one-way 
Anova followed by Tukeys post-hoc). 
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4.3.5. The effect of p53 knockdown on mevalonate pathway 
4.3.5.1. The effect of p53 siRNA transfection on HMGCR 
expression in Ovcar-3 cell line 
The results showed that ectopic overexpression of p53 in Skov-3 cell line cause significant 
increase in level of MP gene expression. To determine if the pre-existing mutation in TP53 
also regulate MP genes, the expression of TP53 in Ovcar-3 cells (which contain a mutation 
in TP53 encoding R248Q) was repressed using four different siRNA oligo’s directed to p53 
mRNA. First, the p53 knockdown was confirmed by western blotting. All of the TP53 
siRNAs showed a reduction by more than 65 % of the p53 protein level compared to cells 
transfect with non-targeting-1 siRNA. Secondly, HMGCR protein levels were decrease 
significantly after transfection with each of thep53 siRNA (Figure 4-14 A). However, the 
quantification revealed that p53#2 and p53#4 oligos induce a reduction in HMGCR level 
which was statistically more significant than p53#1 and p53#3 oligos (Figure 4-14 B). 
 
4.3.5.2. The effect of p53 siRNA transfection on mevalonate 
pathway genes expression. 
RT-QPCR was used to confirm that the knockdown of p53 protein by siRNA directed to 
TP53 reflected reduced transcription of HMGCR. In parallel the expression of GGTI-β, 
GGTII-β and FT-β enzymes was also measured. The expression of HMGCR, GGTI-β, 
GGTII-β and FT-β genes were markedly reduced by transfection of Ovcar-3 cells with four 
separate siRNA directed to TP53 compared to cells transfected with NT#1 siRNA (Figure 
4-15).  
Lastly, it can be summarized that MP enzymes are deregulated in OC. Particularly, HMGCR 
level is higher in OC cell line in comparison to normal human ovarian epithelial cells. In 
addition, p53 play a central role in regulation of MP. Exogenous transfection of Skov-3 cell 
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line with p53 upregulate the expression of key enzymes of MP, such as HMGCR, GGTI-β, 
GGTII-β and FT. in contrast, knockdown of p53 using siRNA downregulate the expression 
of these MP enzymes. 
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Figure 4-14  The level of p53 in Ovcar-3 cell line transfected with non-targeting (NT) 
siRNA or p53 siRNA. 
p53 measured by immunoblotting (A) and quantified (B) after 48 hour of transfection of 
Ovcar-3 cell line with Non-targeting#1 siRNA (NT#1) or 4 different p53 siRNA (#1, #2, #3, 
#4). p53 were significantly different to expression in cells transfected with NT#1 where 
shown (mean ± S.D., n=3, *, P <0.05; **, P <0.01; ***, P <0.001; paired t-test). 
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Figure 4-15 mRNA expression of HMGCR, GGTI-β, GGTII-β and FT-β genes of 
Ovcar-3 cell line transfected with p53 siRNA.  
p53 knockdown using four p53 siRNA and NT#1 siRNA in Ovcar-3 cell lines. Relative mRNA 
expression of HMGCR, GGTI-β, GGTII-β and FT-β genes were measured using QPCR after 48 hour 
of transfection. Relative mRNA expression of genes was significantly different compared to cells 
transfected with NT#1 siRNA (mean ± S.D., n=3, ***, P <0.001; one-way Anova followed by 
Tukeys post-hoc). 
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4.4. Discussion 
Approximately 75% of OC  deaths is caused by HGSOC (Bowtell et al., 2015; Lee et al., 
2015). The tumour suppressor TP53, which is frequently mutated in OC, and up to 99 % in 
HGSOC (Fleury et al., 2015), is considered as a master regulator of diverse cellular process 
in health and disease (Farnebo, Bykov and Wiman, 2010). Once mutated, it is involved in 
several aspect of malignant transformation and resistance to cancer therapy but the actual 
mechanism remains incompletely understood (Brosh and Rotter, 2009). This study describes 
the possible role of p53 in regulation of MP. Exogenous transfection of p53 upregulate the 
level of MP enzymes while knockdown of mutant p53 down regulate the level of MP 
enzymes. Therefore, studying p53 is still an important target to identify their role in 
oncogenesis. 
The expression of MP enzymes, HMGCR, GGTI-β and GGTII-β were determined and the 
result showed high HMGCR expression and to leaser extent of GGTI-β and GGTII-β in a 
panel of OC cell line compared to normal cells. Cancer evolution has been linked with 
metabolic processes that tumour cells successfully hijacks to assist malignant transformation 
(Clendening et al., 2010). For example, ectopic expression of HMGCR promotes 
transformation which led to considered it as a metabolic oncogene (Clendening et al., 2010). 
This increased expression of the HMGCR and other MP enzymes provide the fast-
proliferating malignant cells with copious amount of products which are principally used for 
biosynthesis of the cells component (Parrales and Iwakuma, 2016) to maintain the growth 
and development machinery (Clendening and Penn, 2012). However, there are several 
mechanisms for the regulation of the HMGCR. HIF-1 alpha accumulation increase the level 
and activity of HMGCR by stimulating it is transcription (Pallottini et al., 2008). In addition, 
sterol mediated degradation of HMGCR has been shown to be inhibited by mutations which 
led to increase its enzymatic activity (Lee, Nguyen and Debose-Boyd, 2007). In addition, 
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recent study in our laboratory has defined a promising role for statins in OC (De Wolf et al., 
2017). Regardless of the mechanism by which deregulated HMGCR expression occurs, 
better understanding of the contribution of genes regulating isoprenoid metabolism might 
lead to improved cancer patients care (Clendening and Penn, 2012) and provide a rational 
for the use of the pathway inhibitors as anticancer therapy. 
It was also observed that p53 level were higher than normal cells at least in a subset of the 
OC cell lines. In addition, the status of the p53 has been retrieved form public database and 
this analysis showed that p53 was mutated in most of OC cell lines. Most of the mutation 
are missense and located at DNA binding domain which produce a full-length protein with 
prolonged half-life (Rivlin et al., 2011). In contrast to normal cells, there is a copious 
production of p53 protein in many tumours (Rotter, Abutbul and Ben-Ze’ev, 1983) and this 
tends to accumulate until reach steady state (Rotter, 1983). The accumulation of p53 protein 
causes defect in activation/ repression of target genes to ablate p53-induced apoptosis and 
maintains the malignant phenotype (Wiman, 2007). However, increase of p53 level might 
be a response to stimuli such as DNA damage and hypoxia (Strano et al., 2007; Sionov, 
Hayon and Haupt, 2013). Therefore, it might be suggested that the accumulation is a 
consequence of prolonged stability and extended half-life of the p53 protein by point 
mutation, or it is just a normal physiological response of cells to stimuli in course of 
carcinogenesis process.  
In this study, wild type and several mutant variants of TP53 has been studied to understand 
the relationship between MP and TP53 in OC. The result suggested that p53 controls at least 
four important enzymes of the pathway. Two lines of evidence point to the regulation of MP 
by TP53. Firstly, the ectopic expression of wild type and several mutant p53 variant led to 
increase the expression of HMGCR, GGTI-β and GGTII-β and FT-β in p53 null background 
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OC cell line. Secondly, siRNA directed to R248Q TP53 mRNA significantly decreased the 
level of HMGCR, GGTI-β, GGTII-β and FT-β enzymes. A new role of TP53 has emerged 
in mediating cancer development through regulating the MP. It is found that several enzymes 
of the MP controlled by gain of function of mutant TP53 in breast cancer cells (Freed-Pastor 
et al., 2012; Sorrentino et al., 2014). The result showed that ectopic expression of TP53, 
particularly gain of function variant, increased expression of HMGCR and is likely to be 
common in OC. It reported that gain-of-function mutants p53 prompt the synthesis of 
cholesterol (Laezza et al., 2015; Napoli and Flores, 2017). This hypothesis is supported by 
immunohistochemical studies which have identified HMGCR in 65% of OCs (Brennan et 
al., 2010) as well as other cancer types such as breast, colorectal and gastric tumours 
(Bengtsson et al., 2014; Gustbée et al., 2015; Chushi et al., 2016). In contrast, depletion of 
mutant p53 leads to reduced expression of seven MP genes -HMGCR, MVK, MVD, FDPS, 
SQLE, LSS, DHCR (Freed-Pastor et al., 2012). In addition, the normal morphology 
phenotype of breast cancer cells is restored by knock down of mutant p53 or by inhibition 
of MP by pharmacological agents such as statins (Freed-Pastor et al., 2012).  
The mechanism of the p53 regulation of the MP is not fully understood but much evidence 
points to a role for SREBP, although a direct link between mutant p53 and SREBP has not 
been established. It has been reported that mutant p53 is recruited to gene that encode of the 
MP pathway enzymes by SREBPs to upregulate their expression in breast cancer cells 
(Freed-Pastor et al., 2012). In addition, p53 supresses the expression of the SREBP1c, a 
transcription factor involves in the expression of the two lipogenic enzymes (fatty acid 
synthase and ATP citrate lyase) that regulate fatty acid synthesis. Augmentation of fatty acid 
synthesis in different cancers type has been linked to overexpression of the activity of 
lipogenic enzymes and their inhibition is associated with repression of the cell 
transformation and oncogenesis (Freed-Pastor et al., 2012). Furthermore, another 
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mechanism by which p53 control SREBP are by inhibiting mTOR and activating AMPK. 
The mTOR, which is frequently deregulated in cancer, increases the transcription of SREBP, 
and conversely AMPK inactivates HMGCR by phosphorylation (Budanov and Karin, 2008; 
Mullen et al., 2016). The PI3K/AKT signalling pathway is one of the most frequently altered 
pathway in cancers and especially OC (Sain et al., 2006; Fruman and Rommel, 2014) and 
has also been implicated in regulating the mevalonate pathway. It is activated by multiple 
molecular defects, mainly PIK3CA mutation or amplification (30%)  and PTEN loss (40%) 
(Glaysher et al., 2013). The PI3K/AKT pathway can activate the MP by upregulating the 
transcription, increasing stability or inhibiting the metabolism of the SREBP (Mullen et al., 
2016). Additionally, p53 induction reciprocally downregulates PI3K/AKT activity by 
binding to the PTEN promoter (Singh et al., 2002). These data might provide a further link 
for the p53 role in regulation of MP.  
Interestingly, the data showed that both wild type p53 and mutant p53 increase the 
expression of the MP which might suggest that both the level of the p53 expression and the 
mutational status of p53 are determinant of the pathway activity. It has also been proposed 
that mutant TP53 might retain or exaggerate certain p53 function whereas evading certain 
wild type p53 tumour suppressive activity. Therefore, it might be a remnant of unrecognized 
wild type p53 function is responsible for the maintaining of high level of MP through SREBP 
transcription (Freed-pastor, 2012). In line with this proposition, it is reasonable to propose 
that both wild-type and mutant p53 have a significant role in regulating the expression of 
sterol biosynthesis genes.  
It is well known that mutant p53 cannot activate the expression of its negative regulator 
MDM2, consequently, mutant p53 protein is stabilised and accumulated (Flöter, Kaymak 
and Schulze, 2017). It is possible that this is more pronounced in case of mutant “gain-of 
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function” form which are not subjected to ubiquitination by MDM2. A feed-forward loop is 
formed in cancer cells which harbour a mutant p53. MP enzymes, including HMGCR, are 
upregulated through activation of SREBP transcription by mutant p53. The increase in 
pathway activity and productivity in turn lead to stabilizing the mutant p53 function (Freed-
Pastor and Prives, 2016). In addition, it has recently been reported that statins enhances the 
degradation of mutant p53 protein, a process which is independent on the inhibition of 
protein prenylation (Parrales et al. 2016), supporting the use of statins in the treatment of 
cancers with mutated p53.   
In conclusion, the result suggested that the upregulation of HMGCR enzymes in OC cell 
lines might be involved in malignant transformation in OC. P53, is a pivotal transcription 
factor for control of MP enzymes function in OC and the interplay between p53 and the MP 
suggests that pharmaceutical inhibition of the pathway with statins may be a novel 
therapeutic approach for tumours and warrant a promising role in treatment of OC. 
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5.1. Introduction 
Ovarian cancer (OC) is the 5th leading cause of death in women with more than 14,000 deaths 
reported annually in United States (Siegel, Miller and Jemal, 2016). The disease responds 
initially to treatment but most patients relapse after a period of remission (Vaughan et al., 
2011). Therefore, new therapeutic agents or treatment strategies are required. 
The results of previous chapter suggested that the deregulation of MP might be involved in 
malignant transformation in OC. It is also proposed that p53, which is frequently mutated in 
OC, might be essential transcription factor for control of MP enzymes function in OC and 
the interplay between p53 and the MP suggests that pharmaceutical inhibition of the pathway 
with statins is a novel therapeutic strategy and warrant a promising role in treatment of OC. 
The mevalonate biosynthetic pathway is responsible for the synthesis of several important 
metabolites, producing cholesterol, dolichol, ubiquinone and the isoprenoids farnesol (FOH) 
and geranylgeraniol (GGOH). The rate limiting step in the mevalonate pathway (MP) is 
hydroxymethylglutaryl coenzyme A reductase (HMGCR) which catalyses the production of 
mevalonate (Brennan et al., 2010) and HMGCR has been identified as metabolic oncogene 
which promotes xenograft growth (Clendening et al., 2010; Martirosyan et al., 2010) and 
this has raised interest in the MP as a potential target in oncology. 
Several studies have demonstrated that statins inhibit cell growth and induce apoptosis in 
vitro in cell lines from a range of cancer types (Swanson and Hohl, 2006; Gazzerro et al., 
2012; Osmak, 2012). It has also been reported that statins inhibit tumour xenograft growth 
in mice (Kobayashi et al., 2015; Tsubaki et al., 2015) and recently publish data from our 
laboratory have demonstrated that pitavastatin causes tumour regression in mice fed a 
controlled diet (De Wolf et al., 2017). However, relatively high doses of statins are likely to 
be necessary to achieve an adequate plasma concentration of drug in patients (Dudakovic et 
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al., 2008; Robinson et al., 2014) and this raises concerns about the potential risk of 
myopathy, a side effect commonly associated with statins (Likus et al., 2016). Therefore, it 
desirable to identify drugs which synergize with statins and potentially reduce the dose of 
statin that is necessary to treat patients. 
Bisphosphonates (e.g. zoledronic acid, risedronate) are drugs which are already approved 
for the management and prevention of bone disease and bone metastasis (Stresing et al., 
2007). Bisphosphonates can also inhibit the MP enzyme farnesyl diphosphate synthase 
(Wasko, Dudakovic and Hohl, 2011).  Inhibition of farnesyl diphosphate synthase depletes 
both farnesyl diphosphate and geranylgeranyl diphosphate which in turn are required for 
protein isoprenylation of small G-proteins (Gnant and Clézardin, 2012). Bisphosphonates 
have shown potential anti-cancer activity in different cancer cell lines including ovarian, 
colon and hepatic cells (reviewed in (Stresing et al., 2007)). In addition, several studies 
showed that bisphosphonate use correlates with reduced cancer risk (Rennert, Pinchev and 
Rennert, 2010; Rennert et al., 2014). Bisphosphonates can also enhance the anticancer 
activity of several chemotherapeutic agents in vitro  (Jagdev et al., 2001; Neville-Webbe et 
al., 2005; Horie et al., 2007; Hafeman, Varland and Dow, 2012). 
There are several reasons to believe that drug combinations may be particularly useful in the 
treatment of cancer. Firstly, tumours represents a heterogeneous group of diseases with 
several different pathological mechanisms participating in their evolution (Bertolini, 
Sukhatme and Bouche, 2015). As a consequence, drug combinations inhibiting different 
underlying pathways might theoretically be more effective than single agents because 
multiple cell populations may be simultaneously affected by the drugs (Rodon, Perez and 
Kurzrock, 2010). Secondly, drug combinations can concurrently affect different signalling 
pathways in individual cancer cells. These drugs may act synergistically to increase the 
efficacy of the treatment above that which would be achieved by the single agents alone. 
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Thirdly, during cancer pharmacotherapy, mutation and epigenetic change can activate 
multiple compensatory pathways in cancer cells, leading to the emergence of drug-resistant 
subpopulations. Therefore, drug combinations or multi-targeted drugs may offer a better 
chance of obtaining a sustained clinical response (He et al., 2016; Han et al., 2017). Lastly, 
there is a historical precedent for the use of drug combinations and many traditional 
chemotherapeutic regimens incorporate several different drugs.  
Recent results from our laboratory have suggested that pitavastatin is superior to other statins 
for use in oncology because it is the only statin that is both lipophilic, rendering it more 
potent than hydrophilic statins, and has a suitably long half-life (t1/2 ~11 hour) (Robinson et 
al., 2013; Jiang et al., 2014; Zhang et al., 2016; De Wolf et al., 2017). The latter property is 
important because it has been shown continual inhibition of HMGCR is necessary to induce 
cell death and the troughs in plasma drug concentration between prolonged dosing intervals 
using short half-life statins are likely to compromise the activity of statins (Robinson et al., 
2013). To reduce the dose of pitavastatin necessary in patients, and potentially minimize 
adverse effects, zoledronic acid, risedronate or the geranylgeranyl transferase I inhibitor, 
GGTI-2133 was investigated to determine if they potentiate the activity of pitavastatin. Any 
effective combinations identified could subsequently be evaluated in clinical trials. 
5.2. Aims 
To identify drugs which may reduce the dose of pitavastatin necessary to treat OC, a 
combinatorial drug approach was used. The following objectives were addressed: 
1.  Does zoledronic acid, risedronate and GGTI-2133 potentiate the activity of pitavastatin 
against OC cell lines ? 
2.  Investigate the mechanism of action of pitavsatstin and the mechanism underlying the 
synergy between it and bisphosphonates. 
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5.3. Results  
5.3.1. Antiproliferative activity of pitavastatin, zoledronic acid, 
risedronate and GGTI-2133 against panel of ovarian cancer cell 
lines 
The potential growth inhibitory activities of pitavastatin, zoledronic acid, risedronate and 
GGTI-2133 as single agents were first determined against a panel of OC cell line in order to 
subsequently evaluate them in drug combination studies. Pitavastatin as a single agent 
displayed concentration- and time- and cell line specific growth inhibitory activity against 
tested cell lines with an IC50s ranging from 0.6-14 µM (Table 5-1) (Figure 5-1 A). 
Pitavastatin’s potency was comparable to its reported activity against breast and brain cancer 
cell lines (Jiang et al., 2014). Zoledronic acid displayed lower potency compared to 
pitavastatin and it showed concentration-dependent growth inhibition activity with an IC50s 
ranging from 21-60 µM (Table 5-1) (Figure 5-1 B). It has been reported that zoledronic acid 
inhibits cancer cell growth (10-100 µM) (Tamura et al., 2011). In contrast, risedronate (IC50 
>100 µM) (Figure 5-2 A) and GGTI-2133 (IC50 > 25 µM) (Figure 5-2 B) did not show 
significant activity against OC cell lines at the concentrations tested and an accurate 
estimation of IC50s could not be made. 
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Table 5-1 IC50s of pitavastatin and zoledronic acid.  
IC
50
 (µM) 
Cell line Pitavastatin (n) Zoledronic acid (n) 
HOE 0.59 ± 0.16 (6) 57 ± 6 (5) 
A2780 0.67 ± 0.34 (9) 29 ± 4 (4) 
CisA2780 14.0 ± 7.00 (9) 36 ± 6 (8) 
Cov-318 3.40 ± 1.40 (8) 28 ± 2 (4) 
Cov-362 3.10 ± 0.70 (8) 42 ± 4 (4) 
Ovcar-3 4.60 ± 0.90 (6) 60 ± 4 (6) 
Ovcar-4 5.20 ± 1.20 (4) 51 ± 7 (4) 
Ovcar-5 2.40 ± 1.30 (9) 30 ± 6 (9) 
Ovcar-8 0.40 ± 0.10 (4) 21 ± 3 (4) 
Igrov-1 1.60 ± 0.10 (9) 43 ± 8 (7) 
Skov-3 3.60 ± 1.00 (5) 26 ± 5 (5) 
Ovsaho 0.69 ± 0.12 (5) 44 ± 7 (3) 
Pitavastatin and zoledronic acid IC50s (mean ± S.D.) were calculated from the indicated number (n) 
of experiments. 
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Figure 5-1 Dose response curve of pitavastatin and zoledronic acid against a panel of 
ovarian cancer cell lines.  
Cells were exposed to a range of concentrations of pitavastatin (A) or zoledronic acid (B) for 72 
hours, except for the slow growing cell lines Cov-318 and Cov-362 (120 hours). The numbers of 
surviving cells were estimated using SRB assay. Dose response curve expressed as a fraction of the 
top of the curve which was recognised by curve fitting (mean ± SD, n ≥ 3). “C” on the x-axis indicates 
control samples measured in the absence of the drug.  
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Figure 5-2 Dose response curve of risedronate and GGTI-2133 against a panel of 
ovarian cancer cell lines.  
Cells were exposed to a range of concentrations of risedronate (A) or GGTI-2133 (B) for 72 hours, 
except for the slow growing cell lines Cov-318 and Cov-362 (120 hours). The numbers of surviving 
cells were estimated using SRB assay. Dose response curve expressed as a fraction of the top of the 
curve which was recognised by curve fitting (mean ± SD, n ≥ 3). “C” on the x-axis indicates control 
samples measured in the absence of the drug.  
Chapter Five | Pitavastatin and Bisphosphonates 
141 
5.3.2. Drug combination  
 
Cell growth assays were employed to assess the drug combinations in a panel of OC cell 
lines and combination index were calculated as an indicator of synergy and antagonism. 
5.3.2.1. Pitavastatin and zoledronic acid synergistically inhibit 
the growth of ovarian cancer cell lines 
The lack of potent activity of both bisphosphonates and GG-2133 led to the evaluation of 
these drugs at fixed concentrations, as suggested by  (Bijnsdorp, Giovannetti and Peters, 
2011), in combination with a range of concentrations of pitavastatin in cell growth assays. 
Pitavastatin and zoledronic acid (10µM) displayed synergistic activity in 8 of 11 cell lines 
tested (A2780, CisA2780, Cov-362, Ovcar-4, Ovcar-5, Ovsaho, Igrov-1 and Skov-3 cells), 
additive activity was observed in two cell lines (Cov-318 and Ovcar-8 cells) and antagonism 
was observed in one cell line (Ovcar-3 cells). When pitavastatin was combined with 
risedronate, additive or synergy was observed in 9 of 11 cell lines, although the synergy only 
reached statistical significance in 3 of the cell lines (A2780, Ovcar-5 and Skov-3 cells). An 
antagonistic interaction was observed in two cell lines (Ovcar-3 and Ovcar-8). In contrast, 
most of the cell lines showed an antagonist interaction when GGTI-2133 (5µM) was 
combined with pitavastatin (Figure 5-3). These data suggest that zoledronic acid might be a 
suitable option for the combination with pitavastatin and led to focus on this combination in 
further studies.  
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Figure 5-3 The effect of pitavastatin combinations in cell growth assays.  
To measure the activity of pitavastatin in combination with other agents, the indicated cells were 
simultaneously exposed to a range of pitavastatin concentrations with fixed concentration of 
zoledronic acid (10 µM), or risedronate (10 µM) or GGTI-2133 (5 µM). Combination indices (CI) 
(mean ± S.D., n=3-4) are quoted at a fraction affected of 0.5 and differed significantly from unity 
where indicated (*, P ≤0.05; paired t-test).  
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5.3.2.2. Confirmation of antiproliferative synergistic effect of 
pitavastatin and zoledronic acid combination 
 In order to confirm the synergy observed between pitavastatin and zoledronic acid, A2780, 
Skov-3 and Ovsaho cell lines were tested because the most significant synergy was observed 
in these cell lines. Cell death was first assessed by staining with trypan blue. The 
combination of pitavastatin with zoledronic acid resulted, in all three cell lines, in 
significantly more cell death after 72 and 96 hours of drug exposure than would have been 
expected from an additive effect calculated using the Bliss independence criterion (Figure 
5-4). To confirm these results, a separate measurement of cell viability was used by 
measuring intracellular ATP level. After 72 hours of drug exposure, significantly less ATP 
was measured in cells exposed to the drug combination than that expected effect from an 
additive effect calculated using the Bliss independence criterion (Figure 5-5).  
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Figure 5-4 The effect of pitavastatin-zolendronic acid combinations on cell death.  
Dead cells were measured by trypan blue staining after 72 and 96 hours of exposure to the indicated 
drug concentration. The results (mean ± SD; n = 3) were compared to the effect expected for an 
additive interaction calculated using the Bliss independence criterion (solid line for each drug 
combination) and determined using the measured effect of the individual drugs in each individual 
experiment. Results were significantly different from the expected Bliss effect where shown (*, P < 
0.05; **, P < 0.01; ***, P < 0.001, paired t-test).  
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Figure 5-5 The effect of pitavastatin-zolendronic acid combinations on cell viability.  
Relative cell viability was measured by ATP-celltiter-Glo assay after 72 hour exposure to the 
indicated drug concentration. The results (mean±SD; n = 3) were compared to the effect expected 
for an additive interaction calculated using the Bliss independence criterion (solid line for each drug 
combination) and determined using the measured effect of the individual drugs in each individual 
experiment. Results were significantly different from the expected Bliss effect where shown (*, P < 
0.05; **, P < 0.01; paired t-test).  
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5.3.2.3. The pitavastatin and zoledronic acid combinations 
synergistically induce apoptosis 
Previous studies have shown that statins and bisphosphonates induce apoptosis in cancer cell 
lines  (Liu et al., 2009; Tamura et al., 2011). To confirm that the reduction in cell viability 
and growth is attributable to apoptosis, the effects of drugs alone and in combination on 
caspase activity and PARP cleavage were assessed. The combination of zoledronic acid and 
pitavastatin caused activation of the caspase-8 (Figure 5-6) and caspase-9 (Figure 5-7) as 
well as the effector caspases-3/7 (Figure 5-8). In all three cases, the caspase activation 
elicited by the combination was significantly higher than that of pitavastatin alone. 
(Calculation of the expected effect of the combination using the Bliss criterion was not 
possible in this experiment because of difficulties in accurately measuring maximum caspase 
activation, required to calculate the fractional effect of each drug). Subsequently, 
immunoblot analysis demonstrated that the combination resulted in accumulation of cleaved 
PARP that was greater than that observed with each single agent (Figure 5-8). However, it 
is noticed that pitavastatin alone at both tested concentrations were able to produce 
significant PARP cleavage in Ovsaho cell line in comparison to A2780 and Skov-3 cell line. 
This might indicate that Ovsaho cell line are more sensitive to pitavastatin induced PARP 
cleavage than other cell lines and that the activity of this drug is cell line dependent. 
Importantly, the addition of geranylgeraniol, but not farnesol, blocked the cleavage of PARP 
induced by pitavastatin or the combination (Figure 5-9). Finally, phase contrast microscopy 
revealed that untreated cells remain attached to culture plate and maintained their original 
morphology. In contrast, more pronounced rounding, blebbing or detachment from the plate 
was observed in cells treated with the drug combination than in cells treated with the single 
agents (Figure 5-10).  
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Figure 5-6 The effect of pitavastatin-zolendronic acid combinations on caspase 8 
activity.  
Caspase 8 activity of A2780, Skov-3 and Ovsaho cell lines were measured by Caspase-Glo assays. 
Cells were treated with the indicated concentrations of pitavastatin and zoledronic acid for 48 hour. 
Drug combinations effects were compared to the effect of the pitavastatin (Mean ± SD; n = 3; *, P < 
0.05; **, P < 0.01; paired t-test).  
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Figure 5-7 The effect of pitavastatin-zolendronic acid combinations on caspase 9 
activity.  
Caspase 9 activity of A2780, Skov-3 and Ovsaho cell lines were measured by Caspase-Glo assays. 
Cells were treated with the indicated concentrations of pitavastatin and zoledronic acid for 48 hour. 
Drug combinations effects were compared to the effect of the pitavastatin (Mean ± SD; n = 3; *, P < 
0.05; **, P < 0.01; paired t-test).   
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Figure 5-8 The effect of pitavastatin-zolendronic acid combinations on caspase 3/7 
activity and PARP cleavage.  
Caspase 3/7 activity of A2780, Skov-3 and Ovsaho cell lines were measured by Caspase-Glo assays. 
Cells were treated with the indicated concentrations of pitavastatin and zoledronic acid for 48 hour. 
Drug combinations effects were compared to the effect of the pitavastatin (Mean ± SD; n = 3; *, P < 
0.05; **, P < 0.01; paired t-test). PARP and PARP cleavage were measured by western blot analysis 
(n = 3). 
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Figure 5-9 The effect of the pitavastatin-zolendronic acid drug combination is blocked 
by geranylgeraniol.  
Cells treated with pitavastatin (A2780 and Ovsaho 1 µM and Skov-3 5µM) and farnesol (10µM) 
geranylgeraniol (10µM) zoledronic acid (10µM) for 48 hour. PARP cleavage was assessed by 
immunoblotting. The results are representative of 3 experiments.  (B) Skov-3 cell line was treated 
with pitavastatin or pitavastatin and zoledronic acid (10µM) and GGOH (10 µM) and FOH (10 µM) 
and after 72 hour relative cell number was determined by staining with SRB.  
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Figure 5-10 Morphological changes of A2780 and Skov-3 cell lines 
morphological changes of A2780 (A) and Skov-3 (B) cell line treated with indicated drug 
concentration for 72 hour were visualized by phase contrast light microscope which revealed that 
untreated cells were attached to culture plate and maintained their original morphology. In contrast, 
it revealed a more pronounced rounding, blebbing or detachment from the plate in cells treated with 
the drug combination than in cells treated with the single agents.  
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5.3.3. The effect of pitavastatin and zoledronic acid on mevalonate 
pathway enzymes and p53 level 
In order to further explore the mechanism of the drug combinations, the effect of the drug 
combination on MP enzymes using western blotting was assessed. The ability of GGOH to 
suppress the effects of pitavastatin led to the hypothesis that the geranylgeranylation branch 
of enzymes of the pathway are more important targets affected by pitavastatin. Pitavastatin 
decreased the level of GGTII-β in A2780 and Ovsaho cell line but without a noticeable 
change in the level of this enzyme in Skov-3 cell line. The reduction in level of GGTII-β 
was blocked by the inclusion of GGOH but not FOH. This might indicate that the pitavastatin 
effects on reduction of GGTII-β is cell line dependent. In contrast, pitavastatin did not a 
significantly affect the level of HMGCR, GGTI-β and p53 levels in A2780, Skov-3 and 
Ovsaho cells. Zoledronic acid, at the concentration tested, did not show significant effect on 
level of the MP enzymes. The combination of pitavastatin and zoledronic acid also reduced 
the level of GGTII-β and this was also ameliorated by the inclusion of GGOH (Figure 5-11).   
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Figure 5-11 The effect of pitavastatin and pitavastatin-zolendronic acid on 
geranylgeranyl transferases.  
A2780, Skov-3 and Ovsaho cell lines were exposed to pitavastatin (1µM, 5µM and 1µM, 
respectively) and zoledronic acid (10µM) with and without geranylgeraniol (10µM) and farnesol 
(10µM) for 48 hours. The levels of HMGCR, GGTI-β, GGTII-β and p53 were measured by 
immunoblotting of whole cell lysate. GAPDH was used as a loading control. The results are 
representative of 3 experiments.  
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5.3.4. Inhibition of both GGTI-β and GGTII-β in combination 
with pitavastatin 
Next the mechanism of action of the drug combinations was considered and in particular 
whether the effect of pitavastatin and pitavastatin drug combinations was mediated through 
inhibition of GGTI or GGTII. It was hypothesized that if inhibition of prenylation by one or 
both of geranylgeraniol transferases was essential for the cytotoxic activity of pitavastatin, 
then knockdown of either or both of them should increase the potency of pitavastatin.  This 
could potentially provide information about which geranylgeranyl modified proteins are 
most crucially affected by pitavastatin. For these studies, Ovcar-4 cells were used because it 
has suggested they are more representative of high grade serous ovarian carcinoma (Domcke 
et al., 2013). 
5.3.4.1. Knockdown of GGTI-β and GGTII-β   
To measure the effects of knockdown of geranylgeranyl transferase, the toxicity of different 
siRNAs targeting GGTI-β and GGTII-β were tested before determining the efficiency of 
knockdown of these enzymes. Ovcar-4 cells were exposed to four different concentrations 
(25, 50, 75 and 100ηM) of siRNA GGTI and GGTII enzymes for 72 hours. It was observed 
that there was no significant effect on cell growth at any of the concentrations tested. A 
concentration of 100nM were used in subsequent studies (Figure 5-12 A). Next, the effect 
of knockdown of GGTI-β and GGTII-β were tested.  All 4 siRNAs targeting each enzyme 
inhibited the expression of these transferases when measured at 72 and 96 hours after 
transfection. (Figure 5-12 B).  
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(A) 
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Figure 5-12  The kinetic of knockdown of GGTI-β and GGTII-β. 
Ovcar-4 cells exposed were exposed to 4 different concentrations (25, 50, 75 and 100ηm) of each 
siRNA to GGTI-β and GGTII-β for 72 hours. Cell growth assay were used to determine relative cell 
numbers by staining with SRB (Mean±SD; n=3). (B) Ovcar-4 cells were transfected with the 
indicated siRNA. The level of GGTI-β and GGTII-β expression measured by immunoblotting after 
72 and 96 hours.  
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5.3.4.2. The effect of knockdown of GGTI-β and GGTII-β on 
sensitivity to pitavastatin 
Next the effect of knockdown on GGTI and GGTII on the sensitivity to pitavastatin was 
measured. Knockdown of either GGTI-β or GGTII-β alone using 3 separate siRNA did not 
significantly increase the potency of pitavastatin against Ovcar-4 OC cell line. However, 
inhibition of both GGTI-β and GGTII-β simultaneously using 3 separate siRNA 
combinations resulted in a significant increase in sensitivity to pitavastatin, shown by a 
significant decrease in pitavastatin IC50 compared to control cells exposed to non-targeting 
siRNA (Figure 5-13). Non-targeting siRNA had no significant effect on the sensitivity to 
pitavastatin.                            
 
Figure 5-13 The effect of GGT-Iβ and GGT-II β knockdown on potency of pitavastatin. 
Ovcar-4 cell line was transfected with siRNA of GGT-Iβ (100nM) or GGT-IIβ (100nM) oligos for 
24 hours before exposed to serial drug dilution of pitavastatin (starting concentration 25µM) for 
additional 72hour. The IC50 were calculated from DRC which were determined by Graphpad Prism, 
(one-way Anova followed by Tukeys post-hoc *, P < 0.05) (mean ± S.D., n = 3).  
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5.3.4.3.  Confirmation of the synergy of GGTI-β and GGTII-β 
knockdown by flow cytometry and PARP cleavage 
To confirm the synergy observed following combined knockdown of both geranylgeranyl 
transferases and exposure to pitavastatin, the effect of the combination on apoptosis was 
measured by flow cytometry. Ovcar-4 cell line were incubated with GGTI-β, GGTII-β for 
24 hours alone then exposed to pitavastatin for additional 48 hours. Flow cytometry analysis 
to measure apoptosis by Annexin V/propidium iodide staining revealed that inhibition of 
each the geranylgeranyl transferase enzymes alone or in combination with pitavastatin did 
not alter the sensitivity of Ovcar-4 cells to the drug. Similarly, knockdown of either 
transferase did not augment PARP cleavage induced by pitavastatin. However, when the 
cells were exposed to pitavastatin with concomitant inhibition of both geranylgeranyl 
transferases, there was significantly more Annexin V/PI labelling and more PARP cleavage 
(Figure 5-14 and Figure 5-15 A) compared to treatment of cells with pitavastatin alone. In 
contrast, inhibition of farnesyl transferase with tipifarnib did not augment the activity of 
pitavastatin in cell growth assays because an additive interaction was observed (Figure 5-15 
B).  
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Figure 5-14 The effect of pitavastatin and pitavastatin–siGGTI-β and siGGTII-β 
combinations on apoptosis.  
Ovcar-4 cells were transfected with siRNA to GGTI-β and GGTII-β and exposed to pitavastatin 
(10µM) for 48 hours. After labelling with annexin V/propidium iodide the cells were analysed by 
flow cytometry (results shown are from single representative experiment, n=3).   
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Figure 5-15 the apoptosis induction by geranylgeranyl transferase knockdown with 
pitavastatin in Ovcar-4 cell line. 
(A) The annexin V and propidium iodide positive cells were quantified (mean ± SD, n=3) 
and were significantly different from cells transfected with non-targeting siRNA where 
shown (one-way Anova followed by Tukeys post-hoc *, P < 0.05; **. P < 0.01; ***, P < 
0.001). In parallel, PARP cleavage determined by western blotting. (B) The activity of 
pitavastatin in a cell growth assays were measured in the absence and presence of tipifarnib 
(0.25 µM) and combination index calculated.  
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5.3.5. The effect of pitavastatin and pitavastatin-zolendronic acid 
on the subcellular localization of small GTPases 
The data suggested that blocking geranylgeranylation may be crucial to the cytotoxic activity 
of drug combinations involving pitavastatin. Attachment of geranylgeraniol to small 
GTPases is necessary for their membrane localization and activity. This suggested that the 
drug combination would alter the subcellular localization of small GTPases. A2780 and 
Skov-3 Cells were treated with pitavastatin and/or zoledronic acid for 48 hours, the cells 
fractionated into cytoplasmic and membrane fractions and the distribution of RhoA, CDC42, 
Rab6A and Ras was examined using western blotting. Actin and NaK ATPase were 
measured as loading markers of the cytosolic and membrane fractions respectively. 
Although zoledronic acid used as a single agent did not affect the membrane localization of 
these small GTPases, pitavastatin decreased the proportion of RhoA, CDC42 and Ras 
proteins found in the membrane fraction and also caused a reciprocal increase in the cytosolic 
fraction. When cells were treated with pitavastatin and zoledronic acid, the loss of small 
GTPases from the membrane fraction to the cytosolic fraction was augmented by this 
combination (Figure 5-16). 
Finally, it can be summarized that zoledronic acid potentiate the antiproliferative activity of 
pitavastatin in panel of OC cell lines in several cell growth and apoptosis assays. It is also 
found that inhibition of both geranylgeranyl transferase enzymes are essential to potentiate 
the cytotoxic activity of statins against OC cell lines. 
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Figure 5-16 The effect of pitavastatin and pitavastatin-zolendronic acid combination 
on the subcellular localization of small GTPases.  
Lysates of A2780 and Skov-3 cells that had been treated with indicated drugs for 48 hours were 
fractionated into cytoplasm and membrane and analyzed by immunoblotting. The graphs show the 
fraction recovered in the cytosolic or membrane fractions (n=3). 
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5.4. Discussion 
Failure of cancer treatment is a significant challenge to the modern medicine (Colombo et 
al., 2014). Regrettably, side effects, toxicity to normal tissue and drug resistance limit the 
activity of chemotherapy. Therefore, multi-drug regimens are prescribed for cancer to 
improve the efficacy and reduce the requirement of high drug doses (Marczak, Bukowska 
and Rogalska, 2014). At the same time, it is well known that cancer is a heterogeneous 
cluster of disorders with different molecular mechanisms of pathogenesis. Therefore, 
targeting multiple pathways is beneficial for inhibition of tumour growth and improving 
survival (Clendening and Penn, 2012; Yeganeh et al., 2014). This study indicated that a 
combination of MP inhibitors potentiates the antiproliferative activity of pitavastatin and 
combined inhibition of geranylgeranyl transferase enzymes are required to potentiate the 
cytotoxic activity of statins in OC. 
5.4.1. MP inhibitors single agent activity 
It has been established that pitavastatin is the statin most likely to be effective in the 
treatment of OC (Robinson et al., 2013; De Wolf et al., 2017). Although repurposing statins 
for use in oncology is attractive, there are legitimate concerns about the potential for 
myopathy (Saito, 2011) and this makes it desirable to identify drugs which could potentially 
reduce the dose of pitavastatin administered to patients.  
The result revealed that pitavastatin has concentration-, time- and cell-dependent growth 
inhibitory effects against a panel of OC cell lines. Pitavastatin was more potent than 
zoledronic acid while risedronate and GGTI-2133 were the least effective agents. Beside the 
restriction of the pathway products by MP inhibitors, NBPs may also  act by causing the 
accumulation of  metabolite of MP upstream of the site of inhibition (Okamoto et al., 2014). 
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Accumulation of metabolites such as isopentyl diphosphate, caused by inhibition of the FPP 
synthase leads to the production of another metabolite, ApppI (triphosphoric acid 1-
adenosin-5'-yl ester 3-(3-methylbut-3-enyl) ester), an ATP analogue which is toxic and can 
induce apoptosis by inhibiting mitochondrial ADP/ATP translocase protein (Räikkönen et 
al., 2009). GGTI-2133, an inhibitor of GGTI enzyme, restrains the activity of small GTP 
proteins. GGTI-2133 did not display a potent growth inhibitory activity compared to 
pitavastatin. It has an IC50 for the enzyme inhibition about 40 and 5400 nM for GGTI and 
FT, respectively (Vasudevan et al., 1999). In these studies, concentrations up to 25µM were 
tested, with only modest growth inhibitory effects. This suggests that inhibition of GGTI on 
its own does not have a profound effect on cell growth. This was subsequently confirmed in 
siRNA experiments in which knockdown of GGTI did not appreciably affect cell growth. 
5.4.2. Pitavastatin and MP inhibitors combination activity 
In this study, it was observed that zoledronic acid act synergistically with pitavastatin using 
several different assays and in several different cell lines. The drug combination was 
synergistic when assessed in two cell growth assays, a cell survival assay and also in several 
assays measuring apoptosis. It is observed that PARP cleavage in Ovsaho cell line are more 
prominent than other tested cell lines exposed to pitavastatin alone and in combination with 
zoledronic acid. In addition, the discrepancy between the caspase activity and PARP 
cleavage might be related to the method used for the measurement. This is significant 
because zoledronic acid is a drug in clinical use and so may reasonably be combined with 
pitavastatin in the treatment of cancer patients. Pitavastatin inhibits HMGCR, reducing the 
supply of mevalonate that is used to synthesize isoprenoids and zoledronic acid is known to 
inhibit farnesyl diphosphate synthase (Mukhtar, Reid and Reckless, 2005; Thurnher, 
Nussbaumer and Gruenbacher, 2012; Dhar, Koul and Kaul, 2013; Okamoto et al., 2014) 
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which is also part of the MP. Previous studies have identified synergy between statins and 
zoledronic acid (Budman and Calabro, 2006; Dudakovic et al., 2008; Rogers et al., 2015; 
Elsayed et al., 2016; Göbel et al., 2016). The underlying mechanism of this synergy has not 
been fully elucidated but it likely that statin augment the activity of the FPPS inhibitors by 
additionally restraining protein geranylgeranylation by inhibiting the supply of isoprenoid 
substrates (Issat et al., 2007). In this study, the mechanism underlying synergy between 
pitavastatin and zoledronic acid was further explored. In particular, it was found that 
pitavastatin reduces levels of GGTII-β. This is significant because it demonstrates that the 
drug combination inhibits the MP at three different points. The drug combination also 
profoundly reduces the amount of small GTPases associated with the cell membrane, 
suggesting a potential mechanism by which the drugs trigger apoptosis. It was also noticed 
that simultaneous inhibition of both GGT-I and GGT-II, but not either transferase 
individually, potentiates the activity of pitavastatin. This has significant implications for 
understanding the mechanism by which pitavastatin induces cell death and for drug 
discovery programmes to identify compounds which inhibit geranylgeranyl transferases 
synergistically with pitavastatin. Drugs which inhibit both transferases are likely to be 
necessary. 
This study and several previous studies, have suggested that the cytotoxic effect of statins in 
cancer cells result from inhibiting the synthesis of geranylgeraniol (Zhong et al., 2003; 
Gazzerro et al., 2012; P Jiang et al., 2014). Indeed, the importance of this isoprenoid in 
oncogenesis is underlined by the observation that geranylgeraniol promotes tumour growth 
in xenograft-bearing mice (Duncan, El-Sohemy and Archer, 2004). In this study, 
geranylgeraniol was able to inhibit the cytotoxic effects of the pitavastatin-zoledronic acid 
drug combination in wild-type TP53 (A2780 cells), mutated TP53 (Ovsaho) and cells 
lacking TP53 (Skov-3). This observation is significant because it was proposed that 
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relatively high doses of statins will be necessary to treat cancer to provide an adequate 
plasma concentration (microMolar) of the drug in patients, leading to the concern that high 
concentrations of pitavastatin might be cytotoxic by inhibiting target other than HMGCR. 
This data provides several other lines of evidence in support of pitavastatin exerting its effect 
through inhibition of HMGCR. Firstly, the observation that geranylgeraniol, a product of the 
MP, suppresses the effects of pitavastatin support pitavastatin working through an “on-
target” mechanism. Secondly, our observation of synergy between two sets of drugs 
inhibiting the same pathway (pitavastatin and bisphosphonates) is also consistent with the 
effect of pitavastatin being mediated by HMGCR. Finally, it was also noticed that siRNA 
directed to geranylgeranyl transferases, a part of the MP, potentiated the activity of 
pitavastatin. In summary, the synergy between pitavastatin and several reagents targeting the 
MP strongly supports the argument that pitavastatin, even at microMolar concentrations, acts 
principally through inhibition of HMGCR and the MP. This conclusion is of crucial 
importance to the design of clinical trials, because understanding the mechanism of action 
of a drug is essential for selecting which patients should receive the drug. 
5.4.3. Role of GGTI-Β and GGTII-Β knockdown in potentiation of 
pitavastatin activity 
The suppression of the activity of pitavastatin-zoledronic acid combinations by 
geranylgeraniol suggested that inhibition of the production of this isoprenoid was central to 
the effect of the drug combination. However, this observation did not indicate whether the 
effect of pitavastatin reflects inhibition of geranylgeranylation of a crucial subset of proteins 
or whether inhibition of protein prenylation more broadly underlies the effect of pitavastatin. 
This is not a trivial issue to tackle because around 2% of mammalian proteins undergo post-
translational prenylation (Nguyen et al., 2009). Although, Ras superfamily GTPases are 
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obvious candidates affected by pitavastatin,  the sensitivity of multiple myeloma cells to 
lovastatin was not modulated by ectopic expression of individual constitutively active Ras, 
RhoA, RhoB, Rac1, and Cdc42 small GTPase proteins (Wong et al., 2007). To begin to 
address this, it is first considered which geranylgeranyl transferases might be most 
significantly affected by pitavastatin. It was been hypothesized that if the effects of 
pitavastatin were mediated by preventing the prenylation of a substrate of either GGTI-β or 
GGTII-β, then synergy would be observed between pitavastatin and siRNA to one of these 
geranylgeraniol transferases. It was anticipated that this information could be used to focus 
on substrates for one transferase to search for the proteins whose geranylgeranylation is 
affected by pitavastatin and pitavastatin-zoledronate combinations and which is necessary 
for the cytotoxic activity of these drugs. However, it is found that siRNA to either one of the 
transferase alone was insufficient to potentiate the activity of pitavastatin in both cell growth 
assays and in two apoptosis assays. However, when different siRNA combined to 
simultaneously repress both geranylgeraniol transferase I and II, the potency of pitavastatin 
was increased. This was observed using three separate siRNA combinations. In contrast, 
inhibiting farnesyltransferase by tipifarnib was not synergistic with pitavastatin. This 
confounded an approach to understanding the mechanism of action of pitavastatin and 
pitavastatin/zoledronate because these results did not implicate one single geranylgeranyl 
transferase. Instead, these data suggest that pitavastatin does not exert its cytotoxic activity 
by preventing the geranylgeranylation of a small number of key proteins, rather that 
inhibition of geranylgeranylation of several proteins, whose prenylation is catalysed by 
GGTI-β and GGTII-β, contributes to pitavastatin’s activity. It is likely that these same 
proteins are affected by the pitavastatin-zoledronic acid combination. It cannot rule out, 
however, that the activity of the pitavastatin-zoledronic acid combination depends on 
blocking the prenylation of a small subset of unidentified proteins that can be redundantly 
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isoprenylated by either GGTI-β or GGTII-β. Redundancy between these prenyl transferases 
explains why inhibition of both GGTI-β and GGTII-β was found to be necessary for synergy 
with pitavastatin because one transferase can compensate for the depletion of the other. The 
idea of redundancy between the transferases is plausible because these enzymes do not 
exhibit absolutely inflexible substrate specificity and geranylgeranylation has even been 
reported as a mechanism of resistance to farnesyl transferase inhibitors (Park et al., 2014). 
The apparent redundancy observed between GGT-I and GGT-II also provides important 
information for drug discovery programmes designed to identify compounds which are 
synergistic with pitavastatin. The data suggests that targeting selectively either GGT-I or 
GGT-II may be futile because one transferase may compensate for inhibition of the other. 
Compounds which inhibit both transferases may be necessary. Indeed, the synergy has not 
been observed when pitavastatin combined with GGTI-2133 which inhibits GGTI-β but not 
GGTII-β. Rather, GGTI-2133 was antagonistic with pitavastatin, although this may reflect 
off-target effects of this compound (Vasudevan et al., 1999; Delarue et al., 2007). It has been 
previously shown that MP inhibitors can disrupt cellular signalling mechanism through Ras 
and Rho proteins. RhoB contributes to the process of apoptosis in cancer cells. Apoptosis is 
suppressed upon deletion of this protein and sensitisation of cells to apoptotic stimuli 
following stable expression of RhoB has been reported (Morgan et al., 2005). Therefore, 
inhibition of GGTI by GGTI-2133 might inactivate RhoB and inhibit the induction of 
apoptosis and lead to the antagonism with pitavastatin. 
5.4.4. The effect of drug combination on protein prenylation 
To confirm that pitavastatin, zoledronic acid and the combination of the two drugs resulted 
in altered protein prenylation, the effect of these drugs on several small GTPases were 
measured. It seems reasonable to consider these as relevant targets affected by pitavastatin 
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because small GTPases proteins are involved in regulation of several signalling pathways 
involved in cell growth and survival (Rogers et al., 2011) Pathways known to be regulated 
by small GTPases include the PI3K/AKT and Raf/Mek/MAPK/ERK pathways which 
regulate in cell cycle progression and apoptosis (Swanson and Hohl, 2006). Substrates of 
GGTI-β (RhoA, CDC42) or GGTII-β (Rab6A) as well as of farnesyltransferase (Ras) were 
selected (Park et al., 2014) to evaluate the effect of the pitavastatin-zoledronic acid 
combination. Pitavastatin increased the proportion of all four small GTPases that was found 
in the cytosolic fraction, consistent with inhibition of prenylation. In both cells lines 
pitavastatin also increased the amount of RhoA, Cdc42 and Ras found in the cell membrane, 
suggesting that loss of prenylation may lead to an increase in the abundance of these small 
GTPases. Upregulation of Ras and Rho by statins has been observed previously (Mo and 
Elson, 2004; Göbel et al., 2016) as a result of increase translation or reduced turnover 
(Mohamed, Smith and de Chaves, 2015). In contrast, there appeared to be a reduction in the 
total amount of Rab6A, consistent with our previous results (Robinson et al., 2013). The 
combination of zoledronic acid with pitavastatin increased in most cases the proportion of 
small GTPases found in the cytosolic fraction. Taken together, this study suggests that the 
synergy between pitavastatin and zoledronic acid inhibits the MP at multiple points and leads 
to a profound reduction in the membrane localization of small GTPases. Since several of 
these GTPases regulate cell survival and proliferation, the loss of membrane localization of 
these proteins is likely to contribute to the synergistic inhibition of cell growth and survival. 
It cannot be ruled out, however the possibility that the cytosolic form of these proteins 
inhibits cell growth and survival (Dunford et al., 2006). 
It was observed that pitavastatin, alone and in combination with zoledronic acid, decreases 
the level of GGTII-β. Thus, the pitavastatin-zoledronic acid drug combination inhibits at 
least three points on one biosynthetic pathway and it is likely that this contributes to the 
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synergy which it has been observed in almost all cell lines tested. This is also significant 
because it suggests that reduced GGTII-β is likely to contribute to the activity of these drugs, 
although the mechanism underlying the reduction in GGTII-β is not yet clear. MP enzymes 
are regulated by feedback and feedforward mechanisms (Katz, 2005; Henry et al., 2015). 
The reduced supply of geranylgeraniol may cause changes in the level of the enzyme for 
which it is a substrate. This may explain why pitavastatin altered the level of GGTII. This 
observation also raises the possibility that pitavastatin may be particularly useful in cancers 
in which GGTII-β is either abundantly expressed or mutated such as OC (Lackner et al., 
2005; Ageberg et al., 2011). In addition, overexpression of GGTII enzyme substrate such as 
Rab25, Rab5 and Rab7, has been reported in breast, ovarian, prostate and bladder cancers, 
and some of these substrate mutation is determinant of aggressiveness of cancer and 
predictors of poor outcome (Watanabe et al., 2008). 
Finally, it can be concluded that inhibition of farnesyl diphosphate synthase by zoledronic 
acid offers a promising strategy to increase the efficacy of statins in cancer patients. Statins 
and bisphosphonates generally have a good safety profile and are available clinically in 
relatively cost-effective generic forms (Manzoni and Rollini, 2002; Katz, 2005; Chen and 
Sambrook, 2011), making this approach particularly attractive. The inclusion of zoledronic 
acid alongside pitavastatin in clinical trials of patients with OC warrants urgent 
consideration. Although, it has been recently suggested that statins’ adverse effect might not 
be dependent on the inhibition of protein prenylation (Gee et al., 2015) but these trials will 
need to evaluate whether the inclusion of zoledronic acid potentiates the efficacy of 
pitavastatin without an increased risk of myopathy which is associated with statin use.  
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6. Screening a library of compounds reveals a 
novel synergistic drug combination: 
pitavastatin and prednisolone   
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6.1. Introduction  
The fundamental goal of cancer chemotherapy is eliminating malignant tissues. Combining 
drugs is important strategy for cancer treatment after the failure of single agents (Devita, 
Young and Canellos, 1975). The main rationale for drug combinations involving cytotoxic 
chemotherapy is that this targets several cellular components simultaneously. This offers 
several advantages including augmenting tumour cell killing and correspondingly 
therapeutic efficacy, reducing the occurrence of resistance and potentially minimizing the 
toxicity associated with high dose chemotherapy (Rodon, Perez and Kurzrock, 2010; Al-
Lazikani, Banerji and Workman, 2012).  
The high cost of new molecularly-targeted agents is likely to put significant strain on health 
care budgets in most countries (Bertolini, Sukhatme and Bouche, 2015). The process of new 
drug discovery requires a long time and a considerable cost to translate the agent to the clinic. 
It is currently estimated that it requires approximately $2 billion to bring a new drug to 
market. This results  in the average cost of the new targeted therapy being extremely high, 
with annual treatment costs frequently in the range $50,000-$100,000 per course of 
treatment (Pantziarka, Bouche, Meheus, Sukhatme, Sukhatme, et al., 2014).  
Since 1950, the number of new licensed drugs has fallen by half every decade. A recent 
report has described the process of drug development as a productivity crisis. The crisis is 
particularly problematic for oncology drugs discovery. The number of non-oncological 
drugs approved by FDA between 2003 and 2011 are double the number of oncological drugs 
that approved (Pantziarka, Bouche, Meheus, Sukhatme and Sukhatme, 2014). At the same 
time, the cost of cancer drug approval had increased dramatically and doubled several times 
from 1990 to 2011 (Bertolini, Sukhatme and Bouche, 2015). Therefore, drug redeployment 
is an attractive alternative strategy to develop new treatments. 
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Drug redeployment might be defined as the process of validating and marketing previously 
approved pharmaceutical active agent for new indications outside the scope of their original 
medical uses (Brown and Patel, 2017; Corsello et al., 2017). This offers a promise of rapid 
clinical impact with a low development cost compared to de novo drug development 
(Corsello et al., 2017). The goal of pharmaceutical companies in oncology drug development 
is to obtain market approval by demonstrating that the efficacy and superiority of their drug. 
Pharmaceutical companies may lack incentives to investment in drug combinations because 
this may involve working with competitor pharmaceutical companies. This problem is 
exacerbated in the case of drug repositioning where there may be only a limited period of 
patent protection remaining for their product which minimizes financial return (Keith, 
Borisy and Stockwell, 2005). Despite this, drug repositioning has a potential advantage of 
safer, cheaper and faster validation protocols (Bertolini, Sukhatme and Bouche, 2015). 
Repurposing of known drug with a history of clinical application also comes with a wealth 
of data that is readily available and which includes the pharmacokinetic, pharmacodynamics, 
toxicological and dosing schedules. The availability of this data reduces the duration of 
clinical drug development, which typically ranges from 5-7 years (Ashburn and Thor, 2004). 
The use of generic drugs with low cost is another key advantage of drug repurposing. It 
reduces the potentially high cost of therapy which can impose a substantial strain on the 
public health finance of the developed countries and it can be unaffordable for poor and 
middle income countries (Pantziarka, Bouche, Meheus, Sukhatme and Sukhatme, 2014). 
There are many example of successful drug repositioning which bypass the hindrance 
associated with new drug development and hasten the potential therapeutic discovery 
(Langedijk et al., 2015). One of the accounts of drug repositioning is “The fall and rise of 
thalidomide”, a drug which was originally prescribed to pregnant women for the 
management of morning sickness in 1957 in Germany and England (Raje and Anderson, 
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1999). The drug led to newborns with severe malformations such as deafness, blindness, 
limb growth defects in at least 15,000 children born to a mother who had used thalidomide 
during the first trimester of their pregnancy. In 1964, thalidomide was accidentally 
discovered to be effective for treatment of erythema nodosum laprosum (ENL) which is an 
inflammatory condition of leprosy. The drug was given to relieve the pain of critically ill 
patient with ENL in University Hospital of Marseille although thalidomide is contraindicated 
for pregnant women. The drug relieved not only the pain but also healed the patient’s sores 
(Ashburn and Thor, 2004). Consequently, a follow up study sponsored by WHO of more 
than 4000 ENL patients showed complete remission of the disease within less than two week 
(Brynner and Stephens, 2001). Thalidomide was  reported to inhibit the formation of new 
blood vessels induced in rabbit corneal model explaining the teratogenic effects of this drug  
(Iacopetta et al., 2017). This activity is also clinically useful. In 1994, the antiangiogenic 
activity of thalidomide, which was  discovered at Children’s Hospital in Boston, allowed it 
to be redeployed as candidate in oncology and opened the way for its use in the treatment of 
cancers such as multiple myeloma and breast cancer (Ashburn and Thor, 2004).  
Several other examples of successful drug repositioning such as aspirin, a cyclooxygenase 
inhibitors, to treat coronary-artery disease, sildenafil, a phosphodiesterase inhibitor, which 
is originally developed to treat hypertension and angina and then repurposed to treat erectile 
dysfunction, and the antibiotic erythromycin which is now prescribed for impaired gastric 
motility (Ghofrani, Osterloh and Grimminger, 2006; Corsello et al., 2017). Drug screening 
against leukaemia in samples from patients with chronic lymphocytic and acute myeloid 
leukaemia as well as peripheral blood mononuclear cells  for cytotoxic activity revealed that 
quinacrine, an antimalarial drug, exhibits anticancer activity by intercalating the double 
strand DNA (Eriksson et al., 2015; Jones and Bunnage, 2017). An important lesson from 
drug repositioning stories is that the recognised mechanism of action of drug may not provide 
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a complete picture and drug repurposing may be achievable in a broad range of diseases 
(Ashburn and Thor, 2004). 
Drug repurposing can also be used as a way to discover new drug combinations. 
Combinatorial drug screening had been applied to discover novel synergistic therapeutic 
prospects for treatment of cancer. Screening of drug combinations with ibrutinib, an inhibitor 
of tyrosine kinase, revealed that several PI3K inhibitors and the BCL-2 antagonist ABT199 
(venetoclax) potentiate the activity of the ibrutinib against diffuse large B cell lymphoma 
and chronic lymphocytic leukaemia (Mathews Griner et al., 2014; Cervantes-Gomez et al., 
2015). There are now systematic efforts to identify these potential new drug combinations 
(http://www.ecmcnetwork.org.uk/combinations-alliance-researchers). 
6.2. Steroids 
Steroid hormones can be classified as those having effects on metabolism, inflammation and 
immune function (glucocorticoids), those having salt-retaining activity (mineralocorticoids), 
and those having androgen, estrogen or progesterone activity (sex steroids). Steroids affect 
the major systems of the body, including the cardiovascular, nervous, musculoskeletal and 
immune system. Since 1940, steroids have been usually included in chemotherapy protocols 
for the treatment of hematopoietic malignancies such as acute lymphoblastic leukaemia, 
chronic lymphocytic leukaemia, multiple myeloma, Hodgkin’s lymphoma, and non-
Hodgkin’s lymphoma. They also have some activity against some non-haematological 
malignancy such as prostate and breast cancer (Sionov et al., 2008). Steroids reduce the 
adverse effects of radiotherapy and cytotoxic drug administration. The use of steroids is 
associated with improved appetite, reduced weight loss, decreased fatigue, diminished 
ureteric obstruction, reduced vomiting, diminished swelling and preventing severe immune 
reactions. In addition, they can effectively alleviate the pain associated with metastatic bone 
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disease by preventing the synthesis and release of prostaglandins (Lin and Wang, 2016; 
Sundahl et al., 2016). In addition, steroids have anti-inflammatory and immunosuppressive 
properties, and they are indicated to control many chronic and acute conditions such as 
asthma, inflammatory bowel disease, rheumatoid arthritis, psoriasis, anaphylaxis and septic 
shock. Steroids showed excellent efficacy in the clinic in the treatment of these diseases. 
However, their usage is hampered because of adverse effects (Fleuren et al., 2013).  
The adverse effects of steroids included central adiposity, dyslipidaemia, impaired growth, 
hypokalaemia, myopathy, osteoporosis, glucose intolerance, insulin resistance, diabetes, 
increased risk of infections, pancreatitis, hypertension, cataract, gastrointestinal disease, 
psychologic and neurologic side effects (Fleuren et al., 2013). Short term use of steroids is 
generally associated with mild adverse effects which is reversible upon its discontinuation. 
In contrast, long term use can be associated with more severe adverse effects (Buchman, 
2001). For example, 50 % of patients using steroid for more than 12 months may develop 
osteoporosis because steroids inhibit osteoblast function (Becker, 2013). 
6.2.1. Glucocorticoid receptor (GR) 
There are several member of steroid receptor subfamily: estrogen, estrogen-related receptors 
1 and 2, mineralocorticoids, androgens and progesterone receptors (Schmidt et al., 2004; 
Kumar and Thompson, 2005). The actions of corticosteroids are mediated by glucocorticoid 
receptor (GR). The GR is a ligand-activated transcription factor of the superfamily of nuclear 
receptors. There are α and β isoforms of GR, which are generated by alternative splicing of 
a single gene. The α isoform, which is responsible for transcriptional activation of 
glucocorticoids target genes, is expressed in majority of tissues. In contrast, the function of 
the β isoform remains to be discovered (Lin and Wang, 2016). The conformational changes 
induced by ligand binding to the GR stimulates receptor dissociation and translocation into 
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the nucleus where it subsequently binds to glucocorticoid response elements in the 
regulatory regions of target genes. This is followed by either induction or repression of a set 
of genes in a tissue specific manner (Schoneveld, Gaemers and Lamers, 2004; Löwenberg 
et al., 2008). The GR had also the ability to induce gene expression without direct binding 
to glucocorticoid-response elements through interaction of the GR with other transcription 
factors and this process is known as tethering (Ratman et al., 2013).  
It has been suggested that GR may have a role in tumourigenesis and tumour progression. 
Hence, the potential role of glucocorticoid receptor in non-hematopoietic cancers has been 
confirmed in several immunohistochemical studies. It is observed that about 50% of non-
small cell lung cancer have positive GR immunoreactivity (Lu et al., 2005) and an improved 
therapeutic outcome of non-small cell lung cancer patients has been associated with higher 
expression of GR (Lu et al., 2006). A high percentage of oesophageal squamous carcinomas 
(98.1%) and hepatocellular carcinomas (92.9%) express GR and it has been suggested that  
this may cause dexamethasone induced resistance in those tumour types (Lien et al., 2008). 
In addition, the overall survival in patients with GR positive adenocarcinoma tends to be 
shorter in comparison with GR negative adenocarcinomas (Sionov et al., 2008). A much 
earlier study found that GR expression in 88 % of OC patients (Galli et al., 1981). However, 
a recent study has highlighted that GR is expressed in 39 % of OC and the expression was 
associated with histologic subtype, higher grade, and advanced stage. It is also found that 
GR expression correlates with decreased PFS, in OC patients (Veneris et al., 2017). 
Glucocorticoids have been indicated for the treatment of hormone-refractory prostate cancer 
for many years. However, the alteration of GR expression, function and availability of their 
targets in prostate cancer cells limits the objective response to about 25% of patients. 
Reconstitution of the GR in prostate cancer cells using lentivirus increases the sensitivity of 
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those cells to glucocorticoid anti-proliferative activity. In contrast, alteration of GR function 
or loss of their expression might undesirably affect the sensitivity of cancer cells to the anti-
proliferative effect of steroids (Yemelyanov et al., 2007).  
6.2.2. Glucocorticoids 
Glucocorticoids hormones are derived from cholesterol and are secreted by the adrenal 
gland. The level of these hormones is regulated by the hypothalamic–pituitary–adrenal axis 
(Figure 6-1). At the tissue level, natural glucocorticoid availability is regulated by the 
corticosteroid-binding globulin level in serum and by the local expression of 11β-
hydroxysteroid dehydrogenase (which converts cortisol to cortisone). Disturbance in 
glucocorticoid synthesis causes pathological conditions such as Cushing’s syndrome and 
Addison’s disease (Kadmiel and Cidlowski, 2013).  
The hypothalamic–pituitary–adrenal (HPA) is a biological circuit capable of co-oridinating 
physiological signalling in response to stressful conditions such as severe infection and 
severe blood loss (Herman et al., 2016). An extensive regulatory control is exerted on 
corticosteroid level (Coleman, 1992; McKay and Cidlowski, 2003). For example, in a 
stressed state, the cerebral cortex activates paraventricular nucleus of the hypothalamus to 
produce corticotrophin-releasing hormone (CRH) and vasopressin which are carried by the 
hypophyseal portal system to the pituitary gland (Goncharova, 2013). Both hormones act on 
pituitary to stimulate the release of adrenocorticotropic hormone (ACTH), which in turn acts 
on the adrenal cortex to promote steroid hormone secretion. Corticosteroids regulate 
vascular tone, and metabolic processes on variety of tissues. In addition, steroid hormones 
complete the negative feedback control mechanism by supressing the production of the CRH 
and ACTH from the hypothalamus and pituitary gland, respectively (Papadopoulos and 
Cleare, 2011; Boron and Boulpaep, 2012; Volden and Conzen, 2013). In contrast to natural 
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glucocorticoids, synthetic glucocorticoids such as prednisolone, dexamethasone, and 
budesonide, are artificial compounds that resemble natural glucocorticoids in functions but 
differ in their potency and metabolic clearance (Lin and Wang, 2016).  
 
  
Figure 6-1 Schematic representation of glucocorticoid regulation by the hypothalamic–
pituitary–adrenal axis. Synthesis and release of glucocorticoids is under regulation of 
the hypothalamus (Kadmiel and Cidlowski, 2013). 
 
 
6.2.3. Glucocorticoids and cancer 
Growth arrest and apoptosis induction are among several different functions mediated by 
glucocorticoids (Pufall, 2015). Activation of GR induces apoptosis in number of cells and 
tissues such as of osteoblasts, osteosarcoma, eosinophils, prostate, pancreatic β-islets and 
brain cells (Sionov et al., 2008). There are two phases by which corticosteroids effects 
proceed. The first step is initial growth arrest followed by subsequent stage of cell death. In 
vitro, the initial phase lasts for 24 hours and with continuous administration it will progress 
to cell death which takes 2-3 days. The most commonly observed mechanism of cell death 
is apoptosis, while necrosis and necroptosis had been reported, as well (Pufall, 2015).  
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In haematological malignancies, the mechanism of glucocorticoid-mediated apoptosis 
appears to be complex and involving multiple signalling pathways. Despite studies that have 
lent some insight on the regulation of genes required to induce apoptosis, it is still not well 
defined (Ayroldi et al., 2007). Steroids activate apoptotic pathways by tipping the balance 
of Bcl-2 family apoptosis regulators through upregulation of pro-apoptotic Bim protein and 
downregulation of the anti-apoptotic Bcl-2 proteins. Glucocorticoids have the ability to 
repress the activity of c-Myc and NF-κB, prosurvival transcription factors (Wang et al., 
2003). Progesterone use, which reduced the risk of OC, can induce programmed cell death 
in OC  cells through stimulation of the apoptotic pathways (Han et al., 2013) via activation 
of caspase-8 stimulated by Fas/ FasL signalling pathways (Syed and Ho, 2003). In addition, 
it was reported that apoptosis induced in thymocytes from p53 knockout mice by two 
pathways; the first one initiated by DNA damage which requires p53, and the second is 
stimulated by glucocorticoids and Ca2+ ionophores which is p53-independent (Clarke et al., 
1993). In contrast, the mechanisms of glucocorticoid-mediated growth arrest include 
downregulation of cyclin D1 and D3 and upregulation of p21Cip1 and p57Kip2 (inhibitors of 
cyclin-dependant kinases). In addition, steroids can inhibit the activity of the MAPK and  
Ras signalling pathway (Greenberg et al., 2002; Ayroldi et al., 2007).   
The mechanism of resistance to steroids’ antitumour activity may be provoked by activation 
of SGK1 and MKP1. The anti-apoptotic effects of glucocorticoids were reversed by 
knockdown these genes using siRNA directed to SGK1 or MKP1 in breast epithelial cells 
(Wu et al., 2004). In addition, the expression of the small GTPase RhoB which is a negative 
regulator of proliferation, is stimulated by corticosteroids. RhoB drives inactivation of c-
Myc facilitated by nuclear accumulation of GSK3, which in turn has direct involvement in 
apoptosis induced by steroids. Suppression of RhoB expression by siRNA also inhibits 
glucocorticoid mediated growth arrest (Sionov et al., 2008). However, the corticosteroid-
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induced resistance might be caused by downregulation of apoptosis pathway genes (Herr et 
al., 2003).  
In vitro and in vivo data on the effect of glucocorticoids on solid tumour are controversial, 
they may either promote or suppress tumour progression (Sundahl et al., 2016). The activity 
of several first line therapy were antagonised by corticosteroids (Huang et al., 2000; Lu et 
al., 2006). An extensive statistical analysis of 150 cells derived from either primary 
malignant, solid tumour or established cell lines tested in cell culture or in tumour xenografts, 
suggested that glucocorticoids induced resistance toward cytotoxic therapies in majority 
(89%) of analysed tumour samples (Zhang et al., 2007). In contrast, steroids might also 
inhibit tumour growth, metastasis and sensitize tumour cells to chemotherapy (Leo et al., 
2004; Palmiere et al., 2005; Sundahl et al., 2016). Dexamethasone was shown to potentiate 
the antitumour activity of carboplatin, gemcitabine and adriamycin possibly by increasing 
intracellular drug accumulation in several human cancer xenograft models, including breast, 
colon, lung and glioma cells (Wang et al., 2004, 2007; Moutsatsou and Papavassiliou, 2008). 
Taken together, these data suggest that corticosteroids have dual actions with both pro and 
anti-apoptotic potential in many tissues in which the regulation of cell survival is cell type-
dependent (Schmidt et al., 2004; Wu et al., 2004). 
Steroids have been indicated for advanced breast cancer patients for many years. The doses 
of prednisolone evaluated varied between 10-100 mg daily, and the results reported were 
widely different, as well.  Minton et al., (1981) tested prednisolone (15 mg daily) in 111 
women over the age of 64 with advance breast cancer. Objective response to prednisolone 
therapy were found to be 13/91 assessable patients, and 19/91 achieved stable tumour for at 
least half a year. The median time to progression for responding patients was 15 months and 
for those with stable disease was 9 months (Minton et al., 1981). In addition, administration 
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of 50 to 100 mg of prednisolone daily for three months to forty-five patients with 
disseminated breast carcinoma causes generalized tumour regression in eight patients and 
after one year, two patients are still in regression (Kofman et al., 1958). There is uncertainty 
about the true value of prednisolone, which is a frequent component of combination 
chemotherapy regimen in advanced breast cancer. Despite that, prednisolone has a role in 
improving survival, reducing bone marrow toxicity, antiemetic effect and improving the 
sense of well-being of patients in general (Coleman, 1992). 
6.2.4. Prednisolone 
Prednisolone is a synthetic glucocorticoid. The pharmacokinetic properties of prednisolone 
are complex. It is rapidly absorbed from the gastrointestinal tract with maximum plasma 
level achieved after 1-2 hours of oral administration. Prednisolone has high systemic 
availability ranging from 75-98 % of administered oral dose (Frey, 1987). The drug is 
interconverted between the active form prednisolone and inactive form prednisone (Xu et 
al., 2008). Elimination half-life varies from 2-4 hours. However, the biological half live of 
steroids are much longer and range from 18-36 hours (Becker, 2013).  Hepatic metabolism 
by cytochrome P450 and renal excretion are the main routes of elimination. Steroids are 
largely present in a protein bound form (around 95%), bound to corticosteroid binding 
globulin and to less extent to albumin. The remaining 5% is free and available to exert effects 
on target cells (Katzung, B. G., Masters, S. B., & Trevor, 2012).  
There is evidence that links prednisolone therapy with the MP, at least indirectly. 
Prednisolone presumably causes downregulation of Ras phosphorylation in prednisolone-
sensitive cells. Inhibition of survival protein (AP-1) by prednisolone might be the mediators 
of apoptosis and this inhibitory activity of AP-1 is likely to be suppressed by Ras mutation 
in resistant cells (42% Ras mutation) (Ariës et al., 2015). Prednisolone upregulates the 
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expression of TSC22D3 which in turn decreases the expression of antiapoptotic proteins 
Bcl-XL and increase the activity of capase-8 and caspase-3 in transgenic mice. Furthermore, 
TSC22D3 negatively regulates Ras and Raf induced proliferation (Kajiyama et al., 2010). It 
was observed that trametinib, a MEK1/2 inhibitors, potentiates the anti-proliferative activity 
of prednisolone on myeloma cells with K-Ras and N-Ras mutation (Ariës et al., 2015). 
Steroids have also been evaluated with statins to treat multiple myeloma in clinical trials. 
Simvastatin (15mg/kg/day) was administered orally on days 1-7 of the 28-day cycle, 
followed by intravenous infusion of vincristine, doxorubicin and dexamethasone orally on 
day 7 to 10. The study stopped as the response was insufficient and the reported adverse 
effect were haematological (neutropenia and thrombocytopenia) and gastro-intestinal 
toxicity but not rhabdomyolysis. It is believed that although simvastatin is very effective in 
vitro, its short half-life was the main cause for failure of the study (Robinson et al., 2013). 
Statins with long half-life and continuous administration are required to maintain high 
plasma level in patients (Van Der Spek et al., 2006; van der Spek et al., 2007). 
To reduce the risk of statins causing myopathy, it is desirable to identify drugs which are 
synergistic with pitavastatin. In 2011, Khanim, et al., (Khanim et al., 2011) tested a library 
of 100 licensed oral drug for treatment of multiple myeloma. Drugs in the library were 
selected because of their oral availability, being off-patents with low toxicity. They found 
niclosamide, an anthelmintic drug, displayed significant antiproliferative activity against 
myeloma cell lines.  
To utilize pitavastatin for cancer management, new synergistic combinatorial approaches are 
required. In this study, pharmacological screening of Dr. Khanim’s library was conducted in 
combination with pitavastatin to identify a drug with synergistic activity against OC. The 
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results from the screen identified prednisolone as being synergistic with pitavastatin in a 
panel of OC cell lines.  
6.3. Aims 
To identify drugs which may reduce the dose of pitavastatin necessary to treat OC, a 
combinatorial drug screening approach was used. The growth inhibitory activity of 
pitavastatin was tested in combination with a library of 100-off patent orally available drugs 
against OC cell lines to identify effective combinations which could potentially be further 
evaluated in clinical trials for treatment of OC.
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6.4. Results 
 
6.4.1. Testing library of compound in combination with 
pitavastatin in ovcar-4 cell line 
The Ovcar-4 cells line, which is considered representative of serous OC (Domcke et al., 
2013), was used to identify compounds that synergize with pitavastatin. A panel of 100 off-
patent orally-bioavailable drugs were tested alone and in combination with pitavastatin in 
cell growth assays. To assess whether the compounds potentiated the activity of pitavastatin, 
the expected effect of the compounds if they acted additively was calculated using the Bliss 
independence criterion. Drugs were considered to potentiate the effect of pitavastatin if they 
exhibited a positive “Bliss excess”- those which resulted in more cell death than that 
expected from an additive interaction. Five compounds potentiated the effect of pitavastatin. 
These compounds are prednisolone (71.6 µM), rifampicin (12.2 µM), praziquantel (3.5 µM), 
flutamide (6.22 µM), mefenamic acid (41.4 µM). Six compound showed significant growth 
inhibitory activity against Ovcar-4 cell line when they were tested as single agents: zinc 
acetate (0.323mM), niclosamide (3.2 µM), mebendazole (1.69 µM), desferrioxamine 
mesilate (1.32 µM), methotrexate (1 µM) and bortezomib (0.291 µM) ( Figure 6-2 and 
Appendix I). 
Prednisolone, which is a glucocorticoid drug, showed the most significant synergistic effect 
in combination with pitavastatin with Bliss excess around 0.4. Therefore, it was chosen for 
further analysis in several authenticated OC cell lines (Cov-318, Cov-362, Ovcar-4, Ovcar-
3, Ovsaho).  
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Figure 6-2 The heat map of the bliss excess 
Ovcar-4 cells were exposed to the vehicle, pitavastatin (10µM), library compounds and to a 
combination of individual compound with pitavastatin. A triplicate of each drug addition was made 
and drugs effect measured using SRB assay. The heat map expressed as bliss excess which is 
calculated by subtraction of predicted bliss independence from the observed effects of drug 
combinations. Predicted bliss independence in turn, were calculated from the measured individual 
drug effects. The heat map expressed as mean of two independent experiments.  
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6.4.2. Prednisolone single agent activity in panel of ovarian cancer 
cell line. 
The results of the screen were confirmed in cell growth assays. Firstly, the activity of 
prednisolone (and pitavastatin) used as a single agent was assessed using Ovcar-4, Ovcar-3 
and Ovsaho, Cov-318 and Cov-362 OC cells growing in monolayer culture. Prednisolone, 
showed weak growth inhibitory activity using concentrations up to  500 µM. Complete 
concentration-response curves were not obtained hence IC50s  are reported as ”approximately 
or greater than 500 µM” (Figure 6-3). This agrees with other studies report that 
corticosteroids had insignificant activity against solid tumours (Lin and Wang, 2016; 
Sundahl et al., 2016). 
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Figure 6-3 Dose response cure of prednisolone against a panel of ovarian cancer cell 
lines 
To measure growth inhibitory activity of prednisolone, cells were exposed to the indicated 
concentration of prednisolone for 72 hours (Ovsaho, Ovcar-3, Ovcar-4) or 120 hours (Cov-318, Cov-
362) and stained using SRB assay. The results are expressed as a fraction of the top of the curve 
which was determined by curve fitting (mean ± SD, n ≥ 3). “C” on the x-axis indicates control 
samples measured in the absence of the drug. 
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6.4.3. Pitavastatin single agent activity in panel of ovarian cancer 
cell line 
Pitavastatin’s activity against authenticated OC cell lines growing in monolayer cell culture 
plates were evaluated using SRB assay. Pitavastatin significantly inhibited the growth of all 
of the cells with a IC50s ranging from (1.1 – 4.8µM) (Table 6-1and Figure 6-4). 
Table 6-1 Single agent potency of pitavastatin in cell growth assays 
Cell lines Pitavastatin IC50 (µM) N of experiments 
Cov-318 3.1±0.55 4 
Cov-362 3.3±0.73 4 
Ovcar-3 4.1±0.12 3 
Ovcar-4 4.8±0.56 3 
Ovsaho 1.1±0.27 4 
  
 
 
 
 
 
 
 
Figure 6-4 Dose response cure of pitavastatin against a panel of ovarian cancer cell 
lines 
To measure growth inhibitory activity of pitavastatin, cells were exposed to the indicated 
concentration of pitavastatin for 72 hours (Ovsaho, Ovcar-3, Ovcar-4) or 120 hours (Cov-318, Cov-
362) and stained using SRB assay. Dose response curve expressed as a fraction of the top of the curve 
which was determined by curve fitting (mean ± SD, n ≥ 3). “C” on the x-axis indicates control 
samples measured in the absence of the drug.  
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6.4.4. Pitavastatin combination with prednisolone 
Drug combination studies were subsequently performed in cell growth assays using a fixed 
concentration of prednisolone (70µM) combined with a range of concentrations of 
pitavastatin. At this concentration, prednisolone has no measurable effect when used as a 
single agent, so any change in the pitavastatin IC50 is indicative of drug interaction. 
Prednisolone potentiated the activity of pitavastatin against OC cell line (Ovsaho, Cov-318, 
Cov-362, Ovcar-3 and Ovcar-4), with a significant reduction in pitavastatin IC50s (Figure 
6-5). To confirm this formally, combination indices were calculated. The combination 
showed significant synergy in tested cell lines with a combination index 0.43-0.65 calculated 
using the Chou and Talaly equation (Figure 6-6 and Figure 6-7).  
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Figure 6-5 Pitavastatin IC50 changes after the addition of prednisolone 
The figure shows the changes in pitavastatin IC50 after the addition of fixed dose prednisolone 
(70µM) in panel of OC cell line. All cell lines showed increased sensitivity to pitavastatin effect after 
the addition of prednisolone. The IC50 changes were significant in all the tested cell lines (n=3, **, P 
< 0.01; ***, P < 0.001, respectively, paired t.test). 
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Figure 6-6 Pitavastatin combination with prednisolone in panel of ovarian cancer cell 
lines 
To measure the activity of pitavastatin in combination with prednisolone, cells were exposed to 
indicated concentration of pitavastatin alone and in combination with fixed dose of prednisolone 
(70µM) for 72 hours (Ovsaho, Ovcar-3, Ovcar-4) or 120 hours (Cov-318, Cov-362) and stained using 
SRB assay. Dose response curve are expressed as a fraction of the top of the curve which was 
determined by curve fitting (mean ± SD, n = 3). “C” on the x-axis indicates control samples measured 
in the absence of the drugs. 
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Figure 6-7 Combination indices of pitavastatin with prednisolone 
Combination indices (CI) (Mean ± SD, n=3-4) are quoted at a fraction affected of 0.5. *, ** differed 
significantly from unity where indicated (*, P ≤ 0.05; **, P < 0.01, paired t.test). 
6.4.5. Effect of mevalonate pathway intermediate metabolites on 
the combination 
To determine if the activity of pitavastatin and prednisolone combination in cell growth 
assays had resulted from inhibition of the MP, Ovcar-4 and Cov-362 cells were exposed to 
the combination supplemented with mevalonate, farnesol or geranylgeraniol. The addition 
of mevalonate to cells significantly reduced the growth inhibitory activity of drug 
combination. Furthermore, supplementing the combination with geranylgeraniol but not 
farnesol also significantly prevent growth inhibition (Figure 6-8). These results suggested 
that the growth inhibitory activity of combination is mediated mainly through inhibition of 
MP and most likely by inhibition of geranylgeranylation. 
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Figure 6-8 Addition of mevalonate pathway intermediate metabolite to pitavastatin 
prednisolone combination 
Rescuing the effect of pitavastatin and prednisolone combination by the addition of geranylgeraniol 
(10 µM) and mevalonate (20 µM) but not farnesol (10 µM).  Ovcar-4 and Cov-362 cell lines were 
exposed to serial dilution of pitavastatin in combination with prednisolone (70µM) for 72 and 120 
hours, respectively. The data was represented as a fraction of the top of the curve which was identified 
by curve fitting (mean ± S.D., n = 3). “C” represents the control cells exposed to solvent alone.  
Chapter Six | Pitavastatin and Prednisolone 
192 
6.4.6. ATP assay in spheroid cultures  
To recapitulate a tumour environment more closely in vitro, multicellular aggregates 
(spheroid) were used to provide a 3D architecture of OC. The pitavastatin and prednisolone 
drug combination was evaluated using 3D cell culture of Ovcar-4 and Cov-362 by measuring 
ATP levels (Figure 6-9). The combination of prednisolone and pitavastatin reduced ATP 
significantly more than would have been anticipated from the Bliss independence criterion 
if the two drugs had been acting additively (Figure 6-10).  
 
Figure 6-9 Phase contrast microscopy images of ovarian cancer cells aggregates 
Ovcar-4 and Cov-362 (500 cell /well) were seeded in Gravity TRAP ULA Plates (InSphero) to build 
a spheroid structure from monolayer cells. The cells were observed under the phase contrast light 
microscope after 3-5days. Representative image for the Ovcar-4 and Cov-362 OC cell line grown on 
3D culture are shown. 
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Figure 6-10  ATP assay for pitavastatin prednisolone combination 
Cells were treated with the indicated drug concentration for 72 hours (Ovcar-4) or 120 hours (Cov-
362).  The relative viability of Ovcar-4 and Cov-362 spheroid cells were then measured by celltiter-
Glo assay (relative ATP) and expressed as fraction of that measured in control samples treated with 
solvent (mean ± SD; n = 3). The observed drug combinations effects were compared to the effect 
expect if the drug effects were additive and calculated using the Bliss independence criterion (shown 
with a line for each drug combination) and calculated from the measured effect of the individual 
drugs in each individual experiment. The results were significantly different from the Bliss expected 
effect where shown ( *, P < 0.05; paired t-test).  
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6.4.7. The synergistic antiproliferative effect of combination 
involve induction of apoptosis 
To explore the mechanism of pitavastatin and prednisolone combination induced 
cytotoxicity, the cell death process was analysed. To determine whether the decrease in ATP 
activity after exposure to the combination was due to an apoptotic response, morphological 
assessment and annexin V staining was performed. 
Morphological changes were observed under the phase contrast light microscope. Ovcar-4 
cells were incubated with tested agents alone and in combination for 72 hours and compared 
to control, untreated cells. The cells treated with solvent or with prednisolone were attached 
and maintained their original morphology. In contrast, treated cells displayed dramatic 
morphological changes. Cells exposed to pitavastatin alone were detached from plate 
surface, round, shrinking and blebbing, and this was more pronounced in cells treated with 
the drug combination ( 
Figure 6-11). 
To assess Annexin V labelling as a marker of apoptosis, Ovcar-4 and Cov-362 cell lines 
were exposed to pitavastatin or prednisolone or to the combination of pitavastatin and 
prednisolone. On its own, prednisolone had no significant effect on the number of apoptotic 
cells. However, the number of live, early apoptotic and dead cells, defined by Annexin V 
and propidium iodide stained were significantly different from control in both cell lines and 
in both treatment regimens of pitavastatin alone and in combination with prednisolone. 
However, there were significantly more early apoptotic or dead cells in samples treated with 
the drug combination than in cells treated with pitavastatin alone (Figure 6-12, Figure 6-13). 
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Lastly, to confirm further that the reduction in cell viability and cells growth is attributed to 
induction of apoptosis, caspase-3/7 activity and PARP cleavage were assessed for each drug 
either alone and in combination. The combination caused significant activation of the 
effector caspases-3/7. Consistent with this, immunoblot analysis demonstrated that the 
prednisolone and pitavastatin combination caused significant accumulation of cleaved 
PARP that was greater than that observed with control and with each single agent (Figure 6-
14).  
 
 
Figure 6-11 Phase contrast microscopy images of Ovcar-4 cell line 
Ovcar-4 cell line exposed to the indicated drug concentration for 72 hours. Cells were exposed to 
vehicle, pitavastatin alone and in combination with prednisolone and visualized under phase contrast 
light microscope (representative of three experiments).  
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(A) 
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Figure 6-12 The effect of pitavastatin/ prednisolone combination on annexin 
V/propidium iodide staining on Ovcar-4 cell line 
(A) Ovcar-4 cells were exposed to the indicated drug concentrations for 48 hours, the cells were 
labelled with annexin V and propidium iodide and assessed by flow cytometry. The results shown 
are representative of 3 experiments. (B) The graph shows the percent of cells and were compared 
with the control untreated cells (*) or with pitavastatin alone (#). The results (mean ± S.D., n= 3) 
were significantly different were indicated (**, ##, P <0.01; ***, ###, P < 0.001) (ANOVA test 
followed by Tukey's post hoc test). 
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(A) 
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Figure 6-13 The effect of pitavastatin/ prednisolone combination on annexin V / 
propidium iodide staining on Cov-362 
(A) Cov-362 cells were exposed to the indicated drug concentrations for 72 hours, the cells were 
labelled with annexin V and propidium iodide and assessed by flow cytometry. The results shown 
are representative of 3 experiments. (B) The graph shows the percent of cells and were compared 
with the control untreated cells (*) or with pitavastatin alone (#). The results (mean ± S.D., n= 3) 
were significantly different were indicated (#, P < 0.05; **, ##, P < 0.01; ***, P < 0.001) (ANOVA 
test followed by Tukey's post hoc test). 
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Figure 6-14  Caspase 3/7 and PARP cleavage of Ovcar-4 and Cov-362 cell lines after 
exposure to pitavastatin and prednisolone combination. 
Caspase3/7 activity was measured by Caspase 3/7-Glo assay and the results expressed as fold of 
control (Mean ± SD; N=3). Cells were treated with the indicated concentrations of pitavastatin and 
prednisolone for 48 hours (Ovcar-4) or 72 hours (Cov-362). (n=3, **, P <0.01, ***, P < 0.001; Paired 
t-test). Note that it was not possible to calculate the expected additive effect from the Bliss 
independence criterion in these experiments because of the technical difficulty in accurately defining 
the maximum caspase 3/7 activity. PARP and PARP cleavage were measured for by western blot 
analysis (n=3). 
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6.4.8. The effect of pitavastatin/ prednisolone drug combination 
on mevalonate pathway 
Prednisolone regulates the expression of genes by binding to the glucorticoid receptor. This 
raised the possibility that the synergy between pitavastatin and prednisolone occurred as a 
result of modulating the expression of MP genes. Previous work has identified genes whose 
expression is altered in 3T3-L cells exposed to prednisolone. HMGCR, GGTI, GGTII, 
isopentenyl diphosphate isomerase (IDI1), mevalonate decarboxylase (MVD) and farnesyl 
diphosphate synthase (FDPS) were reported (Fleuren et al., 2013) to show decreased 
expression and so were selected for analysis by immunoblotting. 
The result showed that neither pitavastatin nor prednisolone when used as single agents 
significantly altered the levels of HMGCR, FDPS, IDI1, MVD, GGTI-β. However, the 
combination causes significant reduction in level of HMGCR and FDPS enzyme when 
compared to the control of untreated cells. In contrast, GGTII-β was reduced upon exposure 
to either pitavastatin or prednisolone as single agents as well as in cells exposed to the 
combination of these two drugs (Figure 6-15). 
Lastly, it can be concluded that the antiproliferative activity of pitavastatin against OC cell 
lines is potentiated by prednisolone. The mechanism of this potentiation might be due to 
reduction of the level of HMGCR, FDPS and GGTII-β enzymes level. 
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Figure 6-15 The effect of pitavastatin/ prednisolone combination on mevalonate 
pathway enzymes. 
Ovcar-4 and Cov-362 cell line were exposed to the indicated drug concentrations for 48 hours or 72 
hours, respectively. The level of MP enzymes was detected immunoblotting for HMGCR, GGTI-β, 
GGTII-β, FDPS, MVD, IDI1 and GAPDH, (n = 3).   
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6.5. Discussion  
Statins in general are well tolerated when used at standard doses as anti-
hypercholesterolemia agent in clinic (Ose et al., 2010). However, to cause apoptosis in 
cancer cells, high doses are likely to be required, creating a challenge for redeployment of 
statins as chemotherapeutic agent. A previous study has suggested that continuous inhibition 
of MP in vitro is required to elicit the anti-cancer activities of statins (Robinson et al., 2013). 
The use of statins at a high dose with continuous administration brings with it the substantial 
risk of an increase in adverse effects. The identification of appropriate drug combinations 
has the potential to increase the therapeutic window for statins. Thus pitavastatin was 
evaluated in combination with library of 100 off-patent drugs. The screen identified 
prednisolone, rifampicin, praziquantel, flutamide, mefenamic acid as hits which potentially 
potentiate the activity of pitavastatin against OC cell line. Of these, prednisolone showed the 
most significant synergy with pitavastatin. In addition, six compounds showed significant 
growth inhibitory activity against Ovcar-4 cell line when they were tested as single agents.  
It is well known that steroids have the ability to induce apoptosis in lymphoid cells (Sionov 
et al., 2008). In contrast to haematological malignancies, steroids as monotherapy show only 
limited activity in breast and prostate cancers but not in other cancer types (Ishiguro et al., 
2014; Lin and Wang, 2016). In accordance with these reports, the results showed that growth 
inhibitory activity of prednisolone were limited against OC cell lines. Despite the limited 
antitumour activity of steroids in solid tumour, it is still indicated as adjuvant therapy to 
reduce the adverse effects associated with cytotoxic drugs (Lin and Wang, 2016). In contrast, 
pitavastatin had significant growth inhibitory activity. It had been discussed previously that 
pitavastatin mediates cell death through reduction of MP intermediate metabolite (Casella et 
al., 2014; Robinson et al., 2014). Inhibition of the MP cause disruption of several GTPase 
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function which are involved in cell signalling, regulating cell cycle progression and cell 
survival (Swanson and Hohl, 2006; Rajalingam et al., 2007). In support of this, statins induce 
apoptosis associated with an increase in release of mitochondrial cytochrome C to cytosol, 
and activation of caspases 3, 8 and 9 (Hoque, Chen and Xu, 2008; Tu et al., 2011).  
The synergy between the pitavastatin and prednisolone combination identified in the screen 
was verified in several assays including cell growth assays in monolayer and in 3D cell 
culture. Phase contrast microscopy shown some features of apoptosis induction (Elmore, 
2007). Cells observation under microscopy revealed more significant rounding, blebbing and 
detachment from the plate in cells treated with the drug combination than in cells treated 
with the single agents. Cell death was mediated, at least in part through induction of 
apoptosis, because the combination synergistically increased caspase activity and PARP 
cleavage. The observation that the combination is synergistic in several assays gives 
confidence in the claim that pitavastatin and prednisolone interact synergistically. 
It had been shown that MP intermediate metabolite, mevalonate and geranylgeranyl 
pyrophosphate reverses statin-induced apoptosis in cancer cells (Wong et al., 2007). In 
addition, in the previous chapter, it has been observed that inhibition of both GGTI and 
GGTII are responsible for the potentiation of pitavastatin activity. To confirm that the 
mechanism of pitavastatin prednisolone combination induced apoptosis in OC cells through 
MP, cells were co-incubated with mevalonate, geranylgeraniol or farnesol. Only mevalonate 
and geranylgeranyl pyrophosphate were able to rescue cell growth, whereas farnesol could 
not rescue cells from the antiproliferative effect of pitavastatin prednisolone combination. 
This confirms that the combination works through inhibition of the mevalonate pathway and 
also suggests that geranylgeranyl transferases play a more critical role than farnesyl 
transferases in the activity of the combination. 
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To unveil the precise mechanism by which prednisolone was synergistic with pitavastatin, 
levels of MP enzymes were investigated by immunoblotting. An earlier study which aimed 
to characterize prednisolone-induced alterations in gene expression was considered. 
HMGCR, GGTI, GGTII, IDI1, MVD and FDPS showed altered expression and so were 
selected for analysis in these experiments (Fleuren et al., 2013). The result revealed that the 
prednisolone-pitavastatin combination cause significant reduction in level of HMGCR and 
FDPS enzymes. However, a reduction of GGTII-β was observed following exposure to 
either drugs when used as single agents or in the combination. This suggests that 
prednisolone-pitavastatin combination is particularly synergistic because multiple points in 
the MP are affected by the drug combination. The effect of steroids on MP enzymes activity 
had been reported previously. Investigation of the short term effects of dexamethasone in rat 
hepatocytes revealed that there is reduction in cholesterol synthesis (Giudetti and Gnoni, 
1998). Dexamethasone also causes down regulation of HMGCR and FTase enzymes activity 
in rat AR 4-2J cells. Specifically, the authors found that there is significant reduction in FT-
α subunit upon treatment of the cells with dexamethasone for 48 hours. In contrast, the β-
subunit of the enzyme was either unchanged or slightly reduced (Lambert and Bui, 1999). 
However, it was claimed that even 50 % reduction of FT activity is not sufficient to prevent 
Ras isoprenylation and Ras protein were even found to accumulate during dexamethasone 
treatment (Lambert and Bui, 1999). Therefore, it is plausible that a relatively small amount 
of enzyme is sufficient to maintain prenylation process, or the interplay between 
prenyltransferases enzymes allows one to compensate for the reduction of one of the other 
enzymes which maintain the cell growth and integrity. It is perhaps for this reason that 
relatively high concentrations of pitavastatin are required to induce apoptosis (Bell et al., 
2011; Cerami et al., 2012; Gao et al., 2013). This highlights the critical role of the 
mevalonate pathway in OC. 
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The identification of at least some of the mechanisms by which the drug combination reduces 
the level of MP enzymes is not trivial because the regulation of MP is extremely complex 
(Dimitroulakos et al., 1999). The enzymes of MP, especially HMGCR, are exposed to a  
stringent level of feedback control mechanisms which is mediated by sterol and non-sterol 
products of the pathway (DeBose-Boyd, 2008). The HMGCR enzyme is regulated at several 
levels including regulation of its catalytic activity, its rate of degradation and synthesis 
(Smith and Johnson, 1989). Oxysterol, which is a natural endogenous regulator of 
cholesterol biosynthesis, is a product of MP participates in cholesterol homeostasis by 
altering enzymes stability and/or activity. It has been reported that oxysterol affects the 
activity of HMGCR, sequalene monooxygenase, FDPS and several enzymes in cholesterol 
biosynthetic pathway (Smith and Johnson, 1989; Schroepfer, 2000). For example, oxysterol 
accelerates the degradation of HMGCR through sterol-sensing domain in an Insig-dependent 
approach  (Luu et al., 2016). Oxysterol prevents the SREBP and SCAP complex from 
translocating to the Golgi complex and the subsequent proteolytic cleavage of SREBPs 
stimulate the transcription of genes encoding most of the enzymes in sterol biosynthetic 
pathway (Horton, Goldstein and Brown, 2002). Therefore, it might be speculated that 
steroids, which have the same ring structure as oxysterols, might  bind to  SREBP (Zhang, 
Dricu and Sjövall, 1997) leading to SREBP degradation and eventually decreasing the 
expression of MP enzymes. Therefore, it is possible that prednisolone triggers the reduction 
of HMGCR and FDPS enzymes either by decreasing transcription or increasing the 
degradation or both. Thus, adding prednisolone to pitavastatin may compensate for the 
reduction in sterols resulting from inhibition of the MP. The loss of the sterols can upregulate 
HMGCR as a result of the sterols no longer activating negative feedback through SREBP. 
Inclusion of prednisolone may prevent upregulation of HMGCR by reactivating the 
negative-feedback mechanism and hence synergize with pitavastatin. 
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In addition to sterols, another line of evidence for a negative feedback regulatory role of the 
pathway products is provided by the steroid hormones (Zhang, Dricu and Sjövall, 1997; 
Dimitroulakos et al., 1999). For example, the addition of either dehydroepiandrosterone or 
5-pregnen-3β-ol to diet strongly supress the HMGCR activity and cholesterol synthesis in 
the liver of mice and rat (Zhang, Dricu and Sjövall, 1997). Furthermore, an in vitro study 
has shown that dehydroepiandrosterone depleted the intracellular mevalonate pool and 
protein prenylation of human colonic adenocarcinoma cells exposed to growth inhibiting 
concentrations of the hormone (Schulz and Nyce, 1991). In contrast, there were more 
complicated responses to the effect of dexamethasone on a Rab protein isoforms on 
pancreatic AR42J cells. Dexamethasone causes downregulation of Rab3A, Rab3C and 
Rab3D, whereas Rab3B was upregulated at the mRNA and protein level (Klengel et al., 
1997).  
The observed synergy of pitavastatin and prednisolone might also be explained by the 
modulation of glucose metabolism induced by statins. It has been reported that inhibition 
of glycolysis enhances the sensitivity of resistant acute lymphoblastic leukemia cells to 
prednisolone therapy (Hulleman et al., 2009). Statins induce cell death by reduction of 
the MP product but the accumulation of the upstream product such as Acetyl CoA, might 
play a role as well. The accumulation of this metabolic precursors blocks glucose uptake 
through feedback inhibition of the glycolysis pathway (Jenkins et al., 2011; Warita et al., 
2014). GLUT1, a glucose transporter protein, is highly expressed in OC and its expression 
was correlated with the tumour type (benign, borderline, or malignant) (Kellenberger et 
al., 2010). In addition, it has been reported that statin cause reduction of GLUT activity 
in number of cells such as hepatic, adipose, muscle, or endothelial origin (Malenda et al., 
2012). Furthermore, the presence of glucose is essential for Akt pathway to promote 
mitochondrial integrity and inhibit cytochrome c release. Therefore, reduction of glucose 
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uptake might promote the process of programed cell death (Robey and Hay, 2006). There 
is considerable evidence that steroids might induce the apoptotic pathway. Although 
prednisolone did not induce caspase activity and PARP cleavage at the concentration tested, 
it was observed following exposure to the combination with pitavastatin. Steroids had the 
ability to induce the pro-apoptotic member of the Bcl-2 family, such as Bim, Bad and Bid 
and/or repress the anti-apoptotic members, such as Bcl-2, Bcl-xL and Mcl-1 (Schlossmacher, 
Stevens and White, 2011). In addition to the caspase-9 and -3 activation, steroids might 
induce the activity of caspase-8, as well (Sionov et al., 2008). The activation of intrinsic and 
extrinsic apoptotic pathway allows procaspase-9 processing which activates the effector 
caspase-3 (van de Donk et al., 2003).  
In conclusion, drug repositioning holds a great opportunity to find new indications and new 
drug combinations. Pitavastatin, but not prednisolone, reduces the viability of OC cells. 
However, the anti-cancer activity of pitavastatin is potentiated significantly upon the 
combination with prednisolone and was found to be mediated through the MP by rescuing 
cells upon the addition of pathway intermediate metabolite. In addition, exploring the 
mechanism of synergy by the combination revealed that there is significant reduction in level 
of HMGCR and FDPS. It has been proposed that because of structural similarity of 
prednisolone and sterols, prednisolone might replace the sterol pool depleted by statins, and 
maintain the negative feedback loop in the pathway. Therefore, there is a potential 
therapeutic advantage of combined application of pitavastatin and prednisolone. Clinical 
trials of prednisolone and pitavastatin are warranted.
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Conclusion and further work 
Drug resistance is one of the main hindrances to improving a patient’s prognosis and 
contributes significantly to the poor survival rate of OC patients (Cruz et al., 2017). 
Therefore, new strategies for treatment of OC are a pressing requirement. Targeting 
metabolic pathways offers an exciting new potential therapy in the treatment of malignant 
disease.  
Understanding the association between MP and malignancy is important for determining 
new therapeutic strategies (Likus et al., 2016). Therefore, several enzymes in MP have been 
evaluated in this study and the results showed that HMGCR, a metabolic oncogene, is 
overexpressed in OC cell lines in comparison to normal ovarian cells and the level of GGTI 
and GGTII is also higher in at least a subset of OC cell line compared to normal cell line. 
This indicated that the MP is deregulated in OC cell lines. The deregulation of MP has been 
linked with carcinogenesis process and resistance to cytotoxic drugs (Mullen et al., 2016). 
Malignant cells are more dependent on metabolites supplied by the pathway compared to 
their normal cellular counterparts (Siperstein, 1970). A previous study found that there is 
elevated level of mevalonate synthesis in breast, lymphoma, leukaemia and prostate cancer 
(Koyuturk et al., 2007) which might be caused by aberrant activation of SREBP, a master 
regulator of the MP enzymes (Swinnen, Brusselmans and Verhoeven, 2006). In addition, the 
role of TP53 in regulation of MP had been evaluated in OC cell lines and it was found that 
ectopic expression of p53 increases the level of MP enzymes and knockdown of the mutated 
p53 form reduces the level of MP enzymes. This highlights the importance of p53, which is 
almost ubiquitously altered in high grade serous OC, in the regulation of the MP. It also 
underscores the potential for MP inhibitors to treat OC. However, evaluation of the effect of 
p53 mutations in the sensitivity of OC cell line to statins therapy might reveal new avenues 
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for more targeted therapeutic interventions. A computational approach using gene expression 
has shown a number of pathways that may result in synthetic lethality if targeted in mutant TP53 
tumours (Wang and Simon, 2013). Additionally, many of the TP53 mutant gain of function 
properties rely on  p63 and p73 (Mantovani, Walerych and Sal, 2016). Therefore, 
investigation of the effects of these two family members deserves further investigation. 
The preclinical studies showed that MP inhibitors are effective in vivo and in vitro (Demierre 
et al., 2005; Kumar et al., 2006; Lim et al., 2009; Kidera et al., 2010; Martirosyan et al., 
2010; Cao et al., 2011; Vallianou et al., 2014; Vogel et al., 2017). The most important 
advantage observed with statins antitumour effects is that they retain their potency against 
OC cell line which is relatively resistant to the chemotherapy (Robinson et al., 2013). 
Previous study found that continual blockade of HMGCR with long half-life statins was 
required for inducing cell death (Robinson et al., 2013). In addition, there are several 
pharmacologically tractable targets in MP which could be evaluated to identify potential 
combination to increase the sensitivity of OC cells to pitavastatin. The result presented in 
chapter 5 showed that inhibition of the FDPS with zoledronic acid and to lesser extend 
risedronate potentiate the activity of pitavastatin. In contrast, inhibition of the GGTI, by 
GGTI-2133 or GGTI-β or GGTII-β using siRNA were unable to increase the sensitivity of 
OC cell lines to pitavastatin. However, the sensitivity of the OC cell lines to pitavastatin 
activity increase by combined inhibition of both GGTI-β and GGTII-β. Therefore, it might 
be argued that the redundant prenylation by the geranylgeranyl transferases enable the cells 
to survive. It has been reported that resistance to FTase inhibitors arise as result of 
redundancy (Park et al., 2014) leading to geranylgeranylation in place of farnesylation. In 
addition, it seems likely that the activity of pitavastatin is driven through inhibition of broad 
range of Ras family of proteins or at least subgroups of these proteins from each transferase. 
This suggests that designing inhibitors that target both transferases might be superior to 
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molecules that inhibit either enzymes. However, this raises a concern about the possible 
adverse effects that might resulted from inhibition of broad range of isoprenylated proteins.  
Screening a library of oral available off-patent drugs for combinatorial application with 
pitavastatin revealed that there are number of compounds that enhance the activity of 
pitavastatin. The results showed that prednisolone significantly potentiated the activity of 
pitavastatin. It is found also that the prednisolone-pitavastatin combination reduces the level 
of HMGCR and FDPS enzymes, which reinforces the importance of these two enzymes 
which were also inhibited by the previously assessed combination of pitavastatin and 
zoledronic acid. These combinations of zoledronic acid or prednisolone and pitavastatin 
might be a suitable option to improve the therapeutic windows of pitavastatin. Evaluation of 
these combinations in clinical trials will determine the usefulness of this strategy in the 
treatment of OC.  
In addition, there are still several compounds that might be a potential candidate for 
combination with pitavastatin. These compounds were identified in the screen described in 
chapter 6 and include rifampicin, praziquantel, flutamide, mefenamic acid. Furthermore, 
evaluating the effect of drugs which showed significant activity against Ovcar-4 cell line 
when they were tested as single agents (zinc acetate, niclosamide, mebendazole, 
desferrioxamine mesilate, methotrexate and bortezomib) may be worthwhile.  
The antitumour activity of statins has been confirmed in OC (Melichar et al., 1998). 
However, to achieve plasma concentration that inhibit the growth, statins may need to be 
used close to their maximum tolerated doses which might cause adverse effects (Robinson, 
2015). Although it has been stated that inhibition of prenyltransferases by statins might not 
be the causative of cytotoxicity in muscle (Gee et al., 2015). Myopathy, and particularly 
rhabdomyolysis remains as one the most devastating consequences of high dose of statins 
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(Chaipichit et al., 2015). The combination of either zoledronic acid or prednisolone with a 
statin might aggravate the myopathy induced by the statin. Therefore, patients should be 
monitored during clinical trials, and laboratory analysis including frequent routine studies 
which include hematological studies, liver function test, urinalyses, and determinations of 
creatine phosphokinase, alkaline phosphatase,  serum calcium, electrolytes and fasting blood 
sugars (Kofman et al., 1958). However, it has been suggested recently that curcumin, a 
natural dietary polyphenol, might supplemented as an adjunct to statin therapy in patients 
with muscle symptoms (Sahebkar et al., 2017).  
Research is underway to identify a therapeutic marker in order to select which patients might 
benefit from treatment with pitavastatin. In this study there were no significant correlation 
between HMGCR level and statin sensitivity in OC cell lines which might indicate that other 
molecular features influence the sensitivity to statins (Goard et al., 2013). It is found that the 
level of GGTI-β were positively correlated with the OC cell line sensitivity to pitavastatin 
activity. The importance of the MP suggests that a complete screening of the expression of 
pathway enzymes using immunohistochemistry tissue microarray might be worthwhile. This 
will provide an overall picture of these enzymes in OC tissue compared to the normal tissue 
counterpart. Looking at this from a slightly different perspective, biomarkers may also 
predict which patients are resistant to pitavastatin. In contrast to GGTI,  a number of Rabs 
are also involved in drug cytotoxic drug resistance (Recchi and Seabra, 2012). For example, 
Rab8 overexpression in sensitive cancer cells enhance the resistance to cisplatin (Shen and 
Gottesman, 2012). In addition, It was reported that Rab25 is overexpressed in OC and it is 
correlated with poor prognosis (Mitra, Cheng and Mills, 2012). The results showed that 
pitavastatin decrease the level of GGTII-β and Rab6A. Therefore, this study highlights the 
significance of GGTI and GGTII enzymes not only in potentiation of the activity of 
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pitavastatin but also as a potential marker for statin sensitivity which warrant further 
evaluation.  
For the pitavastatin combination with zoledronic acid, a number of issues remain to be 
addressed. Although zoledronic acid was synergistic with pitavastatin in the majority of cell 
lines, the drug combination was antagonistic in Ovcar-3 cells. It is also unclear why less 
synergy observed when pitavastatin was combined with risedronate instead of zoledronic 
acid. Indeed, an antagonistic interaction as observed between risedronate and pitavastatin in 
Ovcar-3 cells as well as Ovcar-8 cells. It can currently only be speculated what is the cause 
for these observations. In the case of Ovcar-3 cells the presence of insulin in the Ovcar-3 
growth medium, but not in the media for other cell lines, may contribute. The genetic 
background of the cells is also likely to play a key factor (Jukema et al., 2012), but the 
identification of additional cell lines in which antagonism is observed would be necessary to 
assist in identifying mutations or epigenetic changes which are associated with antagonism 
between bisphosphonates and statins. There is also currently no clear model that links 
reduced protein prenylation and the induction of apoptosis. It has been observed activation 
of both caspase-8 and caspase-9, as well as the effector caspases3/7. This may represent 
separate activation of both the extrinsic and intrinsic pathways or cross-talk between these 
pathways, for example by cleavage of BID. Further studies are required to address these 
issues. 
The consideration of statins selection and dosing frequency in clinical trial for treatment of 
cancer has been mentioned. However, a recent study from our laboratory has implemented 
further consideration of the patient’s diet for successful use of pitavastatin in clinical trials. 
It is found that presence of geranylgeraniol in mouse food may reverse the cytotoxic activity 
of statins and feeding mice with controlled diet led to improve statin efficacy (de Wolf et 
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al., 2017). It is also had been reported that adding high fat diet reduce the activity of statins 
and increase renal tumour cell growth in mice (Koike et al., 2011, 2012). In addition, feeding 
mice with a high fat diet has been found to inhibit the antitumour activity of the monoacyl 
glycerol lipase enzyme in xenograft study (Nomura et al., 2010). Further research could 
determine the effects of different foodstuffs on statin activity and help to establish a guide 
line for suitable food consumption during clinical trials.  
Most of the OC patients are diagnosed at late stage (75%) when the disease has already 
spread beyond the ovary at the diagnosis and those patients have very low cure rate (>20%) 
(Lorusso et al., 2003). Successful adhesion of transformed cells is a key feature for the 
peritoneal spread of OC. Peritoneal metastasis is associated with resistance to chemotherapy 
(Ayantunde and Parsons, 2007). It has been reported that mutant TP53 gain of function 
stimulates adhesion of OC cells to mesothelial cells (Lee et al., 2015). For instance, several 
TP53 mutant variant, such as R175H, R248Q and R273H have been reported to promote cell 
migration and invasion in endometrial and lung cancer cells (Pabla and Dong, 2008; 
Yoshikawa et al., 2010; Yeudall, Wrighton and Deb, 2013). In addition, the role of MP in 
metastasis is well documented (Likus et al., 2016). Therefore, understanding the role of 
different TP53 mutations on cell adhesion, migration and invasion and exploring the role of 
statins might provide a new therapeutic approaches to prevent peritoneal metastasis. 
In addition to prenylation, some of GTPase family proteins are subjected to phosphorylation 
as well. The induction of phosphorylation of Cdc42, RhoA and K-Ras by protein Kinase C 
mediates their relocation from plasma membrane to cytosol (Forget et al., 2002; Bivona et 
al., 2006). However, it is not known whether the translocation induced by phosphorylation 
leads to loss or change in the function of Ras proteins (Berndt, Hamilton and Sebti, 2011). 
For example, K-Ras phosphorylation by PKC mediates its removal from cell membrane to 
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mitochondrial membrane where is interact with BclXL and induces programed cell death 
(Bivona et al., 2006). In addition, phosphorylation of Rab6, RhoE and RalA by aurora kinase 
A activated their functions (Berndt, Hamilton and Sebti, 2011). Therefore, this suggest that 
statins activities might synergize with PKC agonists such as bryostatin or Aurora kinase 
inhibitors. In addition, it is important to peruse a potential role of the unprenylated Ras 
proteins in driving the activity of the MP inhibitors.  
The data presented here has pointed to a role for the inhibition of geranylgeranyl transferase 
enzymes to potentiate the activity of pitavastatin. However, this approach might be 
associated with several adverse effects. Therefore, another major challenge in the field of 
exploring the mechanism of MP inhibitors is to identify the prenyl transferase substrates 
which are responsible for mediating the antitumour activity in different cancer types. It has 
been confirmed experimentally that more than 100 proteins undergo prenylation and several 
hundreds of other proteins also bearing the CAXX box whose prenylation is waiting to be 
confirmed (Maurer-Stroh et al., 2007; Berndt, Hamilton and Sebti, 2011). The importance 
of prenylated proteins in malignant transformation has promoted interest in developing 
inhibitors of the prenyl transferases enzymes as anticancer agents. However, the standard 
method for the following the activity are dependent on individual protein (Berndt and Sebti, 
2011). Therefore, global scale analysis protein prenylation is required to understand and 
interpret the effects of MP inhibitors on signalling transduction pathways which might lead 
to identify the mechanism of action and discover a biomarker for the therapy. 
Taken together, these evidence suggest that the MP is an important target for cancer 
treatment. In addition, these data suggest that drug combinations inhibiting multiple points 
in the MP may increase the therapeutic window for pitavastatin and offer a potential 
treatment option for management of OC. 
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Appendix (I) 
Ovcar-4 cell line (5000 cells/well/96 well plate) were exposed to the vehicle, pitavastatin (10µM), 
library compounds and to a combination of individual compound with pitavastatin for 72 hours. A 
triplicate of each drug addition was made and drugs effect measured using SRB assay (Mean±SD; 
n=2).  
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